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Abstract: 
X 
 
Dapsone (DDS) is an antibiotic associated with hypersensitivity reactions in 0.5 to 3.6 % of 
patients. Although clinical diagnosis is indicative of a drug hypersensitivity reaction, studies 
have not been performed to define whether dapsone or a metabolite activates specific T-cells. 
Thus, the aims of this study were to (i) explore the immunogenicity DDS and nitroso DDS 
(DDS-NO) using PBMC from healthy donors and splenocytes from mice, (ii) generate human 
T-cell clones to characterize mechanisms of T-cell activation and (iii) explore how the two 
antigenic forms of the dapsone interact with HLA-B*13:01, which is associated with the 
development of the DDS hypersensitivity among patients with leprosy. Naïve T-cell priming 
to DDS and DDS-NO was successful in three human donors.DDS-specific CD4+ T-cell clones 
generated from 2 donors were stimulated to proliferate in response to the drug via a MHC class 
II restricted direct binding interaction. Cross reactivity with DDS-NO, DDS-analogues and 
sulfonamides was not observed. DDS-NO clones were CD4+ and CD8+, MHC class II and I 
restricted, respectively, and activated via a pathway dependent on covalent binding and antigen 
processing. DDS and DDS-NO-specific clones secreted a mixture of Th1 and Th2 cytokines, 
but not granzyme-B. Splenocytes from mice immunized with DDS-NO were stimulated to 
proliferate in vitro with the nitroso metabolite, but not DDS. In contrast, immunization with 
DDS did not activate T-cells. To explore whether similar T-cell responses are detected in 
hypersensitive patients expressing HLA-B*13:01, we obtained samples from 6 patients, and 
evaluated T-cell specificity and the phenotype of drug-specific clones. Lymphocytes from 
certain patients proliferated in the presence of DDS and DDS-NO. DDS and DDS-NO-specific 
CD4+ clones were generated: DDS-specific clones were activated by the drug binding directly 
to HLA molecules on antigen presenting cells, while DDS-NO-specific clones were activated 
via a hapten mechanism involving formation of drug protein adducts and antigen processing 
by antigen presenting cells. Mass spectrometry was used to show that DDS-NO modified 
cysteine residues on mouse serum albumin and human glutathione-S-transferase P1. 
XI 
 
Collectively, these data show that DDS- and DDS-NO-specific T-cell responses are readily 
detectable in healthy human donors and hypersensitive patients, whereas in murine systems, 
only DDS-NO activates T-cells. Additional studies are required to explore how the two 
antigenic forms of DDS interact with HLA-B*13:01, which is associated with the development 
of the DDS hypersensitivity among human patients with leprosy.  
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1.1 Adverse Drug Reactions 
Drugs have therapeutic properties, and often they are accompanied with undesirable effects 
known as adverse drug reactions (ADRs).These reactions have been present since the evolution 
of modern day pharma and the drug development process and are considered as a large public 
health issue throughout the world. An  ADR is defined as “an appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, which predicts 
hazard from future administration and warrants prevention or specific treatment, or alteration 
of the dosage regimen, or withdrawal of the product.” (Edwards and Aronson, 2000).  
1.1.1  Importance of ADRs 
ADRs have great influence on health care systems and are a major concern for health care 
providers as it has been reported that 6-7% of all hospital admissions are associated  with ADRs 
(Gomes and Demoly, 2005). Furthermore, ADRs are associated with significant patient 
morbidity and a high mortality rate (Pirmohamed et al., 1998, Classen et al., 1997, Ring and 
Brockow, 2002).  The incidence of ADRs in Western countries is between 0.15% to 0.41% 
(Lazarou et al., 1998, Pirmohamed et al., 2004).  They are the seventh most common cause of 
death (Wester et al., 2008). A study conducted in England found that there has been a 76.8 % 
increase in the annual number of ADRs and a 10% increase in mortality rate over the period of 
10 years from 1999-2009 (Wu et al., 2010). The same increasing trend in mortality has been 
reported in the US (Shepherd et al., 2012).The ADR incidence in US is reported to be 6.7 % 
and fatal ADRs being 0.32% in hospital patients (Lazarou et al., 1998) . In the European Union, 
ADRs cause 197,000 deaths annually (Bouvy et al., 2015). In the pharmaceutical industry, an 
ADR is one of the most important cause of drug attrition (Daly, 2013). 
Clinically, ADRs mainfest as symptoms such as skin rash, urticaria, itching, fixed dose 
eruptions, angioedema, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis 
Chapter 1 
 
3 
 
(TEN) in addition tonumerous hematologic problem and GI disorders (Sharma and Sethuraman 
1996; Sharma et al. 2001). The most affected organs are the liver and kidney (Arndt and Jick 
1976; Hunziker et al. 1997; Chen et al. 2013) 
1.1.2 Classification of Adverse Drug Reactions 
There are different classification systems for grouping ADRs, but generally they are classified 
as Type A and type B reactions (Riedl and Casillas, 2003). The main differences are 
summarized in Table 1.1. These are also called dose dependent and idiosyncratic reactions 
respectively. This simple classification is based on dose dependence and predictability 
(Rawlins, 1981). 
Type A reactions depend on the dose and because of the established pharmacology of 
the drug, they are predictable. These reactions are non-immunological in nature.  Type A 
reactions are most common and account for 80% all drug reactions (Park and Coleman, 
1988Ritter, 2008).  These reactions are caused by either pharmacological or toxic properties of 
a drug and may occur in anyone (Rieder, 1994). 
Type B reactions do not depend on the dose of the drug and are for the most part non-
predictable. Studies have shown that 10-15 % of all reactions are Type B (Jick, 1984). There 
is variation in literature studies about the classification of Type B reactions and the use of 
various terms.  Most of the scholars classify type B reactions into two types (a) immune 
mediated and (b) non immune mediated. 5 to 10% of all drug reactions involve activation of 
the host adaptive immune system and are referred to as immune mediated which include 
hypersensitivity reactions and IgE mediated allergic reactions (1999, deShazo and Kemp, 1997, 
Anderson and Adkinson, 1987). They involve different components of the adaptive immune 
response including IgE antibodies, drug-specific T-cells and immune complexes (deShazo and 
Kemp, 1997, Thong and Tan, 2011) which will be discussed in detail in this thesis. The 
remaining non-immune mediated Type B reactions are classified into various types such as as 
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pseudo-allergic, idiosyncratic and  intolerance (Riedl and Casillas, 2003). Others have used the 
term idiosyncratic to describe Type B reactions, which can be further subdivided into immune 
mediated and non-immune mediated reactions (Aberer et al., 2003, Pichler, 2003). 
It is not possible to put all drug reactions into type A and B because of the complications so 
scholars extended this system with more types, also labelled alphabetically. These types are 
Type C, D, E, F, and G.Under the Group C, reactions are classified based on biological 
characteristics dependent upon a drug’s chemical structure. The Group D reactions are 
associated with delayed type reactions.  The Group E deals with drug administration 
programmes with a particular focus on the ‘end of treatment’ effects. The Group F has to do 
with therapy failure and describes the adverse behaviour of the drug. The Group G is primarily 
focused on predisposed genetic reactions (Ritter, 2008).  
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Table 1.1 General classification of ADRs 
 
 
1.1.3 Epidemiology of Adverse Drug Reactions 
 
The epidemiology of ADRs has been a major focus for scholars and clinicians for the last 50 
years because of their complications. In most cases, the total number of individuals affected 
with ADR in different regions of the world are not known because of underreporting. For 
example one study found that underreporting of ADRs can be as high as 94% (Hazell and 
Shakir, 2006). Although ADRs are a global problem, there is high variability in data across the 
world. It has been found that 5 % of all hospital admissions in Europe are caused by ADRs  
(Bouvy et al., 2015). In USA and Canada ADRs account for 4.2-30% of hospital admissions, 
and 5.7-18.8% of admissions in Australia ( Howard et al., 2007). Jemal at al (2005) suggest  
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that  ADRs are the fourth leading cause of death in USA coming after heart disease, cancer and 
stroke (Jemal et al., 2005) and the annual death toll is 106,000 (Lazarou et al., 1998). Another 
study in USA found that between 3% and 6% of ADRs are fatal or have serious concerns, with 
an assessed 140,000 fatalities secondary to ADRs happening yearly in the USA (Wester et al., 
2008, Lazarou et al., 1998). Ethnicity and advances in health care medical practices are some 
of the factors which cause variability in epidemiology data in various regions of the world 
(Raschetti et al., 1999; Fattinger et al., 2000; Davies et al., 2009). 
There are a number of risk factors associated with ADRs. The factors are related to drug 
and patient while the rest are pathophysiological (Fig 1.1).  Chemical properties, structure and 
molecular weight of the drug are one the most important drug related-risk factors associated 
with ADRs (Riedl and Casillas, 2003). Drugs with complex structure and high molecular 
weight are more likely to cause immunological ADR (Holt and Ju, 2006, Uetrecht, 2007). 
Additionally, the dose of drug administered is a vital susceptibility factor (Leach and Roy 1986; 
van der Ven et al. 1991). Regarding gender, females are more affected than males (Barranco 
and Lopez-Serrano, 1998, Haddi et al., 1990). Different diseases also make individuals 
susceptible to ADRs. For example  patients with AIDS are 10 – 50 times more likely to develop 
ADRs (Coopman et al., 1993). Other risk factors reported in literature studies are rural 
residential location, socioeconomic status (Sikdar et al., 2012) cardiovascular disease, 
depression and diabetes mellitus (Naranjo et al., 1981, Hallas et al., 1990) impairedrenal 
function (Conforti et al., 2012) and liver disease (Wawruch et al., 2009). 
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Figure 1.1 Risk factors associated with adverse drug reactions 
 
1.1.4 Clinical and economic influence of adverse drug reactions 
ADRs not only cause injury and death but they are also significantly associated with increased 
costs related to healthcare. There is a considerable burden of ADRs in both in- and out-patient 
settings (Bouvy et al., 2015). It has been suggested that 10% of healthcare costs are related to 
ADRs in hospitals (Moore et al., 1998). According to White et al and Patel et al the expected 
impact on hospital costs go above $30 billion (White et al., 1999, Patel et al., 2007). A recent 
survey found that patients experiencing ADRs costs $2284–5640 per  head (Rodriguez-
Monguio et al., 2003). In another survey done in Sweden, it was reported that individuals with 
ADRs had a 150% higher overall cost of illness compared to patients without ADRs 
(Gyllensten et al., 2013).  The costs of ADRs in Intensive care unit are much higher than non-
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Intensive care unit. For example a study done by Cullen et al found that ADRs in intensive care 
unit costs $19,685 compared to $13,994 in a non-Intensive care unit (Cullen et al., 1997). In 
the UK, extended hospital admission resulting from ADRs is estimated to be eight days and 
accounts for approximately 4% of the total capacity of hospital beds, costing the NHS about 
£466m (Pirmohamed et al., 2004). Moura et al. (2009) evaluated the occurrence of ADRs in 
the intensive care unit and assessed their effect on the staying period. Each ADR presented by 
the patient was correlated to a rise of 2.38 days in the intensive care unit (Moura et al., 2009). 
The reasons which constitute the source of financial burden are increased hospitalization, 
prolongation of hospital stay and additional clinical investigations in more serious cases, and 
the out-patient care (Sultana et al., 2013,Field et al., 2005).Furthermore, there are also 
numerous secondary costs for patients and their care givers that are incurred by ADRs, such as 
missed days from work and/or morbidity such as anxiety due to the ADR episode (Wu and 
Pantaleo, 2003) Drug surveillance studies have found that ADRs such as fever, bleeding, 
diarrhoea and cardiac arrhythmia have great economic burden in health care setting (Classen 
et al., 1997). 
1.1.5 Drug Hypersensitivity Reactions 
There is not a single definition of drug hypersensitivity reaction. The terms “drug 
allergy,” “drug hypersensitivity,” and “drug reaction” are often used simultaneously. Drug 
hypersensitivity is defined as an immune-mediated response to a drug molecule in a sensitive 
patient while drug allergy is limited to a reaction mediated by IgE. Drug hypersensitivity 
reactions are also refered to as type B or idiosyncratic drug reactions (Park et al., 1998,Uetrecht, 
1999). These reactions are difficult - to predicted from the known pharmacology of the drug.  
Hypersensitivity drug reactions represent up to one-third of adverse drug reactions (Bates et 
al., 1995, Lazarou et al., 1998, Pouyanne et al., 2000, Smith et al., 1996).  
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Gell and Coombs established their broadly accepted classification of these hypersensitivity 
reactions (Gell and Coombs, 1963). It has been widely accepted that drug hypersensitivity 
reactions are mediated by immunoglobulin (Ig) E or T cells (Johansson et al., 2001) and this 
has also been included in the Gell and Coombs classification (Pichler, 2003) . More recently, 
the European Academy of Allergy and Clinical Immunology and the World Allergy 
Organization suggesteda new and revised nomenclature to differentiate between allergic and 
non-allergic drug hypersensitivity Reactions (Johansson et al., 2001, Johansson et al., 2004). 
1.1.6 Time Course of Drug Hypersensitive Reactions 
To diagnose and treat drug hypersensitivity reactions it is very important to know the time 
course of the appearance of the clinical symptoms. Based on this clinically, drug 
hypersensitivity reactions are classified in to two types. 
1. Immediate: reactions which occur less than one hour after the intake of the drug. 2. Delayed-
type drug hypersensitivity reaction which occur one hour to many days after using the 
medication. (Demoly et al., 2014).  Delayed type are also classified as non-immediate drug 
reactions  (Torres et al., 2003). 
Immediate drug hypersensitivity reactions include IgE-mediated reactions presenting as 
urticaria, angioedema, bronchospasm, or anaphylaxis. Non-immediate drug hypersensitivity 
reactions, which are generally T cell-mediated, include: urticarial, maculopapular, and more 
severe exanthema. However, it is now becoming apparent that adverse events affecting internal 
organs also fall under this definition of drug hypersensitivity, onset of clinical symptoms can 
take minutes, several hours or days after drug ingestion  (Romano et al., 2004) These kinds of 
reactions are related to different immunological mechanisms (IgE or T cells), activated by the 
drug (Pichler, 2003, Torres et al., 2003, Blanca et al., 2009, Romano et al., 2011).  As this 
classification has both mechanistic and clinical implications, some authors consider it 
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problematic to separate drug hypersensitivity reaction  based only on a cut-off of 1 hour 
(Bircher and Scherer Hofmeier, 2012). Moreover, considering that the clinical history is often 
unreliable, it is difficult to establish exactly when the reaction started. In the case of 
nonsteroidal anti-inflammatory drugs (NSAIDs), a consensus has been reached on the 
classification of drug hypersensitivity reaction as acute (immediate to several hours) and 
delayed (>24 hours) (Romano et al., 2011) mainly because most reactions are not mediated by 
a specific immunological mechanism  (Bircher and Scherer Hofmeier, 2012).Difficulties in 
clinical assessment rise when evaluating urticarial reactions, which can be immediate or 
delayed, consequently showing that the same clinical image may develop  by different 
mechanisms (IgE, T cells, or even non-immunological mechanisms, such as those involved in 
NSAID hypersensitivity)  (Cornejo-Garcia et al., 2009). 
1.1.7 Classification of Hypersensitive Reactions 
Gell and Coombs (Romano and Demoly, 2007) classified immune-mediated reactions into four 
types: type I reactions (immunoglobulin E mediated); type II reactions mediated (through 
cytotoxic mechanisms); type III reactions mediated by (immune complexes); and type IV (T- 
cell reactions). Type IV reactions are currently split based on the heterogeneity of T-cell 
function into Types IVa, IVb, IVc and IV d (Pichler, 2003, Posadas and Pichler, 2007).Type 
IV hypersensitivity reactions are mediated by cellular immune mechanisms. The 4 categories 
involve activation and recruitment of monocytes (IVa), eosinophils (IVb), cytotoxic CD4+ or 
CD8+ T cells (IVc), and neutrophils (IVd) (Pichler, 2003).  
Type I hypersensitivity is an immediate immune reaction to an antigen (Sicherer and Leung, 
2009). Mast cells and basophils perform a fundamental role in Type I hypersensitivity 
reactions. Following exposure to an antigen, mast cells and basophils undergo process called 
degranulation, where they discharge substances that promote inflammation. In general, 
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antigens binding to IgE molecules result in mast cells degranulation (Yamasaki and Saito, 
2005). Following mast cell degranulation the released inflammatory mediators include 
histamine, proteoglycans, serine proteases, and leukotrienes (Yamasaki & Saito, 2005). The 
immediate secretions of these inflammatory mediators can cause hives, redness, and 
angioedema (swelling of the throat, eyelids, lips and tongue) in what is referred to as an 
anaphylactic reaction (Noone and Osguthorpe, 2003). Sometimes, the anaphylactic reaction 
could cause blocked airways and heart arrhythmias (Noone & Osguthorpe, 2003). Although 
mast cells play a critical role in immediate reactions, it should be noted that antigens also 
activate B and T lymphocytes promoting IgE antibody production and antibody clone 
switching respectively. 
Type II hypersensitivities, also recognized as cytotoxic hypersensitivities, are infrequent 
reactions that are usually caused by IgG and IgM antibodies (Brostoff et al., 1991). One of the 
reasons for the occurrence of the Type II response is the presence of desired antigen on the 
surface of a host cell and these are reported in most of the autoimmune diseases, drug sensitivity 
reactions, and organ transplantations (Brostoff et al., 1991). The binding of IgG and IgM 
antibodies to host cells is the biochemical basis of type 2 reactions and this binding then form 
complexes, activate the complement pathway resulting in the remocal of host cells (Brostoff et 
al., 1991; Kornbrust et al., 1989). B cells, antibodies, and cytokines are major mediators of 
Type 2 hypersensitivity. They work together to induce cell lysis and eventually death. For 
example, the binding of drugs to the red blood cells of the host can be recognized as foreign 
pathogen. This binding then mediates the proliferation of B cells which then secrete antibodies 
and activate the complement system. All these steps finally lead to cells lysis (Kornbrust et al., 
1989). 
Type III hypersensitivities are also mediated by IgG and IgM antibodies. Unlike a Type II 
response, Type III hypersensitivity is associated with responses to soluble antigens that are not 
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combined with host tissues but with antibodies in the blood which can then lead to 
inflammatory responses (Brostoff et al., 1991). The accumulation of antigen-antibody 
complexes in different parts of the body such as kidneys, skin and eyes induce an inflammatory 
response (Ellsworth et al., 2008). The reports have shown that Type III reactions are also 
involved in certain diseases such as systemic lupus erythematosus (SLE), serum sickness, and 
farmer’s lung. A Type III reaction can take hours, days, somtimes weeks to develop (Coico & 
Sunshine, 2009). 
Type IV hypersensitivities are considered to be delayed-type hypersensitivities because a 
reaction can naturally take one or more days to progress (Brostoff et al., 1991). Type IV 
responses are dependent on T cell interactions, which lead to recruitment of further cells to the 
site of exposure (Brostoff et al., 1991). Upon an initial antigen exposure, naive T-cells 
proliferate and specify into memory T cells after differentiation. Now these newly formed 
memory T-cells go into a dormant state until next contact with the same antigen. This provokes 
a quicker response and in response to new encounter with the same antigen, memory T cells 
instantly multiply and differentiate into the new types of cell called effector T cells. These cells 
then quickly eliminate the antigen or antigen bound cells. A common example of Type IV 
reaction is contact dermatitis. In this reaction lymphocyte proliferation produces local 
inflammation, causing a rash which characterise this condition (Nosbaum et al., 2009).  
New studies have shown a new fifth type of hypersensitivity reaction. It is characterized by 
specific formations called granulomas which is a collection of macrophages and epitheloid 
cells, in the form of a round ball which encapsulate and isolate a pathogen (Rajan, 2003, Tercelj 
et al., 2008). Granulomas are formed in response to antigens that escape the primary phases of 
an immune response and are sometimes correlated to a delayed-type hypersensitivity (Tercelj 
et al., 2008). Table 1.2 illustrates Gell and Coombs classification system. 
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Table 1.2 Gell and Coomb’s classification system 
Adapted from clinical aspects of immunology, textbook, 1975 (Coombs, Gell and Lachmann, 
1975). 
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1.1.8 Diagnosis of Drug Hypersensitive Reactions 
It has been difficult to establish a diagnosis of drug hypersensitive reactions due to its variable 
clinical presentation, overlap with other clinical conditions and the often delayed temporal 
relationship between administration of the culprit drug and the appearance of symptoms 
(Knowles et al., 2000). Lack of a reliable and safe diagnostic test plays a major role in the 
significant morbidity and mortality due to drug hypersensitivity (Neuman et al., 2000, Choquet-
Kastylevsky et al., 2001).  
Diagnosis of non-immediate drug hypersensitivity reactions is complex and is usually made 
once the reaction has disappeared. The allergology examination including clinical profile 
history, skin tests, and drug provocation tests help to recognize the immunological mechanisms 
involved and the drug(s) responsible. In clinical practice, an accurate clinical history including 
the chronology of symptoms is necessary before selecting appropriate diagnostic tests. 
However, the clinical history is particularly difficult in patients with non-immediate drug 
hypersensitivity reaction (Aberer et al., 2003). A number of in vitro diagnostic tests have been 
used to aid the diagnosis of delayed-type drug hypersensitivity reactions (Primeau and 
Adkinson, 2001, Romano and Demoly, 2007, Naranjo et al., 1992, Lan et al., 2006). Among 
these tests are those that apply peripheral blood mononuclear cells (PBMC) as target cells, 
including the lymphocyte transformation test (LTT) and Light transmission aggregoymetry 
(LTA). Skin prick testing, intradermal tests with delayed reading, and patch testing have been 
commonly used for diagnosis. Intradermal tests are frequently optional when a dosage form of 
drugs are injectable form; patch tests are suggested when drugs cannot be diluted. However, 
the sensitivity of skin tests in non-immediate reactions is somewhat low, especially in children 
(Caubet et al., 2011, Padial et al., 2008). Hence, the drug provocation test is regularly the only 
test available, in spite of its inherent risk, it’s time-consuming, and hence associated with 
significant cost, contraindicated in severe reactions such as bullous eruptions or desquamative 
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exanthema. In addition, the interval between drug administration and development of 
symptoms ranges from more than a 1 hour to several days, and the distribution and extension 
of skin manifestations can complicate evaluation of the results (Padial et al., 2008). 
Provocation testing also known as immediate-type skin testing is a traditional method to 
diagnose Type I hypersensitivity reactions. In this method, certain topical antigens are 
challenged and later dermal response of patient is noted. (Smith, 1992). Clinically, provocation 
testing can be dangerous because certain antigens can cause a severe anaphylactic reaction 
(Smith, 1992). An alternative method to provocation testing is skin testing which involves skin 
pricks or patches to determine hypersensitivity. In prick test and scratch test, skin is pricked 
with a needle or pin. The needles contains very small amount of certain antigen whereas in s 
patch test a patch containing known antigens is applied to the skin (Williams et al., 1992). The 
presence of redness or swelling at the site of prick or patch is considered a positive diagnosis 
(Williams et al., 1992). Another way to diagnose Type I hypersensitivity is the 
radioallergosorbent tests (RASTs). The amount of IgE antibody that reacts to specific allergens 
is detected in the RAST (Primeau and Adkinson, 2001); Williams et al., 1992). If this test 
shows high level of IgE to a specific antigen, then that person is considered to be allergic to 
that antigen (Primeau & Adkinson, Jr., 2001). Leukocyte histamine release assays, surface 
markers for basophil activation, and leukotriene release tests are other important tests to detect 
Type I hypersensitivity reactions (Primeau & Adkinson, Jr., 2001). 
Type II hypersensitivity reactions are mediated by IgM and IgG antibody responses to host 
tissues. For instance, Goodpasture syndrome is an autoimmune disease characterized by 
inflammation of the glomeruli in the kidneys and hemorrhaging of the lungs  (Salama et al., 
2001). Good pasture syndrome is diagnosed by measuring IgG antibodies to glomerular 
basement membrane (anti-GBM) (Salama et al., 2001). Another important test is the anti-
neutrophil cytoplasmic IgG antibodies (ANCAs) test which is used to detect various 
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autoimmune disorders that may be connected with Type II hypersensitivities (Radice and 
Sinico, 2005). 
Transplant and blood transfusion patients are mostly prone to Type II reactions and in these 
cases allergy is determined by signs and symptoms of patient or by tissue biopsy (Stapel et al., 
2008). 
Although limited data exists about methods for the detection of Type III hypersensitivity 
reactions, some suggest serum IgG antibody testing can be utilized (Stapel et al., 2008). Recent 
literature on food sensitivities recommends that the most important assay to detect IgG 
antibodies to specific dietary proteins is the enzyme-linked immunosorbent assays (ELISA). 
An increased quantity of IgG antibodies to a specific dietary protein was found to be diagnostic 
for a Type III hypersensitivity to that protein. Cessation from eating the reactive food allergen 
in that case would therefore be recommended. However, further research is necessary to 
confirm this test as a reliable method to diagnose Type III hypersensitivities to various antigens 
including drugs (Scott et al., 1990). 
For the detection of type IV hypersensitivities a number of methods have been developed and 
modified. Although, the role of T cells in hypersensitivity reactions has not received good 
attention in the past, advances in recent research has elucidated and investigated the role of T 
cells in hypersensitivity and it has helped a lot in understanding of delayed-type reactions 
(Primeau & Adkinson, Jr., 2001). This has resulted in the more widespread use of testing for 
diagnosis, for the detection and verification of Type IV hypersensitivity in patients (Primeau 
& Adkinson, Jr., 2001). 
There is much similarity in delayed skin testing and immediate-type skin test, except that 
delayed testing is read after 24 or 72 hours rather than 15 minutes after application of the 
antigens to skin (Li, 2002). There is a great chance the skin testing would pretense the danger 
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of developing adverse systemic reactions therefore proper safety should be ensured while doing 
these tests. (Reid et al., 1993). Although skin testing has been used for a long time and have 
proved reliable in several cases it can still be unreliable in certain cases (Sampson and Albergo, 
1984). Due to the low sensitivity of skin testing particularly with several drugs alternative in-
vitro procedures have now been developed for the detection of Type IV hypersensitivities 
including methods such as the Lymphocyte Transformation Test LTT (Pichler and Tilch, 
2004). 
The in vitro study of the cell response in non-immediate reactions mainly assesses the 
T-cell response. A cellular response relating drug-specific-cell activation could be evaluated in 
vitro by measuring T-cell proliferation (Pichler & Tilch, 2004). However, the readout for T-
cell activation can be changed, for example, flow cytometric lymphocyte activation test, which 
detects upregulation of the activation marker CD69 (Beeler et al., 2008). Furthermore, flow 
cytometry, ELISA and ELI spot can be used to detect drug-specific cytokine release (e.g., IFN-
γ, IL-2, IL-5, IL-8 and IL-12) and the process of these assays are discussed in more detail 
below. 
1.1.8.1. Lymphocyte Transformation Test (LTT) 
The terms lymphocyte transformation test (LTT), lymphocyte stimulation test (LST) and 
lymphocyte proliferation test (LPT) are interchangeably used to describe this technique. The 
in vitro lymphocyte transformation phenomenon was first described during the late 1950s. In 
short, human peripheral leukocytes differentiate in short-term primary cultures, forming blasts. 
Phytohemoagglutinin (PHA), of plant source from red kidney beans (Phaseolusvulgaris), was 
used in early studies to isolate blood peripheral leukocytes (Rigas and Osgood, 1955). PHA 
results in erythrocytes aggregation and sedimentation causing leukocytes to separate from 
whole blood preparations (Minor and Burnett, 1948, Li and Osgood, 1949).   
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Leukocytes are present in peripheral blood at densities of 5-7 X 103 cells/mm3; 20 to 50% of 
these cells are lymphocytes whereas 2 to 10% are monocytes. Lymphocytes are favoured as a 
model for investigation of immune-mediated diseases because of their unique characteristics, 
which include that (i) they are easily obtained at adequate density; (ii) they play a significant 
role in the immune system by orchestrating different elements of the immune response and thus 
representing the state of the immune system in the specific patient; (iii) they are metabolically 
active and expressing most of the enzymes that are required for drug activation and 
detoxication; and (iv) individual genetically-based faults in the expression or activity of these 
metabolic enzymes are phenotypically expressed in lymphocytes (Shear and Spielberg, 1988). 
In the LTT  PMBCs, isolated from drug hypersensitive patients and control subject are cultured 
with non-toxic concentrations of the drug implicated in the reaction. Any increase in the rate 
of cell proliferation measured by [3H] thymidine incorporation is a marker of T-cell activation. 
The increase in cell proliferation is expressed as a ratio between proliferation of cells incubated 
with and without the drug. This ratio is defined as the stimulation index (SI) and it is calculated 
as follows: proliferation due to drug divided by proliferation as result of medium control (Rigas 
and Osgood, 1955). 
The LTT has been utilized by different investigators for diagnosis of prospective drug 
hypersensitivity for more than 20 years (Nyfeler and Pichler, 1997). The sensitivity and 
specificity of the LTT in diagnosis of drug allergy has been estimated to range from 56% to 
78%. These estimates are generally based on cases of reaction to β-lactam antibiotics and 
cannot be extended to all other types of drugs (Luque et al., 2001, Nyfeler and Pichler, 1997). 
Moreover, the sensitivity is much lower when the assay is applied to GP diagnosed or self-
diagnosed reactions, likely due to mis-diagnosis rather than a failure of the assay. 
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1.1.8.2 The lymphocyte toxicity assay (LTA) 
Presented by Spielberg and colleagues (Spielberg, 1986,Spielberg,1984, Spielberg, 1980) in 
the 1980s, the LTA is an in vitro test which uses isolated PBMC to explore the pathogenesis 
of idiosyncraticdrug reactions. The test is based on the hypothesis that idiosyncratic reactions 
develop because of a difference between generation of toxic reactive metabolites 
(metabolicactivation or toxication) and detoxication capacity which leads to increase of 
toxicmetabolites (the “reactive metabolite” hypothesis) (Knowles et al., 2000, Uetrecht, 2007, 
Uetrecht, 2008). In general, the test doesnot use lymphocytes as immunogenic cells but rather 
as surrogate target cells (Spielberg, 1980). It based on incubation of PBMC isolated from the 
patient with the hypersensitive drug in the presence of phenobarbital-induced mouse, rat or 
rabbit liver microsomal 9,000 x g supernatant fraction (S9), as a source of cytochrome P450 
(CYP) monooxygenase activity (Uetrecht, 2008). An increased killing of lymphocytes by the 
generated metabolites,when compared with cells from tolerant controls is taken as dignosis of 
hypersensitivty. 
1.1.8.3 Enzyme-Linked Immunospot Assay (ELISPOT) 
Determination of cytokines is a promising in vitro readout system in the diagnosis of drug 
hypersensitivity reactions (Porebski et al., 2011). Production after T-cell activation, which 
occurs at 24-48 hours, could also make the incubation time shorter than that required for cell 
proliferation in the LTT while conserving its advantages.  The ELIspot assay determines the 
increase in the number of cells producing a specific cytokine after their activation. This 
technique, which is similar to a conventional ELISA, is based on detection of the cytokine by 
a plate-immobilized specific antibody and identification by an enzymatically labeled secondary 
specific cytokine-antibody (Czerkinsky et al., 1988). The resulting plate contains a number of 
spots, each corresponding to a different single cell-secreting cytokine or cytotoxic marker and, 
in theory, any other secreted molecule (Rozieres et al., 2009b, Zawodniak et al., 2010). 
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ELISPOT is highly sensitive in certain subjects and can detect fewer than 25 secreting cells per 
million peripheral blood mononuclear cells. ELISPOT has been used to detect lymphocytes 
secreting cytokines such as IFN-γ, IL-5, or IL-13 from allergic patients in the presence of the 
culprit drug. Recently, this test was also utilized to assess the cytotoxic response in drug 
hypersensitivity reaction by determining the release of granule content (granzymes and 
perforin) and cytokines (IFN-γ) by cytotoxic cells after activation with the hypersensitive drug 
(Rozieres et al., 2009b, Zawodniak et al., 2010). The test showed high sensitivity and 
specificity, although in some cases results did not correlate with the LTT, probably because 
cytotoxicity-based tests measure effector cell function, which is different to the proliferative 
response, where the cell subpopulation activated may be heterogeneous. (Rozieres et al., 
2009b). 
A recent study relating ELISPOT with skin testing in the diagnosis of cephalosporin-
inducedmaculopapular exanthems (MPE) revealed that measuring both IFN-γ and IL-5 is more 
sensitive than skin testing for the diagnosis of cephalosporin hypersenstivity (Tanvarasethee et 
al., 2013). Therefore, quantification of cytokines such as IL-2, IL-5, IL-13, and IFN-γ is a 
promising diagnostic tool in most drug hypersensitivity reactions, although further studies are 
needed with larger series of hypersenstive patients and controls to evaluate the sensitivity and 
specificity of the technique, together with appropriatecutoffs to be used. (Porebski et al., 2011). 
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1.1.8.4 Flow cytometry 
Flow cytometric analysis of intracellular cytokines has been used as a general scientific 
application in many cell types in domains such as immunology and rheumatology (Schuerwegh 
et al., 2003). In the study by Martin et al, IL-5/IL-10/IFN-γ measurement with flow cytometry 
and IL-5/IL-2/ IFN-γ with ELISA were evaluated in the PBMC of 19 patients after stimulation 
with the hypersensitive drug (Martin et al., 2010). Drug hypersensitivity was proved by 
stringent history taking. Drug-specific cytokine production by peripheral blood mononuclear 
cells was confirmed in 75% of the patients using flow cytometry and in 79% using ELISA, 
respectively. The combination of flow cytometry and ELISA increased the sensitivity to 100%. 
Other comprehensive studies are required to consider whether a specific-cytokine or 
combination of cytokines is best suited for the diagnosis of drug hypersensitivty. (Nyfeler and 
Pichler, 1997). 
1.1.8.5 T- cell cloning 
T cell cloning is used to determine the involvement of drug specific T lymphocytes in 
hypersensitive patients (Zanni et al., 1998). It is highly valuable tool for studying the way in 
which T cells recognise drugs and the function exerted by drug specific T cells in vivo on drug 
specific stimulation (Pichler et al., 1998). Using the well-established method of serial dilution, 
single T-cells can be expanded and antigen specifcity assessed (Mauri-Hellweg et al., 1995; 
Staszewski, 1984). T-cell clones can then be fully characterised in terms of phenotype, for the 
expression of specific markers, proliferative capacity and their cytokine secretion prolife. 
These studies help to discover the patho-mechanism of drug hypersensitivity. 
1.1.9 Cutaneous Drug Reactions 
In non-immediate drug hypersensitivity reaction, the skin is most commonly involved; other 
sites might not be included (Caubet et al., 2011). The clinical appearances are different 
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depending on the immunological mechanism involved, although maculopapular exanthema 
(MPE) and delayed urticaria are the most recurrent reactions observed (Fernandez et al., 2009, 
Metz and Maurer, 2009). Other, more severe reactions include acute generalized 
exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms 
(DRESS), bullous eruptions such as erythema multiforme, Stevens-Johnson syndrome (SJS), 
toxic epidermal necrolysis (TEN) (Blanca et al., 2000, Ramirez-Gonzalez et al., 2009), fixed 
drug eruption (FDE), contact dermatitis  (Bos and Kapsenberg, 1993), and serum sickness–like 
syndrome (Naisbitt et al., 2007). 
The main reason why a drug administrated orally or parenterally affects the skin is not known, 
although immunological mechanisms and/or the drug metabolism capacity of cutaneous 
cellular components may be involved (Blanca et al., 2000, Naisbitt et al., 2007). The skin was 
traditionally thought to be no more than a physical and biochemical barrier protecting the 
organism from outside agents, but in the last decade it has been revealed to have a role in the 
immune response. The cellular composition of the skin includes mast cells, macrophages, 
dermal dendritic cells, keratinocytes, and Langerhans cells, which are capable of producing 
cytokines that enhance recruitment of other cells that are part of the dynamic component  (Metz 
and Maurer, 2009, Ramirez-Gonzalez et al., 2009). These cells include antigen presenting cells 
(APC), such as Langerhans cells, dendritic cells, monocytes, and macrophages, as well as T 
lymphocytes expressing skin-homing receptors, such as the cutaneous lymphocyte antigen 
(CLA) and various chemokine receptors (eg, CCR10, CCR4, CCR6), which constitute the 
cellular basis of the immunological memory in the skin  (Fernandez et al., 2009, Blanca et al., 
2000, Bos and Kapsenberg, 1993). 
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1.1.9.1 Maculopapular Exanthema (MPE) 
MPE consists of diffuse cutaneous erythema with areas of skin elevation. MPE may evolve to 
become vesicular or papular as part of a more severe clinical entity. There is also a possibility 
that different degrees of angioedema with involvement of subcutaneous tissue may also appear.  
Few studies have been carried out over the last 10 years on the mechanisms of other identities 
with the exception of drug allergy.  MPE reactions are commonly caused by drugs, various 
viruses with skin tropism, such as cytomegalovirus, parvovirus, Coxsackie’s virus, 
paramyxovirus, toga virus and several types of herpes, such as varicella zoster, HHV6 and the 
gamma herpes virus of infectious mononucleosis.  MPE can also be observed in different 
bacterial diseases, in patients with lymphoma, in graft versus host disease and in diseases with 
other causes, such as physical agents. Further studies from Fernandez and his colleagues (2009) 
have shown that cytokine patterns that present themselves in maculopapular exanthema have a 
Th1 or Th0 pattern in accordance with whether the reaction is drug-induced or virus-induced 
and whether CD4+ T-lymphocytes having cytotoxic capabilities are prevalent (Fernandez et al, 
2009). 
Usually accompanied by homogeneous redness of the skin with variable degrees of 
subcutaneous involvement including oedema, MPE consists of maculopapules of different 
sizes elevated over the skin.  Skin lesions usually subside if the drug is stopped soon after the 
appearance of symptoms. Even in patients who are taking the drugfor a long time, exanthema 
does not usually develop to more severe diseases although some scleroderma-like lesions that 
have the potential to be induced by skin fibrosis may appear. The MPE evolves to clearly 
distinguish vesicular lesions when the exanthema forms part of another disease.  Themost 
severe of these vascular lesions are those appearing in the complex Stevens–Johnson–
syndrome. (Fernandez et al, 2009). 
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1.1.9.2 Acute Generalized Exanthematous Pustulosis (AGEP) 
Acute generalized exanthematous pustulosis is a rare drug-induced skin reaction characterised 
by a sudden skin eruptions (Amante et al 2009). According to Sidoroff (2001) acute generalised 
exanthematous pustulosis is distinguished by many non-follicular sterile pustules occurring on 
a diffuse and edematous erythema particularly in the on the face. In addition, patients suffering 
from these symptoms may show signs of fever and have an elevated level of blood neutrophils. 
Onset of the condition has been shown to be extremely acute, with symptoms becoming 
prevalent following the intake of the drug.It should be noted however, that viral infections can 
also trigger onset of the disease. Upon successful diagnosis and discontinuation of the drug 
course, symptoms such as fever and the pustules normally disappear within two weeks. In rare 
cases if left untreated mortality is observed in 5% of patients (Sidoroff et al. 2001).The onset 
of acute generalised exanthematous pustulosis involved the drug-specific activation of IL-8 
secreting T-lymphocytes that recruit neutrophils to the site of the reaction commonly caused 
by the ingestion of anibiotics such as aminopenecillins and sulfonamides (Sidoroff et al. 2007). 
1.1.9.3 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) 
DRESS is also known as the drug hypersensitivity syndrome (Amante et al 2009).  Patient with 
this condition may manifest with symptoms such as high fever, skin rashes, malaise, 
lymphadenopathy and possible damage to multiple internal organs. With respect to this 
syndrome, liver damage is most common and this can often lead to fulminant hepatitis.The 
recruitment of eosinophils which is mediated through T-cell derived IL-5 is characteristic of 
DRESS. A systemic immune response can be elicited by the causative drug.  This can result to 
the reactivation of human herpes viruses, HHV-6 and HHV-7. According to Picard (2010), 
76% of affected patients experienced a reactivation of the herpes virus when affected by an 
offending drug. (Amante et al 2009). The link between viral reactivation and symptoms in the 
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course of DRESS is often used as diagnostic procedure (Suzuki et al., 1998; Tohyama et al., 
1998). However, the role of viral reactivation in the pathophysiology of the disease and if it is 
a concern of the clinical manifestations is not known. Reactivation of human herpes virus 6 
(HHV-6) is not ususally measured for many weeks after symptoms appeared (Shiohara et al., 
2006). Therefore, it is possible that viral reactivation alter a late CD8+ T-cell reponse 
activation. Transient increases in virus-specific immunoglobulins against HHV-7, Epstein-Barr 
virus (EBV) and cytomegalovirus (CMV) have also been detected in patients with DRESS 
(Aihara et al., 2001; Descamps et al., 2003; Picard et al., 2010). Cells from skin lesions have 
been analysed and found to contain high levels of HHV-6 DNA and express viral antigen at an 
early stage (Suzuki et al., 1998). It would be likely that certain clinical manifestations result 
from virus-specific T-cells expansion (Shiohara et al., 2006). And it is therefore possible that 
drugs activate CD4 cells, while viruses activate CD8 cells and both contribute to the 
pathogenesis of the disease. 
1.1.9.4 Stevens - Johnson syndrome (SJS) 
Several uncommon but life-threatening cutaneous adverse reactions such as SJS and toxic 
epidermal necrolysis (TEN) are most frequently caused by drug exposure. Widespread 
epidermal necrosis, resulting in flaccid bullae with epidermal shedding and regular 
involvement of the mucous membrane characterize both of these diseases. Both diseases in 
general improve within several days after the withdrawal of the causative drug. However, it is 
not clear whether these diseases are distinct from each other or simply variants of a related 
disorder. Both the diseases are considered as belonging to such a category as they both involve 
severe epidermolytic effects cutaneous drug reactions that differ only by extent of skin 
detachment (Kim et al. 2014). 
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1.2 The Immune System 
The organ system that decides whether or not an antigen is part of a growing pathogen 
population is the immune system. This system ensures the wellbeing of an organism by 
detecting the invaders and distinguishing them from healthy tissues of the body (O'Byrne and 
Dalgleish 2001). 
The ability of the immune system to distinguish between non-threatening agents and hostile 
invaders is primarily based on pattern recognition.  Studies aimed at identification or mapping 
of pattern recognition receptors (PRRs) have led to identification of chemical structures which 
receptors can recognize and bind to. Classes of microorganisms which stimulate these chemical 
structures have also been identified. Following the discovery of Toll-like receptors (TLRs) in 
1990s, these receptors have assumed a prime position in immunological research. It is now 
well known that when activated TLRs can trigger a rapid immune response. TLRs recognize a 
wide variety of molecules including glycoproteins, liposaccharides, and nucleic acids. Studies 
involving the adaptive immune system have revealed the role of T-cell receptors and B-cell 
receptors in the identification of characteristic short sequences of amino acids (or epitopes) 
which serve as antigen (Bewick et al 2009).   
The immune system in organisms can be divided into two subgroups: (i) innate immune system, 
and (ii) the adaptive immune system.  In the early stages of invasion, the innate immune system 
protects the body and in later stages protection is mediated by the adaptive immune system. 
The different components of adaptive and innate immune systems together protect the body 
against foreign entities. The adaptive immune system is more specific in response to antigens 
than the innate immune system (Market and Papavasiliou 2003). 
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1.2.1 The Innate Immune System 
The innate immune system is the non-specific first line of defence in the body system. There 
are two main components of innate immune system: the humoral and the cell-mediated 
responses. The humoral component includes inflammatory mediators, cytokines, coagulation 
cascades and the complement system, while the cellular component includes phagocytes, 
eosinophils and killer cells (Kumar et al. 2011).  
The key role of the innate immune system is to recruit the immune cells to the site of invasion. 
This is done by the production of various cytokines and the activation of the complement 
cascade in order to identify bacteria, activate cells and promote the clearance of antibody 
complexes or dead cells (Janeway et al. 2001). The innate immune system can also activate the 
adaptive immune system through the process known as antigen presentation (Janeway et al. 
2001). This process starts by setting an initial signal with antigens stimulating innate immune 
system via, for example, Toll-like receptors (TLRs) on dendritic cells. The activated dendritic 
cells then act as antigen presenting cells (APCs) as they process antigens and present in the 
form of peptides antigens to T cells. (Pichler 2008). 
1.2.2 Cellular Components of the innate immune System 
Innate immune system is equipped with a number of cell types which help to initially 
eliminate the pathogens and further activate the adaptive immune system. These cells include 
neutrophils, eosinophils, basophils, mast cells, macrophages, monocytes, natural killer cells 
and dendritic cells. (Janeway et al. 2001). 
Natural Killer Cells: Natural killer (NK) cells are a central component of the innate 
response. They release granulysin after activation and are believed to act in unison with 
cytotoxic T cells to initiate tissue damage in patients. NK cells respond rapidly after exposure 
to virally infected cells in the absence of MHC restriction and T-cell receptor signaling. In 
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recent times Schlapbach et al. (2011) demonstrated that NK cells expressing granulysin make 
up a significant quantity of the cellular infiltrate in many forms of cutaneous ADR. Therefore, 
it is possible that NK cells contribute toward the tissue injury in patients with drug 
hypersensitivity. (Tewary et al., 2010). 
Granulocytes: These are also called polymorphonuclear leukocytes. A subcategory of 
white blood cells, these cells are characterized by the presence of granules in their 
cytoplasm.These cells include neutrophils, eosinophils, basophils and mast cells. The granules 
in these cells contain cytotoxic chemicals that digest the microorganisms. The most aboundant 
granulocyte are neutrophils. The cytokine IL-8 stimulates these cells and causes their migration 
towards the infected area. (Ovchinnikov, 2008) 
Eosinophils: are important in parasitic infections. IL-5 and some exotoxins stimulate 
the eosinophils and they move to the site of infection or damage where they cause the 
destruction of parasitic pathogens with the help of toxic chemicals found in their 
granules.Within blood, basophils are the least abundant of granulocytes and their granular 
contents include histamine, heparin, chondroitin sulphate, and peroxidase enzymes as 
important constituents. Upon activation they cause the release of histamine which plays an 
important role in inflammatory response. (Ovchinnikov, 2008) 
Macrophages:  These are phagocytic cells. They engulf pathogens by the process 
known as phagocytosis and kill and digest them with the help of toxic chemicals present in 
their lysosomes. They also act as antigen presenting cells where they present processed 
antigens to helper T cells. Macrophages are characterized by the presence of CD14, CD40, 
CD11b, CD64 and CD68 markers and they are found in almost every tissue (Ovchinnikov, 
2008). There are various activated forms of macrophages (Mosser and Edwards, 2008) and 
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they are divided broadly into two groups M1 and M2 based on different effect function 
(Galdiero et al. 2013). 
Dendritic cells:  Also known as accessory cells in traditional literature, dendritic cells 
are professional antigen presenting cells and are important components of the immune system. 
They are found in two distinct forms in the body, as mature and immature forms (Mellman and 
Steinman, 2001). Immature dendritic cells are mostly found in peripheral tissues and they are 
poor presenters of antigens to T cells even if they express both MHC I and MHC II. Upon 
activation by pro-inflammatory cytokines or pathogen-derived TLR ligands, dendritic cells 
mature and migrate  to the T cell rich lymphoid organs where they stimulate memory and naïve 
T cells responses through much more efficient antigen presentation (Hammer and Ma 2013). 
1.2.4 The Adaptive Immune System 
When the body is confronted with pathogenic infection or injury, both the innate and 
adaptive immune systems become active in order to maintain homeostasis. These defence 
systems monitor tissues of the vertebrate body by using complex mechanisms to identify the 
threats and take measures to overcome those threats. The two types of defences differ in their 
arsenals and mechanisms. The adaptive immune system aims at prolonged protection over a 
period of time and with great specificity against the danger.  Both means of defence have some 
coordination in order to protect against over expression of defence reaction by enhanced 
inflammation. The immune system has been described as an outcome of evolutionary process 
which distinguished ‘infectious non-self’ from ‘non-infectious self’. This paradigm can be used 
to devise a classification system comprised of adaptive immune responses of five different 
types. Nucleotide-binding oligomerization domain containing receptors or NOD-like receptors 
(NLRs) regulate their responses to these types based on the origin of target antigen: (i) 
antimicrobial immunity, where the target comprise of pathogens antigens, (ii) allergies, 
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involving targets from non-pathogenic sources, (iii) autoimmunity, involving targets within the 
self, (iv) tumor immunity, involving altered self-targets, (v) commensal homeostasis, involving 
foreign self-targets. In each of these response categories, the role of NLRs is different. Due to 
the difference in the source of initiation of immunity, the host response is also different. 
(Charles Janeway 2001). The adaptive immune system, also known as the acquired or specific 
immune system, is a subsystem of the overall immune system that acts to ensure a much faster 
response with regards to the interaction with antigen based on immunological memory. Its main 
function is to destroy invasive pathogens and their toxic products. Cellular and molecular 
interactions occur between the innate immune system and the adaptive immune system which 
allows the innate immune system to activate adaptive immune responses. The adaptive immune 
system differs from the innate immune system in that its responses are highly specific with 
regards to pathogens, with the adaptive immune system capable of providing long-lasting 
protection against disorders. The majority of responses within the adaptive immune system are 
mediated by B and T-lymphocytes, with B-cells being activated in reactions to secrete 
antibodies that will travel through the bloodstream, binding to foreign agents, thereby rendering 
them inactive.  The adaptive immune response can be divided further into a cellular (cell-
mediated) response or a humoral (antibody-mediated) response. Cell-mediated immunity is by 
induced cytotoxic T-lymphocytes that lead to apoptosis of target cells. Humoral immunity can 
be mediated by B-cell production of antigen-specific antibodies (Alberts et al. 2002). 
1.2.5 Cellular Components of the Adaptive Immune System 
T Lymphocytes. Naive CD4+ T lymphocytes differentiate into Th1, Th2, Th9, Th17, 
or Th22 effector cells after antigen exposure (Fig 1.2). The panel of cytokines naïve cells are 
exposed to at the time of priming determines the nature of the effector T-cell response and the 
functional consequences of antigen exposure (Akdis and Akdis, 2009). The classification of 
CD8+ T-cells is much simpler, based on the release of cytolytic molecules (Fas ligand, perforin, 
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granzyme B, granulysin) after antigen stimulation. Cutaneous drug reactions have been 
classified according to the phenotype of drug responsive T-cells isolated from peripheral blood 
of sensitive patients and the cytokine secretion profile (Pichler, 2003).  Keratinocyte damage 
in patients with maculopapular reactions involves CD4+ and CD8+ T cells, and Th1 and Th2 
cytokine release is readily demonstrable (Kuechler et al., 2004, Yawalkar and Pichler, 2001, 
Rozieres et al., 2009a). IFN-γ-secreting cytotoxic CD8+ T cells dominate in bullous skin 
reactions and DRESS (Naisbitt et al., 2003; Nassif et al., 2004Ko et al., 2011, Wu et al., 2007). 
IL-5, which is implicated in eosinophil recruitment and activation, is determinable in drug-
stimulated T-cell cultures from patients with DRESS. Pustular reactions involve CD8+-
mediated cytotoxicity and secretion of the neutrophil chemoattractant IL-8 (Britschgi et al., 
2001).  Chung et al., 2008 showed that granulysin is acritical cytotoxic molecule released from 
T cells in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and proposed 
that high expression of granulysin in this group of patients could be the reason severe reactions 
develop. On the other hand, a latest study shows that granulysin is secreted from drug-specific 
T cells isolated from patients with mild, moderate, and severe cutaneous reactions (Schlapbach 
et al., 2011). However, it should be noted that, this classification is basically based on a 
snapshot of the memory T-cell response, frequently many years after the clinical reaction 
decreases. Further studies are required to compare the nature of the T-cell response at the time 
of drug exposure, during the hypersensitivity reaction, and in the long period of treatment, as 
the patient recovers (Naisbitt et al., 2003). 
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Figure 1.2 The overall development of T-cells from naïve CD4+ T-cells. CD4+T cells show remarkable 
plasticity and are able to differentiate into many different subsets based on the soluble molecules secreted during 
priming of the subsets by antigen presenting cells (APC), e.g., IL-12 for TH1 cells. The different subsets can be 
distinguished by the transcription factors that regulate and maintain their lineage-specific effector functions, e.g., 
T-bet for TH1 cells. The molecules secreted by these subsets, e.g., IFN-γ for TH1 cells, are fine-tuned to control 
the pathogen that mediated the release of the specific molecules by the APC during activation of the naive cells 
into the various subsets. 
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The adaptive immune system is also implicated in Idiosyncratic Adverse Drug Reactions that 
target the liver. However, the role of T cells in drug-induced liver injury is not well 
documented. Histologic investigation of liver from a patient with sulfasalazine-induced liver 
injury showed an infiltration of granzyme-B secreting T lymphocytes (Mennicke et al., 2009). 
The phenotype and function of T cells from patients with flucloxacillin-induced liver injury 
have previously been investigated (Monshi et al., 2013). Flucloxacillin exposure is related to a 
high incidence of cholestatic liver injury. Peripheral blood mononuclear cell responses against 
the drug were detectable in 5/6 patients using an IFN-γ secretion (ELIspot) assay. T-cell 
cloning revealed that the majority of flucloxacillin responsive T- cells were CD8+. Drug –
specific T-cells secreted IFN-γ, and cytolytic molecules, including FAS ligand, perforin, and 
granzyme B (Monshi et al., 2013). 
B Lymphocytes. Restimulation of antigen-specific memory B-cells leads to a rapid increase 
in serum antibodies. Antigen-specific B-cells also effectively present peptide fragments to 
specific T cells (Lanzavecchia, 2007). Enhanced antigen presentation is dependent on 
membrane-associated antibodies that sequester and concentrate the antigen prior to processing. 
Solubleantigen-bound antibodies have also been shown to modulate the presentation of peptide 
antigens to T-cells. The impact on the T-cell response by enhancing antigen capture and 
delivery by modulating processing pathways, hence suppressing the generation of main 
antigenic determinants and by preventing processing (Watts and Lanzavecchia, 1993). Many 
studies haveutilised drug-protein conjugates to identify anti-drug antibodies in certain tolerant 
and allergic patients (de Haan et al., 1986, Christie et al., 1988, Daftarian et al., 1995, Torres 
et al., 1997). However, the dynamics of the drug antigen-specific humoral response and the 
kinetics of antibody production have not been defined (de Haan et al., 1986). It is now 
understood that IgG4 antibodies play a central role in immune regulation after grass pollen 
immunotherapy (James et al., 2011). It is believed that IgG4 antibodies are produced by B cells 
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under the regulation of allergen-specific regulatory T cells that appear during immunotherapy 
(Satoguina et al., 2008). Suppressive IgG4 antibodies are believed to directly inhibit facilitated 
antigen presentation to T lymphocytes. It is therefore important to reflect on the critical roles 
played by specific IgG antibody subclasses in drug reaction (van Neerven et al., 1999). 
1.3 Mechanisms of Drug-Specific T-lymphocyte Activation 
        In drug hypersensitivity reactions, the pathomechanism(s) of T-cell activation is still not 
clear. Many drugs are not protein reactive and metabolic activation is needed to produce an 
electrophilic intermediate with the capacity to haptenate protein. Most of the drugs that cause 
a high incidence of hypersensitivity form reactive metabolites and there appears to be some 
association between the extent of metabolic activation and the potential that administration of 
a drug will be linked with hypersensitivity (Manchanda et al. 2002). 
Antigen processing and presentation are key pathways in the activation of T-cells. During this 
process an antigen is ingested by an antigen-presenting cells (APC) and is digested into peptide 
fragments that are then displayed on the surface of cell by complexing with molecules called 
the major histocompatibility complex. Most of the cells in the body express MHC and can act 
as APC, but macrophages, lymphocytes and dendritic cells are considered professional antigen 
presenting cells.  
The intracellular proteins are processed into shorter peptides by a number of enzymes in an 
organelle known as the proteasome (Meissner et al., 2010). The proteasome is a large organelle 
of the cell with complex structure consisting of a number of subunits. The two prominent 
subunits which play a critical role in the processing of the proteins are LMP2 (Large 
Multifunctional Protease-2) and LMP7 (Large Multifunctional Protease-7).These subnits are 
encoded within the MHC locus. One of the initial steps in degradation of proteins is the binding 
of the proteins with a rather smaller but specialised protein known as ubiquitin. Then this 
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ubiquitin protein complex is targeted towards the proteasome for further processing. Once 
proteins interact with the proteasome, LMP2 and LMP7 subunits induce the proteolytic 
complex of proteasome to cut the proteins and generate smaller peptides. The resulting peptides 
bind to MHC-I molecules. The actual processing takes place in the specialized area of 
proteasome known as channel of proteasome. From proteasome the Peptides move towards 
cytosol and finally are transported into the RER (Rough Endoplasmic Reticulum). Inside ER 
the peptides interact with MHC molecules (Rizvi and Raghavan, 2010).This transportation is 
carried out by a transmembrane heterodimeric protein called TAP (Transporters Associated 
with Antigen Processing). The peptides which are present in RER and are ready to bind with 
MHC consist of 8–13 amino acids. A crucial protein known as tapasin tethers the MHC-I 
molecules to the TAP transporter, and peptides are then loaded onto the MHC-I molecule. In 
the final step the peptide and MHC1 complex is   transported to the cell surface where CD8+ 
T-cells recognize and bind to it (Neefjes et al., 2011). 
 
The mechanism of processing exogenous or extracellular antigens is a bit different. Frist, 
antigen presenting cells (APCs) such as macrophages, dendritic cells and B-cells internalize 
these extracellular antigens. This process of internalization is called phagocytosis or 
endocytosis. The antigens are then processed and are transported to the surface of cell in 
combination with MHC II molecules. (Jensen, 2007). 
 
Once the antigens have been internalized they pass through three acidic endosomal 
enviroments step by step with each next step more acidic than the previous one. These steps 
are early endosomes (pH 6.0–6.5), late endosomes (pH 5.0–6.0) and lysosomes (pH 4.5–5.0). 
Hydrolytic enzymes are present in all three stages which work in acidic environment and 
degrade proteins into smaller peptides consisting of 13–18 amino acids. Class-II Alpha and 
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Beta chains associate within the RER. A specialized protein known as the Ii (Invariant Chain) 
plays a key role in preventing endogenous peptides from binding to MHC II. This protein  also 
plays a crucial role in many other funtions including: 1. Folding of α and β chains, 2. Exiting 
the peptide MHC complex from the ER, 3. Targeting to the endocytic compartments. Other 
than that Ii also helps in transporting the Class-II heterodimer to the late endosomal 
compartments: MIICs (MHC-Class II Compartments) where peptides and MHC-II molecules 
are complexed with each other. Ii is then degraded by a specialized enzymes called proteases 
(Cathepsins). The end product of this degradation is small fragment called CLIP (Class II-
associated Invariant Chain Peptide). These CLIPs keep attached with the peptide-binding cleft 
of MHCII and help to preventing the premature interaction and binding of partially processed 
antigens. Another vesicle membrane protein, known as HLA-DM removes the CLIP from 
peptide binding cleft so that new completely processed peptides could bind there. The MHC-
II-peptide complex then moves to the plasma membrane where the neutral environment 
stabilizes it and presents the peptide to CD4+ T-cells (Costantino et al., 2012). Figure 1.3. 
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Figure 1.3 Antigen presentation Antigen processing is divided into two pathways. Extra-celluar and intra-
cellular pathways. Extracellular antigens are engulfed by phagocytosis and degraded by endosomal enzymes. 
MHC class II molecules are transported in vesicles coming from the endoplasmic reticulum (ER) and Golgi 
apparatus. These vesicles fuse together with the phagolysosome and this is where loading of peptide occurs. The 
peptide bound MHC is then transported to the surface of the cell where the antigen is displayed. Intracellular 
antigens are broken down in the proteasome. Peptides are transported to the ER through TAP and attach to MHC 
class I molecules. The peptide bound MHC is then transported again to the Golgi where it is loaded into a vesicle 
and trafficked to the surface of the cell. Adapted from (Neefjes et al., 2011). 
 
The three theories which explain the role of T-lymphocytes in the drug-specific activation and 
ADRs are the hapten theory, p-i concept and altered-self peptide concept. Figure1.4 
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Figure 1.4 Pathways of drug-specific T-cell activationA) Hapten hypothesis where drug or metabolite 
binds covalently and modifies target proteins. Peptide fragments are presented by MHC molecule to the TCR on 
T-cells. Presentation throughout MHC I provokes a CD8+ T-cell response while MHC II presentation elicits a 
CD4+ T-cells response. Sometimes the drug or a metabolite modifies the MHC-peptide complex directly for 
presentation to T-cells. B) p-I hypothesis where drug or metabolite binds directly to the TCR and/or MHC 
molecule in a non-covalent way, so provoking an immune response. C) Altered peptide hypothesis where 
interaction of peptide with HLA molecule and TCR. Consequently, the presence of drug within the peptide binding 
groove of the HLA molecule alters the repertoire of peptides presented by the HLA to the TCR to initiate the 
immune response/hypersensitivity. 
 
1.3.1 Hapten Hypothesis 
By definition hapten are drugs of molecular weight less than 1000D and as such are very small 
to induce an immune response an their own (Pichler 2008). However, when hapten molecules 
are attached to a larger molecule like proteins they can act as antigens that mightelicit a 
pathogenic immune response. The hapten hypothesis is considered by some as the most 
plausible explanation of hypersensitivity reactions occurring due to the administration of drugs. 
When a hapten or its metabolite covalently binds to a protein (haptenization) it may cause cell 
stress leading to the secretion of cytokines. (Pichler, 2008). 
 
The haptenated protein is recognised and taken up by professional antigen presenting cells 
(e.g., Langerhans cells in skin). The main function of these cells is to screen the cutaneous 
atmosphere for the presence of antigenic stimuli (Gorbachev and Fairchild, 2001). Antigen 
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loaded antigen presenting cells migrate to local lymph nodes, where they prime naïve T cells 
with drug-modified peptides derived from enzymatic antigen processing (Kalish, 1995) 
Fragments of drug-modified peptides are presented on major histocompatibility complex 
(MHC) molecules to naïve T cells (Fig 1.5). Clonal T-cell expansion lead to a population of 
antigen-specific T-cells that migrate to skin following the repeat exposure to target antigen. 
Secretion of cytokines and chemokines from inflamed skin and activated T- cells control the 
nature of the cellular immune response and the extent of tissue damage (Sebastiani et al., 2002).  
Variation in balance between bioactivating and detoxifying pathways which leads to increased 
covalent adduct (hapten) formation is thought to be an important factor determining 
susceptibility to hypersensitivity. However, genetic polymorphisms in enzyme expression have 
been shown not to have a major impact on susceptibility (Umamaheswaran et al. 2014). Drug-
protein-adduct can act as immunogen, with the potential to induce immune responses against 
drug-modified or native proteins. At present, this “hapten hypothesis” is the common model 
used by most groups exploring drug hypersensitivity reactions including halothane hepatitis  
(Bourdi et al., 1996) tienilic acid hepatitis (Lecoeur et al., 1996)1, dihydralazine hepatitis 
(Bourdi et al., 1994) diclofenac hepatotoxicity (Hargus et al., 1994) β-lactam hypersensitivity, 
sulfonamide hypersensitivity (Shear et al., 1986), and certain forms antiepileptic drug 
hypersensitivity syndrome (AHS)(Shear and Spielberg, 1988, Pirmohamed et al., 1991, Leeder 
et al., 1992). 
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Figure 1.5 The general mechanistic pathway by which the hapten hypothesis is theorised to 
operate.Drug metabolism leads to covalent modification of protein. Protein are processed inside the cell, cleaved 
into peptide fragments and linked with MHC molecules then displayed to the cell surface. The T-cell receptor will 
then recognise the MHC/peptide complex. Antigens generated externally, attach to MHC class II molecules and 
stimulate a CD4+ T-cell response. Antigens generated inside the cell are processed through a proteasomal 
pathway, attach to MHC class I molecules, and stimulate a CD8+ T-cell response. According to the inflammatory 
stress hypothesis, IDILI-associated drugs interact with an otherwise benign episode of inflammation to precipitate 
liver injury. 
 
 
1.3.2 Pharmacological Interaction of Drugs with Immune Receptors (PI Concept) 
Beta-lactams need protein processing before antigen presentation, but other drugs have been 
found to directly bind to MHC and produce a T-cell response. Recent research suggests that 
drugs produce immune reactions by direct and reversible binding to MHC T-cell receptors. 
This theory is named the P-I concept. According to Adam (2011) the P-I concept states that “a 
drug is able to stimulate T cells directly without forming a hapten, in a HLA-dependent 
manner.” The concept was instrumental in explaining how some drug produce delayed 
hypersensitivity within a few hours of exposure.  Drugs which have been proven to produce 
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this kind of specific labile binding are lidocaine, sulfamethoxazole, lamotrigine and 
carbamazepine (Posadas& Pichler 2007). In addition, glutaraldehyde-fixed cells which don’t 
process proteins still allow for T-cell activation by specific drugs. The kinetics of T-cell drug-
specific triggering are also too rapid to allow for antigen processing as a mechanism activation  
( Schnyder et al 1997; Hashizume et al 2002; Wu et al 2006; Keller et al 2010 ). The P-I concept 
describes a way in which  drugs lacking hapten characteristics can bind directly with the antigen 
presenting cells and stimulate T-cells (Pichler 2008) (Figure 1.4). 
1.3.3 Altered Self-Peptide Repertoire Model 
 In 2002, Mallal and his colleagues were the first group to describe the correlation between 
abacavir hypersensitivity syndrome and HLA-B*57:01(Mallal et al. 2002). The authors found 
that HLA-B*57:01 was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, 
and in 4 (2%) of the 167 were abacavir tolerant patients. Subsequently, abacavir 
hypersensitivity was found only in patients expressing HLA-B*57:01, suggesting that the drug 
binds with specificity to the HLA-B*57:01 locus. This binding changes the chemical and 
stereochemical shapes of the antigen-binding cleft, which automatically alters the range of self-
peptides that can bind to the groove. Thus 'immunological self’ is altered, leading to CD8+ cell 
activation and autoimmune reactions, which present as the abacavir hypersensitivity reaction 
(Illing et al., 2012; Norcross et al., 2012; Ostrov et al., 2012). These experiments defined the 
‘‘altered self-peptide repertoire model’’ of abacavir hypersensitivity.  
1.3.4 Danger Hypothesis 
The danger hypothesis proposed by Matzinger in 1994 suggests that pathogens and damage 
associated molecular parterns (DAMPS) play a critical role in immune activation  (Matzinger, 
2002). The immune system is more concerned with potential danger than foreignness 
(Gruchalla, 2001). Consequently an exogenous pathogen or chemical, or an endogenous 
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intracellular molecule secreted from necrotic cells, could not stimulate an immune response 
unless the immune system detects ‘danger’ (Matzinger, 1994, Pirmohamed et al., 2002, Li and 
Uetrecht, 2010). In the absence of danger, tolerance will result. Therefore, it is hypothesized 
that exposure to signals such as chemicals, drugs or infectious agents can trigger or amplify the 
innate immune response, with potential to activate the adaptive immune system. There are three 
signals essential for adaptive immune activation, signal one is also called the antigenic signal, 
and antigenic dererminants are presented to TCR in an MHC restricted manner. Signal two or 
co-stimulation occurs via the interaction betweenCD28 on the T cell and CD80 and CD86 
molecules on the DC. Signal three derives from cytokines secreted by DC and are responsible 
for the differentiation and polarization of T-cell differentiation into various effector phenotypes 
such as Th1 and Th2. Fig 1.6 illustrates danger hypothesis. 
 
Figure 1.6: Danger signaling and drug hypersensitivity.Signals may come from chemicals exposure, 
physical trauma and /or infections. In drug-induced hypersensitivity syndrome, danger signalling lead to secretion 
of polarising cytokines that result in either Th1, Th2, Th17 or Th22 immune responses. Chemically reactive drug 
metabolites lead to an antigen (signal 1) in presence co-stimulatory B7 and CD28 to induce cell damage resulting 
in the generation of signal 2 and 3 required for an immune response. 
 
 
 
Chapter 1 
 
43 
 
1.4 Xenobiotic Drug Metabolism 
In our daily lives, humans are exposed to a variety of substances which are foreign (xenobiotic). 
Such substance enter our body through air, foods and water. We are exposed to a variety of 
chemicals such as drugs, cosmetics, flavouring agents, food additives, detergents and so on. 
Our body handles all these xenobiotic substances entering our body in order to make them less 
toxic and rapidly excretes them to minimise damage. (Lamb et al 2009). 
Xenobiotic substances may interact and modify body’s metabolic functions and thereby 
become toxic. Several xenobiotic substances can interact with pharmaceutical agents and their 
metabolites and can cause toxic manifestations leading to ADRs. Some plausible mechanisms 
by which xenobiotic substances cause ADRs are: 1) interference with drug metabolism leading 
to generation of toxic substances capable of exerting an immune response; 2) interaction with 
the drug or its metabolites to produce toxic substances; 3) interference with drug metabolism 
and building up of drug metabolite in the blood to toxic levels leading to damage to organs 
involved in drug metabolism thus affecting the efficacy and safety of the drug. (Patterson et al 
2010). 
1.4.1 Drug Metabolism Enzymes 
Drug metabolizing enzymes have a critical role in the processing of xenobiotics, drugs 
and endogenous substances. The biotransformation process carried out by drug metabolizing 
enzymes can be divided into two separate groups: phase I and phase II processes. By phase I 
process or reactions, parent compounds are transformed into more polar compounds through 
reactions such as N- and O- dealkylation, hydroxylation, N- and S-oxidation and deamination. 
The principal enzymes involved are cytochrome P450 (CYP). Phase II biotransformation also 
act on endogenous compounds and xenobiotics to form metabolites which can be easily 
excreted out of the body.  Phase II transformations are normally conjugating reactions to 
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produce compounds which are more hydrophilic than the parent compound. A number of 
transferases enzymes are involved in phase II transformations (Jancova et al 2010).  
1.4.2 Cytochrome P450 
Cytochrome P450 (CYP) are a superfamily of proteins characterized by the presence of the 
heme cofactor. They use both small and large molecules as their substrates, and are classified 
into several groups including microsomal, mitochondrial and bacterial forms (Guengerich 
2008). Cytochrome P450 (CYP) enzymes catalyses oxidative biotransformation of diverse type 
of xenobiotics including drugs. The nomenclature of Cytochrome P450 (CYP) enzymes is 
dependent on amino acid sequence similarity.A particular nomenclature has been developed 
by committee (figure 1.7). CYP1 (1A &1B), CYP2 (2A, 2B, 2C, 2D & 2E) and CYP3 (3A) 
constitute the major CYP families with eight sub-families all together that account for the 
metabolic elimination of most drugs and xenobiotics in humans (Williams et al. 2004). 
Inhibition of P450 can be the most common mechanism that can cause drug-drug interaction 
(DDIs) (Kalgutkar, Obach & Maurer 2007). P450 inhibition occurs via two means: reversible 
(competitive/non-competitive) or irreversible (mechanism-based inactivation). Inactivation 
involving the irreversible mechanism starts with bioactivation of xenobiotic to a reactive 
intermediate. Irreversible inhibition can also lead to undesirable drug-drug-interactions. An 
understanding of Cytochrome P450 (CYP) inactivation by drug candidate can help in rational 
drug design to circumvent P450 inactivation. This strategy along with pharmacokinetic data in 
humans can help to identify right molecules for drug development.  
Kalgutkar, Obach & Maurer (2007) have analysed the biochemical basis of and structure-
activity relationships of Cytochrome P450 (CYP) inactivation by xenobiotics. The magnitude 
of drug-drug-interactions can be predicted by using in vitro Cytochrome P450 (CYP) 
inactivation data for developing safer drugs. Pharmaceutical companies apply screening 
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paradigms to assess mechanism-based inactivation of Cytochrome P450 (CYP) along with 
human pharmacokinetic of the candidate drug to identify safer molecules.  
Cytochrome P450 (CYP) is responsible for 75% of body’s total metabolic reactions and is the 
main enzyme groupinvolved in drug metabolism. While most drugs will be deactivated by 
Cytochrome P450 (CYP) directly or by facilitation of excretory process, some substances are 
activated to achieve their active state (Lamb et al 2009).  
Cytochrome P450 (CYP) activity can be increased by inducing their biosynthesis or decreased 
by inhibition of its enzymes involved in biotransformation processes. Cytochrome P450 (CYP) 
is the main class of enzyme associated with ADRs. Any change in the activity of Cytochrome 
P450 (CYP) will affect the metabolism and clearance of drugs in the body. If a drug inhibits 
the Cytochrome P450 (CYP) mediated transformation and clearance of another drug, the other 
drug will accumulate in the body and build up toxic levels which can cause an ADR (Lamb et 
al 2009). 
1.4.3 Flavin-Containing Monooxygenases (FMOs) 
FMOs are a family of enzymes that protect us from the threat of chemical substances 
present in our environment. They catalyse the oxidation of foreign chemicals such as pesticides, 
therapeutic agents, dietary food substances and other substances present in the environment. 
FMOs are not as exhaustively studied as cytochrome P450. Recent studies have led to greater 
appreciation of the role played by FMOs in dealing with pharmacological and toxicological 
effects of substances on human body. Unlike CYPs, FMOs are not induced or inhibited by 
foreign substances which give them advantage over CYPs in being less prone to drug-drug 
interactions. According to Philips and Shephard (2008) the differences in FMOs activity 
between individuals are greatly due to inheritance and not due to the environmental factors. 
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Figure 1.7: Nomenclature of cytochrome P450.  
 
1.4.4 Peroxidases 
Peroxidases are critical in inflammation and exacerbation of diseases like asthmatic disorders. 
When inflammatory cells like neutrophils and eosinophils are activated during inflammatory 
conditions their secretory products are associated with the clinical progression of the disease. 
When activated, neutrophils and eosinophils secrete unique peroxidases. According to Reszka 
et al (2011), these unique cell peroxidases are functionally similar to lactoperoxidase present 
in the lining of the lung (Reszka et al, 2011).Peroxidase enzymes catalyse the production of 
reactive drug metabolites in immune cells (Besser et al. 2009). The most common examples of 
peroxidases involved drug metabolism are Myeloperoxidase (MPO), eosinophil peroxidase 
(EPO), and lactoperoxidase (LPO) (Tafazoli and O'Brien 2005). 
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Figure 1.8: A general overview of the drug metabolism pathways observed within the 
human body. 
 
1.5 Phase I Drug Metabolism: The Modification Stage 
Phase I of drug metabolism is the modification step during which certain groups are added to 
drug molecule to facilitate conjugation during phase II. The phase I reactions are of three types: 
oxidation, reduction and hydrolysis. Following these steps, there can be several situations with 
respect to the new compound formed: it can have same activity, it can have a different activity, 
it can be safer or less toxic or can be more toxic. If the reactions involve an increase in water 
solubility, according to Schonborn (2010), the new compound formed can be rapidly excreted 
at this stage.  
(i) Oxidation: During oxidation the drug molecule undergoes insertion of an oxygen atom 
to form unstable intermediate. The intermediate rearranges into the product of drug 
metabolism. These reactions are catalysed by cytochrome P450. The reactions that take 
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place include hydroxylation, epoxidation, dealkylation and deamination and 
dehalogenation. Example of drugs that undergo oxidation are codeine, omeprazole and 
paracetamol (Schonborn (2010). 
(ii) Reduction: These reactions are also catalysed by cytochrome P450 and often are 
performed under anaerobic conditions. Several drugs are known to undergo reduction.  
For example, prednisone (a prodrug) undergoes reduction into active glucocorticoid 
prednisolone and warfarin is inactivated by transformation of a ketone group 
(Schonborn (2010). 
(iii) Hydrolysis: This step is catalysed by esterases and amidases. Some drugs which 
undergo this step are prilocaine which undergoes hydrolysis by amidases in liver and 
remifentanil undergoes plasma ester hydrolysis resulting in a short elimination half-life 
(Schonborn (2010). 
 
1.5.1 Phase II Drug Metabolism: The Conjugation Stage 
This stage increases the drugs solubility by the addition of a conjugating agent. This 
process facilities excretion of the drug in bile and urine. Most phase II reactions inactivate 
drugs or the active molecule formed during the phase I reactions. Some important phase II 
reactions are: 
(i) Glucuronidation: This is the major route of propofol metabolism for allowing excretion 
through liver and kidneys. By glucuronidation, morphine is metabolized to morphine -
6-glucuronide which is 13 times more potent than the parent compound. According to 
Schonborn (2010), the midazolam also undergoes this reaction to form a metabolite 
having prolonged sedative effect. UDP-glucuronosyltransferases (UGTs): These are a 
superfamily of enzymes that perform the detoxification pathway for chemicals, dietary 
Chapter 1 
 
49 
 
components, carcinogenic agents and their oxidized metabolites. According to Wells et 
al (2004), 40-70% of clinical drugs undergo glucuronidation. Mackenzie et al (2008) 
point out that UGTs are critical for the incorporation of UDP-hexose to nucleophilic 
atom in the acceptor molecules. Jancova and Siller (2012) reported that the active site 
of UGTs is localized in the luminal space of  the surface of endoplasmic reticulum (ER) 
(Mackenzie et al, 2008). 
(ii) Sulphation: Among drugs which undergo this reaction is paracetamol. Paracetamol 
(40%) also undergoes N-hydroxylation to N-acetyl-p-aminobenzoquinonimine 
(NAPQI) which is toxic. This is then susceptible to sulphation prior to elimination. 
(iii) N-Acetylation: The various forms of the enzyme give rise to variable rates of 
acetylation in different individuals. Individuals are divided into slow or fast acetylators 
and the effects administration of such as isoniazid and hydralazine. (Barranco, Minor 
& Solomon 1976) 
 
1.6 Dapsone 
Dapsone was synthesized in 1908 and continues to be used as a powerful therapeutic agent for 
skin diseases (Wozel, 1989). Dapsone has an antibacterial spectrum and is the drug of choice 
for leprosy since the 1950s. It can also be used for a broad spectrum of  ailments: acne 
(Prendville, Logan & Russel-Jones  1988), bullous pemphygoid as an adjunct (Jeffes & Ahmed 
1989), pneumonia caused by Pneumocystis carinii (Leoung, Milles &Hopewell 1986), 
dermatitis herpetiformis (Leonard 1991), relapsing polychondritis (Barranco, Minor & 
Solomon 1976), vesico bullous lesions of lupus erythematus as first line therapy (Hall et al 
1982), vasculitis syndrome (Forston et al, 1986), spider bite (Bennavides & Moncada 1990), 
pyoderma gangrenosume (Brunsting & Goeckerman,1930) and pemphigus herpetiformis 
(Leonard 1991).Dapsone is absorbed well from gut and its metabolism is directed through N-
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acetylation and N-hydroxylation (oxidation). People differ in the rate of acetylation resulting 
in slow and fast acetylators in the patient population. ADRs due to dapsone normally develop 
after six weeks of initiation of the drug (Rege, Shukla & Mascarenhan 1994). Kannan et al 
(2009) found dapsone effective both in leprosy and non-leprosy patients causing no serious 
hematological complications; they did not find any case of dapsone hypersensitivity syndrome. 
Kannan et al (2009) have reported peripheral neuropathy as the main ADR of dapsone users in 
35% patients of leprosy patients and 18% of non-leprosy patients.Dapsone hypersensitivity 
differs from other drug reactions because its occurrence takes place after prolonged exposure 
to the drug and the reactions can occur even after six months or more of exposure. Dapsone 
hypersensitivity syndrome have a complex mix of clinical manifestations, such as eosinophilia, 
jaundice, fever, and cutaneous manifestations like erythroderma, maculopapular eruption, 
epidermal necrosis and Stevens-Johnson syndrome (Richardus & Smith 1989; Smith 1988) as 
s well as internal organ damage. The hematologic adverse effects associated with dapsone are 
methemoglobinemia and hemolytic anemia which are believed to be dose-dependent and 
caused by the dapsone hydroxylamine metabolites, which is potent a oxidants. Though dapsone 
is excreted by kidneys, it has significant enterohepatic circulation.  
Severe cases of ADR caused by dapsone involve hypersensitivity syndrome (DHS) which is 
potentially fatal. Dapsone hypersensitivity syndrome involves irreversible organ damage, 
which can be treated by timely use of steroids in oral formulation (Vinod 2013). The 
hypersensitivity reported by dapsone occurs about 20 days after its administration and 
symptoms persist even ten days after its discontinuance. Dapsone hypersensitivity can develop 
even several weeks to six months after drug intake. In rare cases dapsone hypersensitivity is 
also reported to cause bone marrow suppression and pancytopenia in addition to fever, rash, 
and hepatosplenomegaly (Vinod 2013). 
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During the long intervening period of its elimination half-life of 24 to 30 hours, dapsone 
metabolites may be the cause for eliciting ADRs (Gennaro et al, 2000). The hydroxylamine 
metabolite is responsible for methemoglobinemia, hypersensitivity syndrome, neuropathy, and 
agranulocytosis (Kannan et al 2009). 
Several drug-drug interactions (DDIs) have also been observed with dapsone. Interaction with 
the drug fluconazole reduces production of toxic metabolite and reduction of adverse reaction 
of dapsone, while cimetizine reduces methemoglobinemia due to dapsone (Kannan et al 2009).  
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Figure 1.9: Flow chart illustrating the project design. 
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In 2013,Zhang and his colleagues, considered that there is a relationship between HLA-B* 
13:01 and dapsone hypersensitivity syndrome especially among patients with leprosy disease 
(Zhang et al, 2013). Based on Zhang et al (2013) study we designed our project to describe the 
association between T-cell activation and dapsone hypersensitivity with positive or negative 
HLA-B*13:01 donors. Firstly, synthesis of Nitroso Dapsone (DDS-NO)the aims of this study 
is explore the immunogenicity of the DDS and DDS-NO in human test systemsor mouse 
system modelAs summarises above see figure 1.9. 
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2.1 Introduction: 
Sulfonamides are the base of various drugs and the pioneer chemotherapeutic antibacterial 
agents used systematically in modern medicine (Hansch et al., 1990). They have been in routine 
medicine practice for 70 years and are most widely used throughout the world against 
numerous bacterial infections and other diseases (Ozbek et al., 2007). From anti-bacterial 
activity to anti-fungal (Isik et al., 2009), and from antineoplastic (Tiwari et al., 2006) to 
antiviral (Lu et al., 2007), sulfonamides have revolutionized medicinal chemistry since their 
discovery. It has also been reported that they are important in the treatment of rheumatoid 
arthritis (Levin et al., 2002) and Alzheimer’s disease (Roush et al., 1998). Literature shows that 
sulfonamides are an integral component of many anticonvulsant, antihypertensive, 
antipsychotic, diuretic, and hypoglycemic drugs (Shah et al., 2013). Other than these uses, 
sulfonamides also show the ability to inhibit the activity of various enzymes (Supuran et al., 
2003). Numerous studies have stated that a considerable number of highly prescribed drugs 
have a sulfonamide subunit. According to Ding et al. (2013) and Graul et al. (2013) 10% of the 
top 100 drugs recommended in 2011-2012 had a sulfonamide moiety.  
Sulfonamides were first discovered by Domagk et al  in 1935 while they were studying 
Prontosil 1 metabolism. Prontosil is metabolized into an active sulfonamide agent in vivo 
which then interfers with the bacterial growth (Figure 2.1) (Patrick, 2009).
 
Figure 2.1- Metabolism of prontosil. 
Sulfonamides have SO2-NH2 functional group in their structure (Warshakoon et al., 2009). 
Their general formula is RSO2NH2 where R represents any organic group. Sulfonamides differ 
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in the N1 position which alters the strength, solubility and pharmacokinetic properties of the 
molecule (Genc et al., 2008). Based on chemical structure there are two different groups of 
sulfonamides. The first group is sulfonylarylamines in which sulfonamide moiety is directly 
attached to a benzene ring and there is also an amine (-NH2) moiety at the N4 position. Non-
sulfonylarylamines are the second group in which there is also a sulfonamide group attached 
to benzene ring but there is no amine moiety attached at the N4 position  (Johnson et al., 2005). 
The fact that some sulfonamides act as antibiotics while others are non-microbial agents is due 
to the difference in the R components and other variable groups Figure 2.2; 
 
Figure 2.2- Structural formula of sulfonamides 
The para-amine group (R1HN), aromatic ring and sulfonamide groups are essential groups of 
the sulfonamide drug. R2 can vary in different sulfonamides (Vree. Et al. 1986). 
The pharmacokinetics of sulfonamides differ based on lipophilicity and hydrophilicity due to 
differences in the nitrogen containing Para-amino and sulfonamide group. The more lipid 
soluble the drug is, the more it becomes bound to proteins in the plasma (Fujita et al. 1867). 
The P-amine group in most of the sulfonamides is a very important part of the drug because 
any change and modification in the Para-Amino group results in the loss of activity of the drug 
(Anand N et al. 1996). The length of the amide group determines the antibacterial activity of 
the sulfonamide drug. The antimicrobial activity of the drug increases with increase in the 
length of the alkyl group. Thus, sulfamethoxazole has a long aliphatic hydrocarbon group and 
therfore has wide spectrum antibacterial activity (Ozbek et al., 2007).  
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It should be noted that amide groups cannot be ionized and this lowers the polarity of 
sulfonamides group. The alkyl group increases the hydrophobic nature of the drug thus, making 
it easily to absorb and cross the gut wall. Inside the gut wall cells, the drug is metabolized by 
peptidases that generate primary amines. Primary amines are ionizable and thus easily interact 
to perform their action. (Maren et al., 1976). Dapsone as a sulfonamide acts in several different 
ways as it is used to treat a variety of illnesses and diseases. It has an anti-bacterial effect by 
inhibiting bacterial growth, which is especially important when used to treat leprosy. But it is 
also used for the treatment of skin conditions that are not caused by bacteria. Dapsone shows 
that it can be used as an anti-inflammatory and as a therapy in auto immune diseases (Qiang, 
2013). 
2.1.1 Mechanism of Action of Sulfonamides: 
Sulfonamides are bacteriostatic agents and are competitive enzyme inhibitors. They mimic the 
structure of the substrate of PABA, binding to their active site, thus blocking access to PABA 
in a reversible manner Figure 2.3. (Seydel et al., 1968). 
 
PABA Sulfonamides 
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Figure 2.3- Mechanism of action of sulfonamides. 
The antibacterial activity of sulfonamides is due to their resemblance to p-amino benzoic acid 
(PABA) which is required by bacteria for synthesis of DNA. The basic mechanism involves 
the competition of sulfonamides with PABA for the enzyme dihydropteroate synthetase, 
resulting in the inability of bacteria to form dihydrofolate which is essential for DNA synthesis 
of bacteria (Caddick, 2005). 
2.1.2 Metabolism of sulfonamides: 
Most of the sulfonamides are detoxified by the liver and are metabolized by acetylation. The 
acetylation decreases the hydrophobicity of the drug thus rendering it inactive. Sulfonamide 
also form hydroxylamine intermediate which are implicated in hypersensitivity reactions 
(Lipmann & Tuttle 1945). These are discussed in more detils below. 
2.1.3 Hypersensitivity of sulfonamides: 
Sulfonamide therapy has been associated with hypersensitivity reactions including skin 
eruptions,  and fever (Rieder et al., 1989). The exact mechanism of these hypersensitivity 
reactions is complex and not well understood. Various metabolic and genetic factors contribute 
to individual susceptability. It has been hypothesized that these reactions occur because of the 
formation of reactive derivatives (Svensson, 2003). Many studies have shown that these 
metabolites are produced in-vivo by the cytochrome P450 (CYP) monooxygenase system 
(Cribb and Spielberg, 1992), mainly CYP 2C9 (Cribb et al., 1995).‘Sulfa Allergy’ is the term 
used for all the adverse effects of sulfonamide drugs. Hypersensitivity reactions are reported 
in 3-4% of the patients receiving sulfonamides drugs (Kucera et al., 1996). However, this 
increases in disease states such as cystic fibrosis and HIV due to immune deficiency state of 
patient. The signs and symptoms include  anaphylactic shock,  skin eruption  and  reactions 
targeting internal organ (Knowles et al., 2001). Many Antibiotics such as sulfonamides, 
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penicillins, macrolides and clindamycin are involved in acute generalised exanthematous 
pustulosis. It is possible that rashes which start off as maculopapular eruptions may extend into 
full-scale toxic epidermal necrolysis or the Steven-Johnson syndrome. (Schmid et al. 2002; 
Sidoroff et al. 2007).  
2.1.4 Chemical synthesis of sulfonamides and their metabolites 
Because of their importance in the pharmaceutical industry and appearance of drug-resistant 
strains in clinical applications (Cassell and Mekalanos, 2001), a number of chemical methods 
have been reported for the synthesis of new sulfonamide derivatives (Moreno-Diaz et al., 2008 
; Dominguez et al., 2005 ; Ozbek et al., 2007). The most common method for the synthesis of 
sulfonamides is sulfonylation of amines with chlorides in the presence of a base  (Humljan and 
Gobec, 2005). Other methods which have been reported include but are not limited to synthesis 
using thiols (Wright and Hallstrom, 2006), from sulfonic acid (De Luca and Giacomelli, 2008), 
using sulfonamides (Revankar et al., 1990) and transition metal catalyst  (Shekhar et al., 2011). 
A novel method of sulfonamides production is production from sulfenamides such as 2-amin-
9H-purine-6 sulfenamide with the help m-chloroperoxybenzonic acid (m-CBPA) which 
slightly increases the yield of sulfonamide production from 49% to 53%. (Revankar et al., 
1990). 
2.1.5 Dapsone (4,4’-diaminodiphenylsulfone, DDS) 
Dapsone is the main drug used for the treatment of leprosy (Figure 2.4)(Makarov et al., 2006). 
It is an analogue of sulphone and is the simplest of all in the group (Zhu and Stiller, 2001). 
Dapsone does not contain the exact complete sulfonamide moeity although it contains a N4 
arylamine like the sulfonylarylamines of the sulfonamides (Brackett et al., 2004). The 
mechanism of action of dapsone against bacteria is same as of sulfonamides; they also compete 
with PABA and inhibit the synthesis of dihydrofolic acid (Coleman, 1993).  
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Figure 2.4-Structural formula of Dapsone. 
2.1.6 Absorption of Dapsone:  
Dapsone is well absorbed from the gut after its oral administration with a bioavailibity of more 
than 80%. With a single dose, the peak level of the drug is obtained after 2-6 hours. A steady 
state level  is obtained after continuous therapy of 10 days. The serum drug concentration does 
not change unless the dosage of the drug is changed. The half-life of dapsone is about  15-30 
hours (Katz 1999, Lang 1979, Zhu and Stiller 2001, Zuidema et al. 1986). 
In addition to its antileprosy activity, dapsone has shown effectiveness in patients with 
rheumatoid arthritis (Swinson et al., 1981), systemic lupus erythematosus (SLE) (Hall et al., 
1982), and thrombocytopenia (Godeau et al., 1993). Studies have shown that many derivaties 
of dapsone have been synthesized and they also have antibacterial and anti inflammatory 
properties (Kansyl et al., 1992).   
2.1.7 Distribution of Dapsone: 
Dapsone is 70-90% bound to plasma proteins. The metabolite of dapsone; monoacetyldapsone 
MADDS, is 100% bound to plasma proteins. Dapsone is almost equally distributed to all body 
tissues including skin, liver, renal system, heart and the intestines. Dapsone can cross the blood 
brain barrier and pass into the  brain. Data also shows that dapsone can cross the placenta 
resulting in  cases of neonatal hemolysis, documented after oral administration of dapsone to 
pregnant women (Katz 1999, Lang 1979, Zhu and Stiller 2001, Zuidema et al. 1986). 
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Figure 2.5 Acetylation of Dapsone. 
2.1.8 Dapsone metabolism 
Metabolism of dapsone in humans involves N-acetylation producing monoacetyldapsone 
(MACDDS) (Gelber et al., 1971) (Figure 2.5). Dapsone also undergoes hydoxylation by 
cytochrome P450 isozymes CYP2C19, CYP2C9, CYP3A4 and CYP2E1 to produce 
dapsonehydroxylamine (DDS-NOH) (Ganesan et al., 2010). The oxidation of dapsone 
hydroxylamine then produces Nitroso metabolite called nitroso-dapsone Figure 2.6 (Coleman, 
1995). 
 
Figure 2.6 Metabolic oxidation of dapsone: DDS is converted to DDS-NOH by CYP2C9. 
Dapsone hydroxylamine is then autoxidized in DDS-NO. 
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2.1.9 Dapsone and Hypersensitivity 
The use of dapsone is also associated with many adverse effects including pharmacological 
reactions such as anemia, hemolysis, methemoglobinemia, and allergic reactions such as 
dapsone hypersensitivity syndrome (Cucinell et al., 1972;Coleman et al., 1996). The direct 
toxic effects of dapsone are caused by dapsone oxidative metabolites. It has been proposed that 
dapsone-induced hypersensitivity syndrome is immune-mediated and involves the activation 
of T-lymphocytes (Ben m'rad et al., 2009). However the nature of drug-antigen that stimulates 
T-cell has not been defined. 
Lowe and his colleague were first to report dapsone-induced hypersensivity syndromes (Lowe 
and Smith, 1949). Later Allady and Barnas gave the aforementioned term to syndrome and 
described the clinical features further (Allady and Barnas, 1951). Data suggest that multidrug 
therapy in leprosy patients has led to an increase in the incidence of dapsone hypersensivity 
syndrome in the past decade. The syndrome is noted after a month of therapy with dapsone and 
signs and symptoms include fever, nausea, vomiting, malaise, deranged liver function tests, 
anemia, dermatitis, eosinophilia, leukocytosis and other related symptoms. The clinical picture 
and symptoms are quite similar to infectious mononucleosis disease however there is no 
evidence of the Epstein-Barr virus (EBVs) sensitivity or toxoplasmosis. (Prussick et al.1996) 
There is no guideline for the management of dapsone-induced hypersensitvity syndrome, 
however the convention is to stop the administration of dapsone and start introducing 
corticosteroids. Steroids are introduced and given for a long duration as dapsone has a long 
half-life in tissues due to enterohepatic circulation. The exact mechanism of the dapsone 
hypersensitivity syndrome is unknown however the response to steroids and the clinical picture 
of eosinophilia suggest that the syndrome is an idiosyncratic hypersensitivity reaction 
(Mofenson et al. 2009). 
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2.1.10 Chemical synthesis of dapsone metabolites. 
Dapsone was first synthesized in 1908 by Fromm and Wittman (Fromm and Wittman, 1908). 
As a result of increase in drug resistance by bacteria, and their hypersensitive reactions, there 
have been efforts to synthesize the metabolites and derivatives of these drugs in vitro to 
understand the mechanism of toxicity and investigate the effects of these metabolites relative 
to dapsone drug (Kansyl et al., 1992).First experiments to produce metabolites of dapsone in 
vitro were conducted by Uetrecht et al (Uetrecht et al.,1998). Dapsone was incubated with 
polymorphonuclear cells (PMN)- and zymosan-activated human PMN. Gas chromatography 
and high-pressure liquid chromatography were used to characterize the hydroxylamine 
metabolite of dapsone. Further oxidation of dapsone hydroxylamine resulted in the generation 
of nitroso derivatives of dapsone (Drayer et al., 1974;Uetrecht et al. 1988). Despite these 
efforts, nitroso-dapsone was not generated  in sufficient quantities for described in-vitro or in-
vivo challenges of toxicity of immune reactions. 
 
    
(A)     (B)  
Figure 2.7 (A) Chemical structure of Dapsone hydroxylamine. (B) Chemical structure of 
Nitroso dapsone. 
2.1.11 Dapsone Analogues 
To overcome the common adverse effect of hemotoxicity following administration of dapsone, 
structural analogues have been synthesized that retain pharmacological activity, reduce toxicity 
and increase the therapeutic windowof dapsone. It has been found that replacement of sulfone 
group of dapsone by sulfur, oxygen, methylene, or carbonyl substituents significantly reduce 
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the hemotoxicity in the human erythrocytes (Mahmud et al., 1997).There is a lot of data and 
experimental studies on the bioavailability and pharmacokinetics activity of dapsone and 
related dapsone analogues. Studies have shown that many analogues of dapsone have anti- 
inflammatory properties  (Kansyl et al., 1992). It has been found that dapsone and its analogues 
are also useful for preventing and for treating pathologies involving memory loss such as 
Alzheimer’s and related neurodegenerative disorders. However, although many analogues of 
dapsone have been synthesized for better pharmacological activity, there are only a few studies 
on the structure–toxicity relationships of thesecompounds (Coleman et al., 1991). 
2.1.11.1 Dapsone analogue 3, 4’ DDS 
3, 4’ DDS (3, 4’- diaminodiphenyl sulfone) is also an aniline derivative and belonging to the 
group of synthetic sulfones. Like DDS, its structure contains a sulphur atom linking to two 
carbon atoms. It also contains two free amino groups in the structure and thus can act as an 
antimicrobial agent (Figure 2.8, II). The main structural difference between DDS and 3,4’ DDS 
analogue is the presence of an amino group in a different position. This small positional change 
provides greater pharmacological activity than dapsone. It is a water soluble compound and its 
absorption is complete and regular from the gastrointestinal tract. Although it has better 
pharmacological activity than dapsone, Coleman et al (1991) suggested that the 3,4’ DDS 
produces significant amount of methaemoglobin in human erythrocytes. 
2.1.11.2 Dapsone analogue 3DDS 
3, 3’ DDS (3, 3’- diaminodiphenyl sulfone) is also an aniline derivative belonging to the group 
of synthetic sulfones (Figure 2.8,III). It contains two free amino groups in the structure and 
thus can act as an antimicrobial agent. The only structural difference between DDS and 3, 3’ 
DDS analogue is the presence of amino groups in different position. Furthermore, this small 
positional change of amino groups provides it greater pharmacological activity than DDS and 
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good pharmacokinetics properties.3, 3’DDS does not produce significant methaemoglobin in 
human erythrocytes and as a consequence, is associated with  significantly less toxicity 
compared with DDS (Coleman et al., 1991). It has been shown that the haemotoxicity of DDS 
analogues is related to the electron-withdrawing nature of the 4-substituent (Mahmud et al., 
1997). 
2.1.11.3 Dapsone analogue MACDDS 
It is also an active analogue of DDS and chemically known as mono-N-acetyl DDS 
(MACDDS). The main structural difference between MACDDS and DDS is the presence of 
an acetyl group (Figure 2.8, IV). Due to the presence of one free amino group in the structure, 
MACDDS can still act as an antimicrobial agent. It has ten times stronger plasma protein 
binding (97-100%) when compared with DDS (David et al., 2011). Although it possesses better 
pharmacokinetic properties than DDS, it is one of the most potent compound at inducing 
methaemoglobinemia (Coleman et al., 1991).  
2.1.11.4 Dapsone analogue DACDDS 
This dapsone analogue is also known as Acedapsone (4, 4’-diacetyl-diphenyl sulfone) and it 
doesn’t contain a free amino group in the structure (Figure 2.8, V). The most important feature 
of DACDDS is that it does not produce a significant amount of methaemoglobin (Coleman et 
al., 1991). Thus, it is not able to produce significant hemotoxicity. Unlike all formulations of 
sulfones, which are taken orally, DACDDS would need to be administered intramuscularly. It  
releases the drug slowly from the administered site but, after release metabolism occurs rapidly 
and converts into the active form, DACDDS has a long plasma half-life thus, it possible to 
formulate sustained release injectable drug delivery strategies(David et al., 2011). 
 
 
Chapter 2 
 
66 
 
2.1.11.5 Dapsone analogue MACDDT 
The dapsone analogue MACDDT is a thioaniline derivative chemically known as 4-acetyl-4-
amino-diphenyl thioether (Figure 2.8, VII). The main feature of the molecule is a diphenyl ring 
with a sulphur atom linking to two carbon atoms. The main structural difference between 
MACDDT and DDS is the presence of a sulfide or thioether group instead of sulfone group 
and an additional acetyl group. Due to the presence of one free amino group in the structure, 
MACDDT can act as an active antimicrobial agent like DDS. It has been reported that 
MACDDT can cause significantly greater methaemoglobin formation than DDS (Coleman et 
al., 1991). 
2.1.11.6 Dapsone analogue DACDDT 
This DDS analogue is also a thioaniline derivative and its chemical name is 4, 4’-diacetyl-
diphenyl thioether DACDDT (Figure 2.8, VIII). It doesn’t contain a  free amino group in the 
structure. Thus, this analogue is only active after the conversion to metabolites containing one 
or two free amino groups. It also forms a significant amount of methaemoglobin and as a 
consequence causes haemotoxicity (Coleman et al., 1991). 
2.1.11.7 Dapsone analogue DDT 
DDT is another thioaniline derivative of DDS and its chemical name is 4, 4’- diaminodiphenyl 
thioether (Figure 2.8, IX). Unlike DDS, it contains a sulfide group (a sulphur atom linking to 
two carbon atoms) instead of a sulfone group. It also contains two free amino groups in the 
structure and thus can act as an antimicrobial agent. The most important feature which makes 
it superior to 3, 4’ DDS and 3, 3’ DDS is that, it does not produce significant amounts of 
methaemoglobin (Coleman et al., 1991). Thus, it is not able to produce significant 
hemotoxicicy in the human.  
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2.1.11.8 Dapsone analogue DDE 
DDE is known as 4, 4’-diaminodiphenylether. It contains two amino groups in the structure 
and that is why it can act as an antimicrobial agent. DDE has a diaminodiphenylether group 
and this is the most exclusive structural feature which makes it superior than other DDS 
analogues (Figure 2.8, VI). Due to the absence of sulfone group it does not cause a significant 
amount of methaemoglobin (Coleman et al., 1991). 
2.1.11.9 Dapsone analogue F8 DDS 
F8 DDS or 4, 4’-diaminooctofluoro-diphenyl sulphone is a fluorine containing analogue of 
DDS. The main feature of which is a diphenyl ring with a sulphur atom linking to two carbon 
atoms with fluorine atom substitution (Figure 2.8, X). This compound also contains two free 
amino groups in the structure which makes it an active antimicrobial agent. It does not produce 
a significant amount of methaemoglobin in humans (Tingle et al., 1988). The decrease in 
toxicity observed with the electron-withdrawing octofluorodiphenyl groups may be an effect 
of the drug density on the amino group which would reduce the ability of cytochrome P450 to 
N-hydroxylate the compound (Yin et al., 1995). 
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Figure 2.8 Structure of 10 DDS analogues : I. DDS, II. 3, 4’DDS, III. 3DDS, IV. MAC DDS, 
V. DAC DDS, VI. DDE, VII. MAC DDT, VIII. DAC DDT, IX. DDT, X F8 DDS. 
 
2.1.12 Dapsone and the activation of T-cells 
Like most sulfonamides, DDS can cause hypersensitivity reaction that is likely mediated by T-
cells    (type IV hypersensitivity reaction).  T-cells are implicated  because of the time delay 
from beginning therapy to the time of reaction, approximately 4 weeks. The mechanism of T-
cell response to DDS is unknown and three pathomechanisms are assumed.  According to the 
hapten theory a small inert molecule could illicit an immune response by first covalently 
binding directly to an intra- or extra- cellular protein.  Whereas the native protein would 
originally be recognized as “self” and be ignored by the immune system the protein adduct 
could stimulate a T-cell response. Alternatively, the pro-hapten concept asserts that non-
reactive molecules can be metabolized intracellularly and the metabolites then bind to host 
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proteins, modifying them.  Again, when presented to the T-cell receptor peptides driving from 
these adducts are recognized as abnormal and the T cell becomes activated to illicit an immune 
response. This response is seen in reactions with sulfamethoxazole and other drugs (Adam et 
al, 2011). For DDS to activate T-cells via this mechanism, it would need to be metabolized to 
the nitroso intermediate, which would then react with protein.Finally, in the ‘pharmacological 
interactions of drugs with immune receptors’ concept, or pi theory, an inert molecule would 
interacts directly with the antigen presenting cell at the major histocompatibility complex.  This 
binding interaction is  sufficient to interact with the T- cell receptor to induce a response.  The 
pi model is an interesting candidate for dapsone hypersensitivity as there is a 21 fold increased 
risk associated with HLA-B*13:01, an allele common in South East Asia and Australian 
aborigines (Markova et al, 2014). 
2.2 AIMS OF THE INVESTIGATION 
The pathomechanism of T-lymphocyte activation by DDS and DDS-NO has not been 
previously investigated. While the hepatic metabolism of dapsone has been well characterized, 
it is not clear whether the reactive metabolite (DDS-NO) generated within the liver actually 
circulates to the skin to activate T-cells that cause cutaneous reactions. Alternatively, localized 
cutaneous generation of protein reactive metabolites might be responsible for these reactions 
in the skin. The aims of this chapter were: 
 Synthesis / characterization of DDS-NO from DDS hydroxylamine. 
 Determination of whether DDS and/or DDS-NO prime naïve T-cells from healthy 
donors’ and assessment of cross-reactivity.  
 Detection of whether DDS and/or DDS-NO stimulate dendritic cells directly. 
Sulfamthexazole and nitroso sulfamethaxzole were used as controls during the 
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experiments. The T-cell priming assay conditions were optomised with these 
compounds (Falkner et al., 2012; Gibson et al., 2017).    
2.3 MATERIALS AND METHODS 
2.3.1 Study Area and Approval 
The study was approved by the Liverpool research ethics committee. Venous blood (100 mL) 
samples obtained from 3 healthy donors were collected via venipuncture into heparinized 
vacutainer tubes.  Informed written consent was obtained from all donors before the procedure. 
2.3.2 Chemicals and reagents 
Dapsone and dapsone analogues were purchased from Sigma-Aldrich (UK). Dapsone 
hydroxylamine was purchased from Dalton Chemical Laboratories Inc. (Toronto, Canada). 
Tritiated thymidine-(methyl-3H) was obtained from Moravek (California, USA). Analytical grade 
acetonitrile, HPLC grade distilled water, and HPLC grade methanol were acquired from Fisher 
Scientific (Loughborough, United Kingdom). Ammonium formate, DMSO, methimazole, 
phytohemagglutinin (PHA) was obtained from Sigma-Aldrich (Gillingham, Dorset, United 
Kingdom). Chemiluminescent substrate was obtained from Thermo Scientific 
(Northumberland, United Kingdom). Luminex was bought from GE Healthcare Life Sciences 
(Buckinghamshire, United Kingdom). The microplate reader was manufactured by Dynatech 
Laboratories Inc., (Chantilly, VA, USA). 
 
2.3.3 Culture medium  
All type of cells used in this study were grown in RPMI-1640 cell culture medium with required 
supplementation. T-lymphocytes were grown in RPMI-1640 medium supplemented with 10% fetal 
bovine serum, 25 mM HEPES buffer, 2 mML-glutamine, GM-CSF (800 U/mL), IL-4 (800 U/mL), 
penicillin (1000 U/ml), and streptomycin (0.1 mg/ml). Dendritic cells were grown in RPMI-1640 
medium supplemented with 10% human AB serum, 25 mM HEPES buffer, 2 m ML-glutamine, 
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penicillin (100 µg/ml), streptomycin (100 U/ml), and transferrin (25 µg/ml). Naïve T-cells 
were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum and 2 m ML-
glutamine. 
2.3.4 Isolation of peripheral blood mononuclear cells (PBMC) 
Venous blood was carefully layered on top of lymphoprep (25 ml) and spun in centrifuge at 2000 
r.p.m for 25 minutes at 25°C temperature.  The buffy coat layer containing PBMC was removed by 
using a Pasteur pipette and transferred into a new conical tube. Buffy coat was washed in Hanks 
balanced salt solution (HBSS) twice at room temperature by centrifugation. Cells were 
counted using a Neubauer haemacytometer (Sigma-Aldrich) with trypan blue (0.2% w/v) 
exclusion of dead cells under a Leica DME microscope (Leica Microsystems, Milton Keynes).  
The percentage viability was estimated as follows: percentage viability = (viable cells ÷ total 
cells) × 100. Percentage viability was measured at 95% for all isolatations. Cells were used 
immediately or after 24h, centrifuged and resuspended in freeze mix containing with 10% DMSO 
and 90% human AB serum. 107cells/ml per cryovial were then placed in a Mr Frosty freezing 
container at - 80 ˚C, cells were stored at -150˚C for long-term. 
2.3.5 Isolation of PMBCs and separation of subsets of T-cells 
CD14+ monocytes and T-cell populations were separated by using magnetic beads and columns 
following to the manufacturer's instructions (Miltenyi Biotech; Bisley, UK). CD14+ cells were 
positively selected from total PBMC. For isolation of naive and memory T-cells, pan negative T-
cell separation was performed using an anti-T-cell antibody beads cocktail. CD3+ cells were then 
subjected to positive selection for Treg (CD25+) and memory cells (CD45RO+). Finally, the 
fraction that contained naïve T cells were frozen and stored at – 150°C for further use. 
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2.3.6 Generation of dendritic cells (DCs) 
CD14+ monocytes isolated from PBMC using magnetic beads and columns were cultured in 
dendritic cell culture medium supplemented with IL-4 and GMCSF for 7-8 days. DCs were then 
matured using LPS and TFN.  
2.3.7 Lymphocyte Transformation Test (LTT) 
LTT assay was performed on PBMC isolated from healthy volunteers,  to exclude any unlikely 
pre-sensitization prior to the T-cell priming strategies, using an established protocol (Nyfeler 
and Pichler 1997). Briefly, PBMC (1.5×105 cells, 100 µL) were cultured in a 96-well U-bottom 
cell culture plate in triplicate with either 100 µL DDS (0.125-2 mM) or DDS-NO (10-80 µM) 
and incubated at 37°C, 5% CO2 for 5 days. In this assay tetanus toxoid (TT) 5 μg/ml was used 
as a positive control while culture medium was the negative control.  Sixteen hours prior to 
harvesting [3H]-thymidine (0.5 µCi/well) was added and lymphocyte proliferation was 
assessed as counts per minute (c.p.m) using a liquid scintillation counter (Wallac microbeta 
trilux, PerkinElmer, Cambridge, UK). Proliferative responses, countsper minute (cpm) were 
converted to a stimulation index (SI) representing the cpm in drug treated cultures divided by 
the cpm in medium control. 
2.3.8 Priming of naive T cells to DDS and DDS-NO. 
To perform the T-cell priming assay, dendritic cells were plated (0.8×105cells per well) and 
co-cultured at 37 C° with naive or memory CD3+ T-cells (2.5×106 cells per well; 48 well 
plate) in the presence of either DDS (1 mM) or DDS-NO (40 µM) for 8 days. The culture 
period was sometimes extended to four weeks. T-cell cultures were supplemented with IL-2 (5 
µg/mL) every 5 days. T-cell culture was assessed using two methods, [3H]-thymidine proliferation 
and interferon gamma (IFN-γ) secretion in the presence of either DDS (0.125-2 mM) or DDS-NO (10 
- 40 µM).  
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2.3.9 [3H]-Thymidine incorporation proliferation and IFN-γ secretion assays. 
For the analysis the cell proliferation by [3H]-thymidine incorporation, primed T-cells (1×105; 
200l) were harvested and stimulated with autologous dendritic cells (4×103)  in the presence of 
either DDS (1 mM) or DDS-NO (40 M) .  After 48 hours, [3H]-thymidine (0.5 µCi/well) was 
added to the culture plate. Incorporated thymidine was counted after a further 16 hour incubation 
using a MicroBeta TriLux 1450 LSCβ-counter (Perkin Elmer, Cambridge, UK).  ELISpot was 
used, according to the manufacturer's instructions (Mabtech, Nacka Strand, Sweden) to visualize 
IFN-γ secretion after co-culture of the primed T-cell with dendritic cells and either DDS or 
DD-NO under the condition described above. 
2.3.10 ELISpot Assay 
ELISpot plate wells were coated with 100 µL of high affinity monoclonal antibody IFN-γ (15 
µg/ml) and incubated overnight at 4˚C. Plates were washed with HBBS and blocked with T-
lymphocyte culture medium for 30 minutes at room temperature. The culture medium was aspirated 
and naïve T-cells (1×105,100µL) and autologous DCs (1.6×105, 50µL) were plated out to a total 
volume of 200 µL/well. Cells were cultured in the presence of either DDS (0.125-0.5mM) or DDS-
NO (10-40 µM, 50 µL) and incubated at 37˚C, 5% CO2 for 48 hours. Cells were discarded after 
48 hours and the wells were washed five times with 200 µL PBS. For the detection of secreted 
cytokine, biotin-labelled detection antibody was diluted to 1 µg/ml in PBS containing 0.5% FBS 
and 100 µl was added to each well. The plate was incubated at room temperature for 2 hours and the 
wells were again washed five times with PBS. Streptavidin-ALP diluted PBS containing 0.5% 
FBS (1:1000) was added to each well and incubated for 1 hour at room temperature. The wells 
were then washed five times with PBS (200 µL), and BCIP/NBT substrate (100 µL/well) was 
added and incubated in the dark for 15 minutes at room temperature. Finally, wells were 
inspected for the development of spots and then washed under slow running tap water and left to air 
dry. ELISpot signal was counted using an AID ELISpot reader (Cadama Medical, Stourbridge, UK).  
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2.3.11 Synthesis of Nitroso-Dapsone. 
DDS-NO was synthesized from DDS hydroxylamine using iron (III) chloride (Figure 2) 
according to the method of Naisbitt et al. Briefly, DDS hydroxylamine (60 mg, 0.227 mmol) 
was dissolved in absolute ethanol (10 mL) and added to a stirred solution of iron (III) chloride 
hexahydrate (0.5g, 1.85 mmol) in distilled water (10 mL) over a period of 5-10 min. The 
reaction mixture was stirred at room temperature for 5 min and a yellow precipitate was formed.  
The mixture was filtered under vacuum and the yellow solid product was analysed for purity 
using LC-MS/MS. A solution for analysis was prepared immediately by ten-fold dilution with 
acetonitrile. The LC-MS/MS equipment was a 1260 Infinity LC system (Agilent Technologies, 
Waldbronn, Germany) connected to a 4000 Qtrap (Sciex, Warrington, United Kingdom). An 
aliquot (3 µL) was eluted from an Agilent Eclipse XDB-C18 column (3.5-m; 150  4.6 mm) 
at 0.5 mL/min with ACN-formic acid (0.1%, v/v) in formic acid (0.1%, v/v): 25% to 75% over 
10 min; 75% for 5 min; 75% to 25% over 0.1 min. Full scanning positive-ion mass spectra 
were acquired over 5 s between m/z 100-1,000. The ionspray voltage was 5.5 kV; desolvation 
potential, 120 V; source temperature, 500 oC. 
2.3.12 Mass spectrometric analysis of DDS-NO binding to glutathione. 
DDS-NO (10 mM) was incubated with glutathione (10 mM) in potassium phosphate buffer (10 
mM, pH 7.4) at 37 oC for 16 h. The resulting crude products were diluted with 0.1% formic 
acid (1:10 dilution) and analysed by LC-MS/MS as described previously(Meng et al. 2016). 
Samples were delivered into a 4000 QTRAP mass spectrometer (AB Sciex, Framingham, MA,) 
coupled with a 1260 Infinity Quaternary Pump HPLC system (Agilent Technologies, Santa 
Clara, CA) and Kinetex C18 column (2.6 µm C18, 100 mm × 2.1 mm, Phenomenex, 
Macclesfield, Cheshire, U.K.). A gradient from 1% acetonitrile /0.1% formic acid (v/v) to 50% 
acetonitrile /0.1% formic acid (v/v) in 12 min was applied at a ﬂow rate of 150 µL/min. Full 
scanning positive-ion mass spectra were acquired over 5 s between m/z 60 and 1000. The 
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ionspray voltage was 5.5 kV, desolvation potential was 120 V, and source temperature was 500 
°C.  Data were analyzed using Analyst software, version 1.5.1 (AB Sciex). 
2.3.13 Luminex assay  
Luminex is similar to the ELISPOT assay but has a capacity to detect multiple cytokines in the 
same sample (Beeler and Pichler 2006; Chen et al. 2009; Elsheikh et al. 2011). This assay 
utilises beads with known spectral characteristics that are bound to particular capture antibodies 
in order to detect and quantify cytokines secreted by defined cell populations. 
 
Table 1: Summary of the steps involved in the Luminex assay. 
 
2.3.14 Sample preparation.  
Magnetic beads and columns were used to isolate CD14+ monocytes from PBMC (Miltenyi 
Biotech; Bisley, UK). CD14+ cells were cultured in dendritic cell culture medium. This 
medium was supplemented with GM-CSF (800 U/mL) and IL- 4 (800 U/mL). Cells were co-
cultured for 7 days at 37C°, 5% CO2. Dendritic (0.5x106) were incubated with different 
concentration of drugs under study; DDS (0.125-1mM), sulfamethoxazole (SMX) (0.125-
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1mM), DDS-NO (5-40µM), SMX-NO (5-40µM). All conditions were conducted in duplicate 
wells at 37C°,5% CO2 for 24 hr. Supernatants were collected (500µL) in Eppendorf tubes.After 
centerifugationat 1400g for 5 minutes to extend cell debris. 200µL of supernatant were then 
stored at -80C°.  
 
2.4 Results  
2.4.1 Synthesis and characterization of DDS-NO  
A solution of DDS-NO (Figure 2.8A) was prepared and analysed immediately by HPLC and 
mass spectrometry. The purity of DDS-NO was 95% based on HPLC analysis (Figure 2.9B). 
DDS-NO (retention time, 11.6 min) was detected as [M+H]+ at m/z 263 (Figure 2.9B). 
Abundant and characteristic fragment ions were seen at m/z 233 ([M+H-NO]+) and m/z 93 
([PhO]+). The material, typical for an arylnitroso preparation, contained a small amount of the 
azoxy derivative ([M+H]+ at m/z 509; retention time, 12.5 min), which does not bind covalently 
to protein. The reactivity of DDS-NO with the low molecular weight thiol glutathione was 
confirmed by  mass spectrometry (Figure 2.9C). Direct addition of glutathione to DDS-NO 
resulted in a sulfinamide product, which can be further oxidized to form a sulfonamide and an 
N-hydroxysulfonamide adduct. Only two of the three putative DDS-NO/glutathione reaction 
products were detected by LC-MS/MS, namely the [2O] (m/z 586.3) and [3O] N-S conjugates 
(m/z 602.3) (Figure 2.9C&D). The product ion spectra provided confirmative evidence for the 
formation of the proposed sulfonamide and N-hydroxysulfonamide adducts shown in Figure 
2.10. 
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Chemical synthesis nitroso-dapsone from dapsone hydroxylamine. 
 
 
 
 
A. 
B. 
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Figure 2.9: Synthesis of DDS-NO from DDS hydroxylamine. DDS hydroxylamine is converted to DDS-NO in 
the presence ethanol and iron chloride hexahydrate. The yellow solid paste was filtered analysed by LC-MS/MS 
for purity. The DDS-NO fraction as formed at 11.8 min retention time. Anticipated pathways of modificationDDS-
NO to cysteine residues of glutathione is shown. Mass increments resulting from adduction of reactive metabolite 
(DDS-NO) to GSH are involved. 
 
 
 
  
 
 
 
 
Figure 2.10: Scheme showing chemical structure of DDS-NO hapten adduct formed through covalent binding of 
DDS-NO to glutathione. DDS-NO haptenate the protein and peptides by nucleophilic attack at cysteine residues, 
resulting in a mass increases of 570,586 and 602 amu for each modified cysteine residue.The chemistry is 
complicated by the methods conventionally used to process proteins for mass spectrometry analysis, namely 
iodoacetylation of cysteine. The drug itself was shown to be iodoacetylated. 
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2.4.2 Toxicity assay 
To determine the toxic profiles of tested compounds, PBMC were incubated with graded 
concentrations of DDS, DMSO, DDS-NHOH, DDS-NO and SMX-NO in the presence of the 
mitogen PHA. Thymidine incorporation was used to determine inhibition of cell proliferation 
(Figure 2.11). DDS inhibited PBMC proliferation at concentration of 1000µM. In contrast, 
DDS-NHOH and DDS-NO inhibited PBMC prolifereation at 25 µM.   
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Figure 2.11 Toxicity of DDS and DDS metabolites.PBMC (1.5х104 , 100µL) were incubated with graded 
concentration of  A) DDS (125 – 4000 µM) , B)  DDS-NO ( 25 – 800 µM ), C) DDS-NHOH (25-800µM. PHA 
as added to stimulate proliferation. 96-Well U-bottom plates were incubated at 37 C° and 5% CO2 for five days. 
[3]Thymidine was added at final of 16 hr incubation and T-cell proliferation evaluated using scintillation counting. 
 
 
 
 
2.4.3 Lymphocyte transformation test (LTT) 
PBMC samples from 3 DDS naïve donors, which were all HLA-B 13:01 negative and evaluated 
the proliferation of PBMC in the presence of the test compounds. Proliferation of PBMC with 
DDS and DDS-NO was not observed. In contrast, TT (tetanus toxin), used as a positive control, 
stimulated PBMC proliferation. (Figure 2.12). 
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Figure 2.12 Lymphocyte transformation test (LTT) assay using PBMC from healthy donors not previously 
exposed to DDS. PBMC (1.5×104 cells, 100 µL) were incubated with graded concentrations of either (A)DDS 
(0.125-2 mM) or (B) DDS-NO (10-40 µM) in 96-Well U-bottom plates. Plates were incubated at 37°C, 5% CO2 
for 5 days.  [3H]-thymidine  (0.5  μCi)  was  added  for  the  final  16  hours  of  incubation and T-cell proliferation 
evaluated using scintillation counting. 
 
 
2.4.4 Priming of naïve T-cells from healthy donors to DDS and DDS-NO. 
Naive T-cell proliferation responses, following priming with DDS or DDS-NO were assessed 
with T-cells from three heathy donors (Figure 2.12). In order to prime either DDS or DDS-NO-
specific T-cell responses, naïve CD45RA+ T-cells from HLA-B*13:01-negtive volunteers (n 
= 3) were cocultured with autologous DCs in the presence of DDS or DDS-NO. After 8 days 
the primed T-cells were restimulated with fresh DCs and the drug and antigen-specificity was 
assessed using [3] thymidine and ELISpot. Moderate levels of proliferation and IFN-γ release 
with both DDS and DDS-NO was detectable and the response was found to be antigen-specific 
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and dose-dependent (Figure 2.13).T-cells from donor 3 crossreacted with the alternative form 
of the DDS antigen. 
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Figure 2.13- DC-priming of naïve T-cells to DDS and DDS-NO. A, C) Naive T-cells from 3 donors were co-
cultured with monocyte-derived DC and either DDS (0.5mM) or DDS-NO (40µM) for 7 days. Afterwards, fresh 
autologous DC were cultured with the primed T cells in the presence of graded concentration of DDS-NO (10–40 
µM) or DDS (0.125–1 mM). Plates were incubated at for 48 hours at 37°C,  5% CO2. [3H]Thymidine was added 
during the final 16 h of incubation and T cell proliferation evaluated by using scintillation counting. B, D) Cells 
were cultured as described above and IFN-γ ELISpot performed according to manufacturer’s instructions. 
 
 
 
 
 
 
 
 
Chapter 2 
 
82 
 
2.4.5 Cytokine production by DC cultured with DDS, SMX, DDS-NO or SMX-NO. 
Drugs were incubated for 24-hours with DCs and, supernatant (200µL) was assessed using 
luminex according to the manufacturer’s protocol. Cytokines were detected, using serial 
dilutions of the standards of all cytokines for quantification. IL-8, IL-13, IL-15, IL-17and TNF-
a and MIP-1b are pro-inflammatory cytokines, while IP-10, and G-CSF are anti-inflammatory. 
(Table 2.2) 
 
 
 
 
Table 2.2: Cytokines production of DC cocultured with Drug. 
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2.5 DISCUSSION 
Understanding of the patho-mechanism of immunological drug reactions remains an important 
challenge (Uetrecht and Naisbitt, 2013). Due to their complexity they are burden on health care 
systems (Davies et al., 2009) and an impediment to the drug development process. Studies 
show that there are a number of factors involved in hypersensitivity which include genetic and 
environmental factors and the chemical properties of drugs (Knowles et al. 2002; Macy 2004). 
DDS undergoes N-acetylation in the liver which leads to the generation of non-toxic 
metabolites which can then be safely eliminated from the body via urine (Zuidema et al., 1986; 
Gelber et al., 1971). DDS also undergoes CYP-450-mediated metabolism to yield DDS 
hydroxylamine (DDS-NHOH) (Ganesan et al., 2010). DDS-NHOH is not protein-reactive and 
can be excreted through the urine in an unchanged state (Bluhm et al., 1999). Rieder and his 
colleagues in 1988 used a cell based assay to show that DDS-NHOH is toxic, inducing cell 
death at relatively low concentrations. This toxicity is thought to be due to DDS-NHOH ( 
Rieder et al., 1988). DDS-NHOH undergoes auto-oxidation and forms a highly protein-reactive 
DDS-NO intermediate(Coleman, 1995). DDS-NO-modified proteins can be degraded into 
peptide fragments and presented in an MHC class II-restricted manner to CD4+ T-lymphocytes 
or MHC class I-restricted manner to CD8+. If this is the case, DDS-NO would be the primary 
trigger of hypersensitivity reactions.  
DDS is structurally similar to sulphonamides such as SMX (Brackett et al., 2004).  SMX also 
forms a nitroso metabolite and there are number of studies which show that SMX-NO act as 
trigger of immune responses in human and animals. Despite this, complimentary studies have 
shown SMX, the parent drug, also interacts directly with MHC molecules to activate T-cells 
(Naisbitt et al. 2001; Uetrecht and Naisbitt 2013). There is a gap in literature regarding the 
pathomechanism of DDS hypersensitivity in terms of the relationship between the DDS-NO 
formation and T-cell activation. Studies conducted on normal human dermal fibroblasts and 
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normal human epidermal keratinocytes found that DDS hydroxylamine metabolites are formed 
in skin cells and this leads to adduct formation. This suggests that adduct are formed at the site 
of the adverse event, (Bhaiya et al, 2006 ; Vyas et al,2006 ) but studies describing the 
relationship between DDS metabolism and T-cells activation have not performed. There are 
also number of studies which have focused on the role of HLA alleles in drug hypersensitivity 
reactions by different drugs (Illing et al., 2012;Yun et al., 2012). Zhang et al, demonstrated that 
HLA-B*13:01 allele acts as a risk factor of DDS hypersensitivity syndrome (Zhang et al, 
2013). This suggests that binding of the drug antigen (s) to this MHC molecules might be 
important for T-cell activation. To investigate this we synthesized DDS-NO by oxidation of 
DDS-NHOH in laboratory. Inhibition of PBMC proliferation was performed to determine the 
optimumdrug conentrations for the experiments such as priming of naïve T-cells and cross 
reactivity. DDS-NHOH was converted to DDS-NO using ethanol and iron chloride 
hexahydrate. The yellow solid paste had a purity of 95%. DDS-NO was the incubated with 
glutathione to characterize the adduct structures formed as nitroso compounds are known to 
bind selectivity to thiol groups. Similar to SMX-NO, direct addition of glutathione to DDS-NO 
resulted in formation of a sulfinamide product, which was detected after 1 minute incubation 
(Callan et al. 2009). However, the sulfinamide is unstable and can be further oxidized to form 
a stable 2[O] adduct and an N-hydroxysulfonamide adduct. Indeed, two stable adducts were 
detected after incubation of DDS-NO with glutathione. The structure of 2[O] adduct has been 
controversial, however, mass spectrometric data from this study provided evidence for 
formation of the sulfonamide, which was presumably derived from N-hydroxysulfinamide (see 
figure 2.9 C&D) 
 For determination of the optimized priming doses of both DDS and DDS-NO, the inhibition 
of PBMC proliferation was assessed. The toxicity assay revealed that DDS-NHOH and DDS-
NO are   highly toxic, when compared with DDS. The optimized non-toxic dose for DDS was 
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between 0.2-0.5 mM while the optimized dose for DDS-NO was (20 µM). The LTT assay was 
then performed to confirm that naïve healthy donor PBMC are not stimulated to proliferate 
with parent drug or DDS-NO. PBMC from all 3 donors were not activated with DDS or DDS-
NO which indicate that there are no DDS or DDS-NO specific T-cells circulating in their 
peripheral blood.  
The in vitro priming assay model has the ability to explore the immune stimulatory capability 
of drug antigens in naïve donors (Faulkner et al. 2012). In our study naïve T-cells were primed 
to either DDS or DDS-NO.  The assay involved an initial co-culture period of naïve T-cells, 
DCs and DDS or DDS-NO for 7-8 days. The resulting data from [3H] thymidine proliferation 
and IFN-γ secretion assays revealed that naïve T-cells were sensitized to DDS and DDS-NO. 
Drug-primed naïve T-cells were stimulated to proliferate in a dose-dependent manner 
(Figure.2.13). Furthermore, cross reactivity was observed with 1/3 donors (figure 2.13). 
Cytokines play very important role in T-cell reactions. These are soluble proteins that are 
secreted by cells of the immune system. The main function of these cytokines is to  alter the 
behavior and properties of different cell types within and outside the immune system.   
Cytokines produced by DCs impact on the polarization of antigen-specific T-cells deriving 
priming thus, we assessed the cytokines secreted from DCsfollowing exposure to DDS and 
DDS-NO.  
There are a number of ways the cytokines can be measured in biological samples.  These 
include secreted bioassays, enzyme-linked immunosorbent assays (ELISA), radioactive 
immunosorbent assays, microarrays and most recently, multiplex assays. In this study,a 
luminex assay was performed on dendritic cell supernatant, 24hr after DDS and DDS-NO 
treatment. The compounds  did not influence the secretion of most cytokines (Table 2.2), TNF-
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a , IP-10 , IL-8, MIP-1b, IL-17,IL-13,IL-15 and G-CSF was observed in the presence of DDS 
and/or DDS-NO, SMX and SMX-NO (Table 2.2). 
In conclusion, this first piece of work shows that it was possible to synthesize DDS-NO and 
assess its immunogenicity. Both DDS and DDS-NO primed naïve T-cells from healthy donors. 
Subsequent chapters describe the generation of DDS and DDS-NO-specific T-cell clones and 
characterization of their phenotype and functionality. 
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3.1 Introduction: 
Drug-specific T-lymphocytes participate in the pathogenesis of drug hypersensitivity reactions 
through a variety of means including the secretion of cytokines and cytolytic mediators. 
Despite significant advances in recent years, definition of the pathway(s) of drug antigen 
presentation that result in T-cell activation remains a subject of debate. Drugs can activate T-
cells via a hapten pathway involving the formation of protein adducts (Meng et al. 2017; 
Padovan et al. 1997; Brander et al. 1995). The hapten response is dependent on protein 
processing within antigen presenting cells and the generation of an antigen that comprises of 
the MHC binding peptide and the drug moiety bound covalently to a specific nucleophilic 
amino acid. Drugs might also covalently modify MHC molecules or peptides embedded within 
MHC molecules on the surface of antigen presenting cells to activate T-cells. In addition to 
this, drugs have been shown to interact with MHC molecules and T-cells directly via readily 
reversible bonds (pharmacological interaction pathway) (Schnyder et al. 2000; von Greyerz et 
al. 1999; Ko et al. 2011; Watkins & Pichler 2013). Although the precise nature of the 
pharmacological interaction remains ill-defined several drugs have been shown to stimulate T-
cells via this pathway (Wu et al. 2007; Burkhart et al. 2001; Yun et al. 2014). Finally, the 
nucleoside reverse transcriptase inhibitor abacavir activates T-cells by binding deep within the 
peptide binding groove of one specific MHC molecule, HLA-B*57:01, altering the 3-
dimentional space and hence the nature of the peptides that subsequently bind (Illing et al. 
2012;Ostrov et al. 2012;Norcross et al. 2012). It has been proposed, although not yet proven, 
that these altered peptides and not the drug per se activate the T-cells involved in abacavir 
hypersensitivity.  
 
Knowledge of the drug MHC binding interaction is complicated by the fact that most drugs 
undergo extensive metabolism and one or more metabolites might activate T-cells via any of 
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the pathways described above. Furthermore, our ability to study drug metabolite-specific T-
cell responses is limited by: (1) the almost complete absence of synthetic drug metabolites for 
functional studies; and (2) a disconnect between the drug protein binding interactions that occur 
in patients and in vitro in cell culture systems.To date, researchers have shown that T-cells 
isolated from patients with (1) allopurinol-induced hypersensitivity are preferentially activated 
with the active metabolite oxypurinol through a direct binding interaction with HLA-
B*58:01(Yun et al. 2013); and (2) sulfamethoxaozle-induced hypersensitivity reactions are 
activated with the cysteine-reactive nitroso metabolite through a hapten mechanism (Schnyder 
et al. 2000; Castrejon et al. 2010).  
 
Given the limited availability of synthetic reactive metabolites, the aim of this study was to 
focus on dapsone (DDS) and the synthetic metabolite nitroso-dapsone (DDS-NO) to 
investigate the molecular mechanism(s) of antigen-specific T-cell activation using cells cloned 
from healthy volunteers.Cytochrome P-450, flavin monooxygenase and peroxidase-mediated 
N-hydroxylation results in the formation DDS hydroxylamine (Zuidema et al. 1986; 
Roychowdhury et al. 2007; Piyush M Vyas et al. 2006; Piyush M. Vyas et al. 2006). DDS 
hydroxylamine is susceptible to auto-oxidation and the derived nitroso species has been shown 
to bind covalently to protein (Roychowdhury et al. 2007; Bhaiya et al. 2006; Roychowdhury 
et al. 2005).  Despite this, the nature of drug or drug metabolite interaction with T-cells has not 
been defined. 
 
Although DDS is usually well tolerated and suitable for long term treatment, a severe 
hypersensitivity syndrome with a mortality rate of 9.9% develops in 0.5-3.6% of patients 
(Kosseifi et al. 2006). Reactions are characterised by a delayed onset (usually 4-6 weeks) with 
a long latent period (Kosseifi et al. 2006; Agrawal & Agarwalla 2005; Prussick & Shear 1996). 
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Zhang et al found that HLA-B*13:01 expression is a predictor of the hypersensitivity syndrome 
in Chinese patients with leprosy (Zhang et al. 2013). These genetic data suggest that the 
adaptive immune system may be involved in the disease pathogenesis; however, the activation 
of T-cells with dapsone and dapsone metabolites has not been studied. Therefore the aim of 
this chapter was to generate DDS- and DDS-NO specific T-cell clones from healthy volunteers 
and investigate the molecular pathomechanism of dapsone hypersensitivity. 
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3.2 Materials and Methods 
3.2.1 Chemicals and reagents. 
DMSO, dapsone, phytohemagglutinin (PHA) and all the dapsone analogues used in this study 
were purchased from Sigma-Aldrich (UK). Dapsone hydroxylamine was purchased from 
Dalton Chemical Laboratories Inc. (Toronto, Canada). Tritiated thymidine-(methyl-3H) was 
obtained from Moravek (California, USA). Analytical grade (Analar) acetonitrile, HPLC grade 
distilled water, and HPLC grade methanol were acquired from Fisher Scientific (Loughborough, 
United Kingdom). 
3.2.2 Culture medium. 
All type of cells used in this study were grown in RPMI-1640 cell culture medium with required 
supplementation of human serum albumin. T-lymphocytes were grown in RPMI-1640 medium 
supplemented with 10% human AB serum, 25 mM HEPES buffer, 2 mM L-glutamine, 
penicillin (1000 U/ml), streptomycin (0.1 mg/ml), and transferrin (25 µg/ml). Dendritic cells 
were grown in RPMI-1640 medium supplemented with 10% human AB serum, 25 mM HEPES 
buffer, 2 mML-glutamine, penicillin (100 µg/ml), streptomycin (100 U/ml),GM-CSF 
(800U/ml), IL-4(800 U/ml) and transferrin (25 µg/ml).  
3.2.3 Isolation method of peripheral blood mononuclear cells (PBMC). 
PBMC were isolated from venous blood collected in heparinized vacutainer tubes. Blood was 
centrifuged at 2000 rpm for 25 minutes at 25°C temperature. The buffy coat layer containing PBMC 
was removed by using a Pasteur pipette and transferred into a new tube. Buffy coat was washed in 
Hanks balanced salt solution (HBSS) two times at room temperature by centrifugation. Cells 
were then counted using a Neubauer haemacytometer (Sigma-Aldrich) under a Leica DME 
microscope (Leica Microsystems, Milton Keynes). 
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3.2.4 Generation of drug-specific T-cell clones 
Naïve T-cell from healthy volunteers were primed to either DDS (0.5 mM) or DDS-NO (20 
μM). As described in chapter 2, T-cells were then cloned by serial dilution. Briefly, T-cells 
were plated at 0.3,1and 3 cells per well in a 96 weel culture plate. The T-cells were then 
stimulated with cocktail of irradiated allogenic PBMC (5x106) and PHA (20µL/ml) in a total 
volume of 200µL. IL-2 was added every 2 days to maintain the proliferative response. After 
14 days the procedure was repeated and viable clonies were spilt into 4 wells of fresh 96 well 
plate prior to testing antigen specificity. Epstein-Barr virus (EBV) transformed B-cell lines 
were generated by transformation of freshly isolated PBMC using supernatant from the virus-
producing cell line B95.8. 5ml of the supernatant was filtered by a 0.45μm syringe filter on to 
a PBMC pellet containing 5 x 106 cells. 5μl of cyclosporin A (CSA) was then added to prevent 
T-cell mediated suppression of B-cell infection and to inhibit EBV from inducing T-cell 
proliferation. After overnight incubation (37°C, 5% CO2), cells were washed, resuspended at 
1 x 106/ml in antigen-presenting cell medium containing CSA (1μg/ml) and transferred to a 24-
well cell culture plate (1ml/well). Cells were fed twice per week with fresh antigen-presenting 
cell medium and CSA was omitted from the culture medium after 14 days. When confluent 
populations were observed, the cells were transferred to a tissue culture flask.  Autologous 
Epstein-Barr virus (EBV)-transformed B-cell lines were used as APC in assays involving T-
cell clones (TCCs). Antigen-specificity was assessed by culturing irradiated EBV-transformed 
B cells (1x104/well) and DDS or DDS-NO with drug-specific T-cell clones (5x104/well; 200 
μl) for 48 hours. Proliferation was measured by the addition of [3H]-thymidine followed by 
scintillation counting. Clones with a stimulation index (proliferation due to drug/proliferation 
due to medium) greater than 2 were expanded by repetitive stimulation with irradiated 
allogeneic PBMC (5x105/well), IL-2 (5 µg/ml) and PHA (10 µg/ml). 
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3.2.5 Characterization of dapsone – specific TCCs   
For this experiment, DDS and DDS-NO specific TCC (5×104 cells, 50 μL) were co-cultured 
with irradiated autologous EBV-transformed B-cells (1×104 cells, 50 μL) in the presence of  
DDS (0.125-2 mM),  DDS-NO (40 µM) or SMX-NO (40 µM) in duplicate using  a 96-well U-
bottom plate. After this, the plates were incubated at 5% CO2 for 48 hours then [
3H]-thymidine 
(0.5 μCi) was added for the final 16 hours of the incubation. Finally, T-lymphocyte 
proliferation was determined using scintillation counting. 
3.2.6 ELISpot Assay 
ELISpot plate wells were coated with 100 µL of a high affinity monoclonal antibody IFN-γ (15 
µg/ml) and incubated overnight at 4˚C, according to manufacture instructions. Wells were 
washed five times with sterile PBS and blocked with 200 µL of T-lymphocyte culture medium 
for 30 minutes at room temperature. The culture medium was aspirated out of the well and replaced 
with naïve T cells (1×105), autologous DCs (1.6×105) and drug to a total final volume of (200 
µL/well). Cells were then cultured in the presence of either DDS (0.125-0.5mM), DDS-NO (10-40 
µM, 50 µL) and incubated at 37˚C, 5% CO2 for 48 hours. Cells were discarded after 48 hours and 
the wells were washed five times with 200 µL PBS. For the detection of the captured cytokine, 
biotin-labelled detection antibody was diluted to 1 µg/ml in PBS containing 0.5% FBS and 100 µl 
added to each well. The plate was incubated at room temperature for 2 hours and the wells were 
again washed five times with PBS. Streptavidin-ALP diluted PBS containing 0.5% FBS 
(1:1000) was added to each well and incubated 1 hour at room temperature. The wells were then 
washed five times with PBS (200 µL), and BCIP/NBT substrate (100 µL/well) was added and 
incubated in the dark for 15 minutes at room temperature. Finally, wells were inspected for the 
development of spots and then washed under slow running tap water and left to air dry.  Elispot 
plates were then viewed using an ELISpot reader (Cadama Medical, Stourbridge, UK).  
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3.2.7 Antigen presenting cell (APC) fixation and antigen pulsing assays 
Antigen presenting cell fixationwas used to investigate the role of intracellular metabolism in the 
activation of T- cell clones. For this, autologous EBV-transformed B-cells (2×106 cells/ml) were 
washed twice in HBSS to exclude FBS and resuspended in HBSS (1 ml). Next, glutaraldehyde 
(25%, 1 µL) was added andthen the cells were lightly mixed for 30 seconds. After this step, 
glycine (1ml of 1 M) was rapidlyadded to the mixture and the cells were mixed for a further 45 
seconds.  To remove glutaraldehyde, cells were washed fivetimes and then resuspended in T cell 
culture medium. T cell clones (5×104, 50 µL) were co-cultured with glutaraldehyde-fixed EBV-
transformed B-cells (1×104 cells, 50 µL) in the presence or absence of DDS (0.5 mM) or DDS-NO 
(20µM). In other experiments, antigen presenting cell were pulsed with DDS or DDS-NO for 16 
hours and washed extensively with HBSS to exclude free DDS. The pulsed antigen presenting 
cells were co-incubated with drug-specific T- cell clones in a 96-well plate for 48 hours under 5% 
CO2 at 37˚C, [
3H]-thymidine was added during the last 16 hours incubation and antigen a specific 
response evaluated.  
3.2.8 MHC restriction assay 
In order to define whether DDS or DDS-NO presentation to TCCs was MHC class I/II 
restricted, anti-human MHCI (HLA-A, -B, -C), and anti-human MHC II (HLA-DP, -DQ, -DR) 
antibodies (5 µg/mL) were used. In the initial of experiment, autologous EBV-transformed B-
cell lines (1×104, 50 µL) were pre-incubated with either MHC I, MHC II or isotype control 
blocking antibodies (5 μg/ml) at 5% CO2, 37˚C for 30 minutes. The antigen presenting cell 
were then co-cultured with DDS or DDS-NO specific TCC (5×104, 50 µL) with or without 
drug for 48 hours. [3H]-thymidine (0.5 μCi) was added for the final 16 hours of incubation and 
T cell proliferation evaluated using scintillation counting. IFN-γ ELISpot was also performed 
using the same conditions as described a above. 
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3.2.9 T-cell phenotyping (Flow cytometry) 
To determine the CD4 and CD8 phenotype of TCC, flow cytometry was used. T-cell 
suspensions (100 µL) were stained with CD4-PE (3 µL) and CD8-APC (3 µL) antibodies and 
incubated at 4°C for 20 minutes in the dark. Cells were washed and resuspended in 200 µL of 
FACS buffer and CD4, CD8 expression determined using the FACS Canto™ II system. 
3.2.10 Graphs and Statistics 
 Graphs were produced using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). 
Data analysis and statistical tests were conducted using GraphPad Prism 5. In order to 
determine statistical significance when comparing two treatment groups, t test was used. In 
experiments for which more than two treatment groups were compared a one-way ANOVA. 
Differences that gave p values were considered statistically significant as flows (ns P > 0.05, * 
P ≤ 0.05, ** P ≤ 0.001, *** ≤ 0.001). 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
96 
 
3.3 Results: 
Naïve T-cell from healthy donors were primed to DDS and DDS-NO (see chapter 2 section 
2.4.4). 
3.3.1 Generation of drug-specific T cell clones. 
DDS- and DDS-NO-specific TCC were generated from previously primed T-cells of 2 out of 
3 donors to investigate pathways of T-cell activation.  Initial testing revealed that 9 out of the 
92 expanded TCC from DDS-primed T-cells were stimulated to proliferate with DDS (i.e., 
stimulation index of 2 or more; Figure 3.1 A). Three hundred and two TCC were expanded 
from the DDS-NO-primed cells. Of these, 24 were stimulated to proliferate with DDS-NO 
(Figure 3.1B).  The drug and drug metabolite-responsive TCC were expanded for subsequent 
testing. TCC were found to proliferate in a concentration-dependent manner in the presence of 
DDS or DDS-NO (Figure 3.3). Clones were not activated with DDS or DDS-NO in the absence 
of antigen presenting cells (Figure 3.2). Furthermore, DDS and DDS-NO specific clones 
displayed no cross-reactivity with DDS-NO and DDS respectively (Figure 3.4). 
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Generation of dapsone and nitroso- dapsone-specific TCC.  
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Figure 3.1: Generation of DDS- and DDS-NO-specific TCCs from two drug-naive volunteers: - TCC were 
generated using serial dilution method. Clones were co-incubated with irradiated autologous EBV-transformed B 
cells and DDS or DDS-NO. Culture medium was utilised as negative control.  The plates were incubated at 37 
°C, 5%CO2 for 48 h.  Radioactive thymidine was added later on during the last 16 h of incubation.  Clones with 
stimulation index > 2 were selected and expanded for further functional assays. A, B) DDS and DDS-NO TCC 
generated from 2 donors. 
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Antigen presenting cells are essential for the activation of DDS and 
DDS-NO –specific TCC. 
***
 
Figure 3.2: DDS and DDS-NO-specific TCC was co-cultured with irradiated autologous EBV-transformed B-
cells and DDS in a 96 wells plate and incubated at 5% CO2 for 48 h. Proliferation was determined using radioactive 
thymidine incorporation during the final 16 hours of incubation and T-cell proliferation evaluated using 
scintillation counting. 
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Drug-specific TCC are highly selective and shown no cross 
reactivity.  
 
 
Figure 3.3: Dose response and cross reactivity of drug-specific TCC: A) DDS-specific TCCs were co-cultured 
with irradiated autologous EBV-transformed B cellsin the presence of graded concentration of DDS (0.125-1mM) 
DDS-NO or SMX-NO. In a 96 wells plate at 5% CO2 for 48 h. Proliferation was determined using radioactive 
thymidine incorporation during the final 16 hours of incubation and T cell proliferation evaluated using 
scintillation counting. B) DDS-NO-specific TCC was cultured with graded concentration of DDS-NO. Data was 
analysed in the same way as discussed above.  
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3.3.2 T-cell CD phenotyping  
All the three DDS-specific TCC expressed CD4 cell surface protein. In contrast, the one 
DDS-NO-specific TCC that could be expanded sufficiently was CD8+. (Figure 3.4). 
 
CD4/CD8 characterisation of drug-specific TCC. 
 
Figure 3.4:A) The phenotypes of three DDS-specific TCCs were determined using fluorescent activated cell 
sorting with fluorescent antibodies for CD4 (PE) and CD8 (APC). B) The phenotype of one DDS-NO-specific 
TCC was determined using fluorescent activated cell sorting with fluorescent antibodies for CD4 (APC) and CD8 
(PE). 
 
 
3.3.3 The effect of glutathione on the activation of DDS and DDS-NO specific TCC. 
APC and TCC were pre-treated with glutathione (1 mM) before incubation with DDS (0.5 mM) 
or DDS-NO (10µM).Glutathione had no effect on the activation of DDS-specific clones, in the 
contrast to the T-lymphocyte proliferative responses of DDS-NO-specific clones, which was 
reduced in the presence of glutathione. (Figure 3.5). 
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Glutathione alternate the activation of DDS-NO-specific TCC. 
Figure 3.5: [3H]-proliferation assay, DDS-specific TCC was co-cultured with irradiated autologous EBV-
transformed B-cells and DDS in a 96 plate wells at 5% CO2 for 48 h in the presence and absence of glutathione 
(1mM). Proliferation was determined using radioactive thymidine incorporation during the final 16 hours of 
incubation and T cell proliferation evaluated using scintillation counting. B.DDS-NO specific TCC was activated 
with APC and DDS-NO in the absence or presence of glutathione as describe above and proliferate response 
measured using [3H] thymidine. 
 
3.3.4Charactrisation of the mechanism of activation of DDS and DDS-NO-specific TCC. 
The fixation of the APC is important to determine the role of antigen processing in T cell 
activation. Glutaraldehyde fixation of APC abolishes the ability of APC to process antigens 
presenting. DDS-specific T cell clones were stimulated via a processing independent pathway 
involving a direct interaction between DDS-MHC peptide complex and T cell receptors as 
clones were activated with the drug in the precence of fixed APC (Figure 3.6C). Similarly, 
DDS-specfic T-cell clones were not activated with DDS pulsed APC. In contrast, DDS-NO 
pulsed APC activated the DDS-NO-specific clones (Figure 3.6E) and fixation of antigen 
presenting cell blocked the activation of clones with DDS-NO. CD4+ DDS-specific TCC were 
MHC class II restricted (Figure 3.6A). Suprisingly, the DDS-NO-specific TCC was CD8+ 
(Figure 3.4B) and MHC class II (Figure 3.6D). 
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Molecular mechanism of DDS-specific TCC activation. 
0
 Is
ot
yp
e I
  
Iso
ty
pe
 II 
 
MH
C 
I  B
lo
ck
MH
C 
II  
Bl
oc
k
0
100
200
300
400
500
0 Isotype II MHC I BlockIsotype I MHC Block II
DDS-specifc TCC MHC restriction
INF-
pulsing DDS-specific TCC
0 0.5
pu
lse
d 
AP
C
0
100
200
300
0 0.5 pulsed APC
DDS (mM)
INF-
Fixed DDS-specific TCC
DDS(0.5mM)
0
0.5
Gl
u/
DD
S
0
100
200
300
400
0 0.5 Glu/DDS
INF-
0
Iso
ty
pe
 I 
Iso
ty
pe
 II 
MH
C 
I B
lo
ck
MH
C 
II B
lo
ck
0
2000
4000
6000
8000
DDS-NO-specific TCC MHC restriction
0 Isotype I Isotype II MHC II
Block
MHC I
 Block
INF-
          Pulsing DDS-NO-specific TCC
DDS-NO ( M)
0 30
pu
lsi
ng
 A
PC
0
100
200
300
400
0 30 pulsing APC
INF-
0 30
Gl
u+
Dr
ug
A. B. C.
D. E. F.
Figure 3.6 mechanism of activation T-cell: A. DDS-specific TCC generated from two drug-naive donors. 
ELISpot plates were pre-coated with human IFN-γ coating antibodies according to manufacturer’s instruction and 
incubated overnight at 4°C. TCCs were co-incubated with irradiated autologous EBV-transformed B-cells and 
DDS (0.125 -1 mM) using culture medium as negative controlin the presence either MHC I or MHC II blocking 
antibodies. Isotype control were used as negative control the plates were incubated at 37°C, 5% CO2 for 48 h and 
plates developed for image visualisation and spot counts.B. EBV-transformed B-cells were pulsed with DDS for 
24 h and cells washed extensively to remove free drug. Drug-pulsed EBVs were then co-cultured with DDS-
specific TCC, and INF-γ secretion determined as described above. C. EBVs were first treated with glutheraldehye 
to abolish antigen processing then co-cultured with DDS-specific TCC and DDS followed by IFN-γ ELISpot 
assay. In contrast, fixation of APC blocked the activation of DDS-NO-specific T-cell clones. D, E and F represent 
similar experiments described above for DDS-NO-specific TCC. 
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3.3.5 Drug-specific TCC secrete a mixture of Th1, Th2 and cytokines molecules. 
 The cytokines IL-13 and IFN-γ, were secreted from DDS or DDS-NO stimulated clones 
generated from drug-naïve healthy donors. (Figure 3.7) TCC failed to secreted either IL-5 or 
the cytolytic molecules granzyme B. 
Cytokine secretion profiles of DDS-and DDS-NO-specific TCC. 
 
 
Figure 3.7: Cytokine secretion profiles of DDS-and DDS-NO-specific TCC generated from two drug-naive 
donors. ELISpot plates were pre-coated with human INF-γ, IL-5, IL-13 and granzyme-B coating antibodies 
according to manufacturer’s instruction and incubated overnight at 4°C. TCCs were co-incubated with irradiated 
autologous EBV-transformed B-cells and DDS (0.125 -1 mM) or D-NO (10-40 µM) using culture medium as 
negative control.  The plates were incubated at 37°C, 5% CO2 for 48 h and plates developed for image visualisation 
and spot counts. A and C show representative cytokine profile and images for DDS-specific TCC while B and D 
show representative cytokine profile and images for DDS-NO-specific TCC. 
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3.3.6 DDS-specific TCC clone cross reactivity to analogues DDS or sulfonamides. 
Activation of DDS-specific clones was not observed when they were cultured with APC and 
analogues: 4, 4 thiodianiline; (DDE), 4, 4 oxydianiline (DDT) and 3, 3 sulfonyldianiline 
(3DDS); (Figure 3.8) or sulfonamides (sulfamethoxazole, sulfamerazine, sulfadiazine, 
sulfachloropyridazine, sulfadoxin and sulphanilamide (Figure 3.9). However, a weak 
proliferative response and IFN- release was detected when the DDS-specific TCC were 
cultured with the mono- and di-acetylated forms of DDS (Figure 3.8A&B). 
DDS-specific TCC do not cross react with closely related dapsone 
analogues. 
Figure 3.8: A, B) Cross reactivity of DDS-specific TCC with closely related analogues: DDS-specific TCC were 
co-incubated with irradiated autologous EBV-transformed B-cells in the presence of DDS and closely related 
analogues in a 96 wells plate at 5% CO2 for 48 h. C) ELISpot images for DDS-specific TCC incubated with either 
DDS or closely related dapsone analogues (3DDS,DDT, DDE, mAC and DAC - 0.5 mM), D) DDS analogue 
chemical structures.Analogues (4,4 thiodianiline (DDE), 4,4 oxydianiline (DDT) and 3,3 sulfonyldianiline 
3DDS,monoacetyle-dapsone(mAC),Diacetyle-dapsone(DAC). 
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DDS-specific TCC do not cross react with closely related 
sulfonamides. 
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Figure 3.9: A) Cross reactivity of DDS-specific TCC with closely related sulfonamides  : DDS-specific TCC was 
co-incubated with irradiated autologous EBV-transformed B-cells in the presence of DDS or different 
sulphonamides (SMX , SZ,SD , SN , SX ,SCH- 0.5 mM) in  96 wells plate  at 5% CO2 for 48 h. (B) Chemical 
structure of sulfonamide tested in  cross reactivity by using thymidine proliferation assay. 
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3.4 Discussion  
A clear understanding of the mechanistic basis of drug hypersensitivity remains a significant 
challenge as genetic, environmental and chemical factors impact upon susceptibility and the 
nature of the adverse event(Uetrecht & Naisbitt 2013). Layered on top of this is the fact that 
drugs interact with immune receptors in a number of ways to initiate an antigen-specific T-cell 
response. The dearth of synthetic protein-reactive metabolites for functional studies has 
complicated the development of research strategies to explore drug antigen presentation to T-
cells. Thus, the majority of studies have focused on the interaction of parent drugs with MHC. 
For this reason, the aim of the current study was to explore the immunogenicity of the DDS 
and DDS-NO in human test systems. In this study dapsone was selected because of the dapsone 
hypersensitivity syndrome that develops in dapsone treated Chinese patients with leprosy, and 
its strongly association with the expression of a single HLA allele, B*13:01 (Zhang et al. 2013).  
 
DDS-NO was synthesized by oxidation of DDS hydroxylamine using the method established 
by Naisbitt et al (Naisbitt et al. 1996). To explore dapsone immunogenicity, we utilized a 
recently established assay (Faulkner et al. 2016; Faulkner et al. 2012) that involves the culture 
of dendritic cells with autologous naïve T-cells and either DDS or DDS-NO for 8 days. In 
chapter 2, naïve T-cells from healthy donors were primed to either DDS or DDS-NO. TCC 
were subsequently generated from two donors. DDS-specific TCC were CD4+, whereas CD8+ 
TCC were activated with DDS-NO. Importantly, the clones did not display cross-reactivity.  
 
Ourselves and others have developed and utilised a battery of functional assays to distinguish 
between hapten and pharmacological pathways of T-cell activation (Meng et al. 2017; 
Schnyder et al. 2000; Castrejon et al. 2010; Monshi et al. 2013; Burkhart et al. 2001; Nassif et 
al. 2004). The same approach was adopted herein to define pathways of DDS- and DDS-NO-
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specific activation of TCC. The activation of TCC with both DDS and DDS-NO was dependent 
on the presence of antigen presenting cells. Antigen presenting cells were therefore pulsed with 
DDS or DDS-NO followed by repeated washing to remove unbound drug, to explore whether 
TCC are activated by DDS (metabolite)-modified proteins. DDS-NO-specific TCC were 
activated with DDS-NO-pulsed but not DDS-pulsed antigen presenting cells. In contrast, DDS-
specific TCC were not activated with antigen presenting cells pulsed with either DDS or DDS-
NO. In the next experiments, glutathione was added to the T-cell proliferation assay. As 
discussed above, glutathione interacts covalently with DDS-NO limiting protein binding. 
Glutathione reduced the activation of TCC with DDS-NO, while it had no effect on the DDS-
specific TCC. Collectively, these data indicate that DDS-NO forms a protein adduct within 
antigen presenting cells to activate TCC, whereas DDS-specific TCC are activated via a 
pharmacological interaction of the parent drug with MHC and the T-cell receptor.  
Fixation of antigen presenting cells with glutaraldehyde blocks antigen processing, but not the 
display of MHC molecules on the cells surface (Zanni et al. 1998). To confirm that the 
processing of proteins into peptide fragments is involved in the activation of DDS-NO-, but 
not DDS-, specific TCC, glutaraldehyde-fixed antigen presenting cells were used in the 
proliferation assay. TCC were not activated with DDS-NO, whereas DDS activated TCC to a 
similar extent when experiments with fixed and irradiated antigen presenting cells were 
compared.  
Sulfones such as DDS are used rarely in pharmacology, when compared with drug classes such 
as the sulfonamides. For this reason, we chose to explore the reactivity of DDS-specific TCC 
with DSS analogues and a panel of sulfonamides. TCC were not stimulated to proliferate with 
4,4 thiodianiline, 4,4 oxydianiline or 3,3 sulfonyldianiline, which indicates that the sulfone 
moiety (O=S=O) and the position of the amine groups are important for T-cell activation. 
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Similarly, TCC were not activated with the panel of sulfonamides. Hence, the interaction of 
DDS with MHC that leads to the T-cell response seems to be highly structurally specific. 
In addition to N-hydroxylation, which yields DDS hydroxylamine and DDS-NO, DDS is 
metabolized by N-acetyl transferase enzymes to mono- and di-acetylated forms (Zuidema et al. 
1986),  which are presumed to be non-toxic. Certain DDS-specific clones were stimulated to 
proliferate weakly and secrete low levels of IFN- in the presence of both mono- and di-
acetylated DDS, suggesting that these species also interact with MHC molecules to stimulate 
T-cells. Further experiments however are needed to explore whether the acetylated DDS 
metabolites prime naïve T-cells.     
In summary, our data indicate that DDS-NO can activate human naïve T-cells via a hapten 
pathway. In contrast, the parent drug binds to MHC molecules expressed on the surface of 
antigen presenting cells to activate T-cells. It is important to emphasize that our healthy donors 
did not express the HLA risk allele HLA-B*13:01. In chapter 4 we recruited HLA-B*13:01+ 
donors with a history of DDS hypersensitivity to explore the nature of the drug-specific T-cell 
response and whether DDS and/or DDS-NO bind preferentially to HLA-B*13:01 to selectively 
activate CD8+ T-cells.   
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Chapter 4: Generation and characterisation of DDS- and DDS-NO-specific 
T-cell from 6 HLA-B*13:01 positivepatients. 
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4.1 Introduction: 
Drug-induced hypersensitivity is a major cause of anxiety to the patient, hospital and 
pharmaceutical companies. For the patient, it may cause concern that may delay with their 
healing period. In terms of hospital concerns, the challenge is to determine the kind of treatment 
and the prescription of effective medication without causing more suffering. The 
Pharmaceutical industry incure significant loss in income when drugs are withdrawn from 
clinical use due to hypersensitivity reactions. Considering that the estimated cost of inventing, 
developing and testing a new drug is about $5 billion (Tohyama and Hashimoto, 2011) the loss 
of one drug may threaten the existence of the pharmaceutical company. In many nations, 15 to 
20 % of their hospital budget is used in treating adverse drug reactions. Also in England, about 
£2 billion is spent annually in treating adverse drug reactions (Veeren, and Weiss, 2017). 
DDS is an anti-inflammatory agent and a treatment for infections such as leprosy. The use of 
DDS can lead to hypersensitivity in up to 3% of patients. A mortality of 3% has also been 
reported for those who develop DDS-mediated adverse drug reaction (Cornelius et al., 2016). 
According to Pichler et al. (2017) early detection of drug hypersensitivity is important in order 
to prevent the development of life-threating hypersensitivity syndrome. DDS is an aniline 
derivative,  it is metabolized in the liver via N-hydroxylation and N-acetylation pathways. 
Cytochrome P-450 mediated N-hydroxylation of dapsone releases a metabolite called DDS 
hydroxylamine which is thought to be precursor to the ultimate compound responsible for DDS 
hypersensitivity. DDS hydroxylamine is spontaneously oxidised to a protein-reactive nitroso 
derivative DDS-NO.  The organ most frequently and prominently affected in drug 
hypersensitivity syndrome is skin, and generalized exanthema (maculopapular rash) is the main 
cutaneous reaction. It is characterized by an elevated spotted rash which appears one to three 
days after drug intake; it starts on the trunk and then the limbs. Adverse drug reactions may 
also cause hardening of the lymph node and exfoliative dermatitis (Macy et al. 2017). Steven-
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Johnson’s syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most life-threatening 
forms of cutaneous drug hypersensitivity reaction. SJS start as maculopapular rash and 
proceeds to bullae, conjunctivitis, fever and fatigue. TEN is rare but symptomatically presents 
as SJS but causes detachment of a large portion of epidermis and has a mortality rate of 30%. 
DDS causes a hypersensitivity syndrome involving a triad of effects including fever, skin rash 
and eosinophilia often with systemic involvement such as liver or haematological injury. 
Reactions have an onset of 2-8 weeks after commencing DDS treatment which is longer than 
for other forms of drug hypersensitivity. This had led researchers to suggest the 
pathomechanism for DDS hypersensitivity may be different to others form of skin injury. 
Specifically, Picard et al (2010) suggested that the hypersensitivity syndrome may involve an 
anti-viral T-cell responses promoted by exposure to the culprit drug. Both innate and the 
adaptive immunity may be stimulated by drug metabolism and the formation of reactive 
metabolites, either by protein binding which lead to MHC-associated T-cell activation or 
through stress activated triggering of innate cells (Daly, 2013). Drugs are small molecules that 
should not provoke an adaptive immune reaction. As a result, for a drug-induced immune 
reaction to occur, drugs are believed to acts as prohaptens or haptens. These chemically 
responsive molecules then bind to large protein. Traditionally it is believed that sensitization 
of T-cells happens when the drug-protein complex binds to antigen presenting cell (APC) and 
are transported to the nearest draining lymphoid tissue for processing and then presention to 
MHC (Yun et al. 2016). Naïve T-cells are then triggered to proliferate into mature T-cells. 
Drug-hapten specific T-cells are stimulated with drug-modified peptide derived from the 
orginal protein when they are bound to MHC molecules. In this respect, the previous chapter 
found that naïve T-cell from healthy donors are activated with DDS-NO via a pathway 
dependent on covalent binding of the metabolite to protein or a peptide embedded within MHC. 
Pichler et al showed that drugs also activated T-cells via a vastly different pathway involving 
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the direct non-covalent modification of MHC molecules (Pichler et al. 1997; Schnyder et al. 
2000; Zanni et al.1998). Although the binding interaction is labile, it is sufficiently strong to 
trigger T-cell receptors. In the previous chapter, we found that DDS also activates T-cells from 
healthy donors through a direct binding interaction with antigen presenting cells. 
Zhang et (2013) indicated that HLA-B*13:01 was a risk factor for dapsone hypersensitivity 
syndrome, the allele was observed in 86% of Chinese case-patients. Understanding the 
pathomechanism associated with these HLA alleles and may help to identify the initial steps in 
the hypersensitivity reaction. The most recent study using computational modelling suggests 
that the chemical structure of dapsone interacts selectively with the antigen-recognition site of 
HLA-B*13:01 (Watanabe et al. 2017). Therefore the dapsone might interact directly with 
HLA-B*13:01 in patients, and trigger T-cell responses. Despite this, to date the activation of 
hypersensitive patients T-cells with DDS or DDS metabolites has not been studied. Thus, in 
this chapter we obtained PBMC from 6 Chinese hypersensitive patients and studied T-cell 
responses to either DDS or DDS-NO. Furthermore, we investigated the molecular mechanism 
of DDS-induced T-cell activation. 
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4.2. Materials and Methods 
Table 4.1: Summarizes the patients’ demographics 
4.2.1 Patients Characteristics. 
PBMC were isolated from six dapsone hypersensitive Chinese patients. Table 1 summarizes the 
patients’ demographics, medical history and clinical features of the hypersensitivity reactions. 
Approval for the study was acquired from the local research ethics committee in China and material 
transfer agreement was in place for cell transportation; informed written consent was obtained from 
each patient. 
Patients 
ID 
Gender Age 
(years) 
Medication 
history 
Onset of 
symptoms 
(days) 
Clinical 
presentation 
Skin 
patch 
test 
1 Female 43 Dapsone, 
rifampin, 
and 
clofazimine 
3 Fever, rash, and 
abnormal liver 
function tests 
- 
3 Female 25 Dapsone, 
rifampin, 
and 
clofazimine 
28 Fever, rash, and 
abnormal liver 
function tests 
- 
5 Male 39 Dapsone, 
rifampin, 
and 
clofazimine 
30 Fever + 
6 Male  41 Dapsone, 
rifampin, 
and 
clofazimine. 
48 Fever, rash,  and 
lymphadenopathy 
+ 
7 Male  54 Dapsone, 
rifampin, 
and 
clofazimine 
16  Fever, rash, and 
abnormal liver 
function tests 
- 
8 Female 27 Dapsone, 
rifampin, 
and 
clofazimine 
17 Fever and 
abnormal liver 
function tests 
+ 
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4.2.2 T-cell cloning and generating autologous antigen presenting cells (APC). 
PBMC (1x106/ml) from 6 hypersensitive patients were cultured with either DDS (0.5 mM) or 
DDS-NO (20 μM). Culture medium was supplemented with IL-2 (200 IU/ml) on day 6 and 9 
in order to expand the number of antigen-specific T-cells prior to cloning by serial dilutions on 
day 14. T-cells were plated into 96 well plates at 0.3,1 and 3 cells per well and expanded with 
PHA using the protocol described in chapter 3. Epstein-Barr virus (EBV) transformed B-cell 
lines were generated by transformation of freshly isolated PBMC using supernatant from the 
virus-producing cell line B9.58 as described in chapter 3. Autologous Epstein-Barr virus 
(EBV)-transformed B-cell lines were used as APC in assays involving TCCs. Antigen-
specificity was assessed by culturing irradiated EBV-transformed B cells (1x104/well) and 
DDS or DDS-NO with drug-specific TCC (5x104/well; 200 μl) for 48 hours. Proliferation was 
measured by the addition of [3H]-thymidine followed by scintillation counting. Clones with a 
stimulation index (proliferation due to drug / proliferation due to medium) greater than 2 were 
expanded by repetitive stimulation with irradiated allogeneic PBMC (5x105/well), IL-2 (5 
µg/ml) and PHA (10 µg/ml). 
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4.2.3 Lymphocyte transformation test (LTT) for DHS patients. 
LTT was performed using PBMC isolated from the 6 patients using an established protocol (Nyfeler 
and Pichler 1997). Briefly, PBMC (1.5×105 cells, 100 µL) were cultured with either 100 µL DDS 
(0.125-0.5 mM) or DDS-NO (10-40 µM) in triplicate wells in a 96-well U-bottom plate and incubated 
at 37°C under an atmosphere 5% CO2 for 5 days. [3H]-thymidine (0.5 µCi/well) was added for the 
final 16 hours of incubation and lymphocyte proliferation was assessed as counts per minute (cpm) 
using liquid scintillation counter (Wallac microbeta trilux, PerkinElmer, Cambridge, UK). 
4.2.4 Assessment of the specificity of TCC. 
Dose-dependent proliferative responses to DDS-NO (5-20 μM) and DDS (0.125-0.5 mM) and 
the profile of secreted cytokines (IFN-γ, IL-5, IL-13 and granzyme-B) were then measured by 
culturing TCC and irradiated APC with the drug. Proliferation and cytokine release were 
measured using [3H]-thymidine incorporation and ELIspot respectively. Cell phenotyping was 
performed by flow cytometry using CD4-FITC, CD8-PE antibodies.Twenty-four well 
transwell chambers with 5-μm pores were used to measure chemotaxis. T-cells (0.1×105; n=10 
clones) were placed in the upper chambers. CCL17/CCL27 (ligand for CCR4 and CCR10 
respectively) was placed in the lower wells and the cells were incubated for 0.5-24 hours. Cells 
migrating to the lower chamber were counted using a hemocytometer. 
4.2.5 Antigen presenting cell (APC) fixation and antigen pulsing assays 
APC fixation was used to investigate the role of APC metabolism in the activation of TCC. For this, 
autologous EBV-transformed B-cells (2×106 cells/ml) were washed twice in HBSS to exclude 
FBS and resuspended in HBSS (1 ml). Next, glutaraldehyde (25%, 1 µL) was added andthen the 
cells were lightly mixed for 30 seconds. After this step, glycine (1ml of 1 M) was rapidlyadded 
to the mixture and the cells were mixed for a further 45 seconds.  To remove glutaraldehyde, cells 
were washed threetimes and were then resuspended in T cell culture medium. T cell clones 
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(5×104, 50 µL) were co-cultured with glutaraldehyde-fixed EBV-transformed B-cells (1×104 
cells, 50 µL) in the presence or absence of DDS (0.5 mM). In other experiments, APC - pulsed with 
DDS or DDS-NO for 16 hours were washed extensively with HBSS to exclude free drug and 
co-incubated with TCC in a 96-well plate for 48 hours under 5% CO2 at 37˚C. [3H]-thymidine 
was added during the last 16 hours incubation and antigen specifity evaluated.  
 4.2.6 MHC restriction assay 
In order to define whether DDS or DDS-NO presentation to TCC was MHC class I/II restricted, 
anti-human MHC I (HLA-A, -B, -C), and anti-human MHC II (HLA-DP, -DQ, -DR) antibodies 
(5 µg/mL) were used. In the initiation  of the experiment, autologous EBV-transformed B-cell 
lines (1×104, 50 µL) were pre-incubated with either MHC I or MHC II blocking anti-bodies (5 
μg/ml) at 5% CO2 , 37˚C for 30 min. The APCs were then co-cultured with TCC (5×104, 50 
µL) with or without drug for 48 hours. [3H]-thymidine (0.5 μCi) was added for the final 16 
hours of incubation and T cell proliferation evaluated using scintillation counting. 
4.2.7 T-cell Vβ receptor analysis. 
Ten tubes (1-10) were required for TCR Vβ typing of individual clones. T-cell suspensions (50 
μL) were pipetted into each tube. Anti-CD3 antibody (3μL) was introduced into tubes 2-10. 
TCR Vβ antibodies (5 μL) labelled A-H were then introduced into tubes 3-10 containing TCCs 
+ anti CD3 antibody. Each TCR Vβ antibody cocktail was used to investigate three TCRs. 
Tube 1 had no antibody and was used to gate the T-lymphocyte population during flow 
cytometry. Tubes were incubated at room temperature for 20 minutes. Unbound antibodies 
were washed with FACS buffer (1 ml, 1500 rpm for 5 minutes at room temperature). Finally, 
TCCs were resuspended in FACS buffer (200 μL) and samples analysed. 
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4.3 Results: 
4.3.1 Lymphocyte transformation test (LTT) 
 
We obtained blood samples from 6 patients with DDS hypersensitivity syndrome all of whom 
were HLA-B 13:01 positive PBMC were isolated and proliferative responses to DDS and DDS-
NO were evaluated. Lymphocyte proliferation to graded concentrations of DDS and DDS-NO 
was observed. The proliferative responses were observed with PBMC from 6 patients in the 
presence of DDS and 4 patients with DDS-NO. TT (tetanus toxin) was used as a positive 
control. (Table 4.2, Figure4.1). 
 
Table 4.2: Summary of the patients’ demographics and LLT and IFN- γ results. 
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Figure 4.1: Lymphocyte transformation test (LTT) assay. PBMC (1.5×104 cells, 100 µL) were incubated with 
graded concentrations of either (A) DDS  (0.125-2 mM) or (B)  DDS-NO (10-40 µM) in 96- well U-bottom 
plates. Plates were incubated at 37°C, 5% CO2 for 5 days.  [3H]-thymidine  (0.5  μCi)  was  added  for  the  final  
16  hours  of  incubation  and  T-cell proliferation evaluated using scintillation counting. 
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4.3.2 Secretion of IFN-γ from patient PBMC co-cultured with DDS or DDS-NO.  
 PBMC from six patients were cultured with DDS or DDS-NO and IFN-ϒ was measured by 
ELIspot. PBMC from 3 patients were stimulated to secrete IFN-γ with DDS and DDS-NO. 
Represntitive images with PBMC from responsive and non-responsive donors as shown in 
(Figure 4.2). 
IFN-γ ELISpot for Dapsone-induced DHS patients 
 
Figure 4.2:ELISpot plates were pre-coated with human IFN-γ coating antibodies according to manufacturer’s 
instruction and incubated overnight at 4°C.  PBMC (4×106 cells, 100 µL) were co-incubated with DDS (0.5 
mM,100µL) or DDS-NO (20 µM,100µL) using culture medium as negative control and PHA as positive control.  
The plates were incubated at 37°C, 5% CO2 for 48 h and plates developed for image visualisation and spot counts. 
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4.3.3 Generation of drug-specific T-cell clones. 
Forty T-cell clones were generated from one DDS hypersensitive patient (P8, Figure 4.3). Of 
these, 12 showed a DDS-specific dose-dependent response. Cross reactivity with DDS-NO and 
DDShydroxylamine was observed with 50% of the clones.  Out of 200 clones tested from 2 
patients only two clones were DDS-NO responsive (P1, P8 Figure 4.3).  These DDS-NO-
specific cell clones showed a dose-dependent response to DDS-NO without cross reactivity to 
SMX-NO or DDS. None of clones were activated with SMX-NO (Figure 4.4). 
 Generation of dapsone and nitroso- dapsone-specific TCCs.  
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Figure 4.3: Generation of DDS-specific TCCs from one hypersenstive patients and DDS-NO-specific TCCs from 
two patients: TCCs were generated using serial dilution method. Clones were co-incubated with irradiated 
autologous EBV-transformed B cells and DDS or DDS-NO. Culture medium was utilised as negative control.  
The plates were incubated at 37 °C, 5%CO2 for 48 h.  Radioactive thymidine was added during the last 16 h of 
incubation.  Clones with stimulation index > 2 were selected and expanded for further functional assays. A) DDS 
and B,C) DDS-NO TCCs generated from 2 patients. 
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Dose dependant activation of TCC and assessment of cross 
reactivity. 
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Figure 4.4: Dose response and cross reactivity of drug-specific TCCs clones: A) DDS-specific TCCs were co-
cultured with irradiated autologous EBV-transformed B cells andin the presence of graded concentration of DDS 
(0.125-1mM), DDS-NO or SMX-NO in a 96 wells plate at 5% CO2 for 48 h. Proliferation was determined using 
radioactive thymidine incorporation during the final 16 hours of incubation and T cell proliferation evaluated 
using scintillation counting. B, C) DDS-NO-specific TCCs were cultured with graded concentration of DDS-NO. 
Data was analysed in the same way as discussed above. 
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4.3.4 T-cell phenotyping (Flow cytometry) 
To determine the CD4 and CD8 phenotype of TCCs, flow cytometry was used. T cell 
suspensions (100 µL) were stained with CD4-PE (3 µL) and CD8-APC (3 µL) antibodies and 
incubated at 4°C for 20 minutes in the dark. Cells were washed and resuspended in 200 µL of 
FACS buffer and CD4, CD8 expression determined using the FACS Canto™ II system. The 
data shows that both DDS and DDS-NO specific clones express the CD4+ (Figure 4.5) 
 
CD4/CD8 characterisation of drug-specific TCC. 
 
 
Figure 4.5:A.The phenotype of DDS-specific TCCs were determined using fluorescent activated cell sorting with 
fluorescent antibodies for CD4 (PE) and CD8 (APC). B,C. The phenotype of DDS-NO-specific TCCs was 
determined using fluorescent activated cell sorting with fluorescent antibodies for CD8(APC) and CD4(PE). 
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4.3.5 Drug-specific T-cells secrete cytokine molecules. 
 The cytokines IFN-γ, IL-5 IL-13, GB, IL-22, perforin and Fas-L, were secreted from DDS 
stimulated clones (Figure 4.6A). In contrast, drug-specific IL-17 secretion was not detected. 
The 1 DDS-NO responsive clones assessed secreted a similar panel of cytokines (Figure 4.6B). 
Interestingly, one clone also secreted IL-17 after stimulation with DDS-NO and autologous 
antigen presenting cells. 
 
Cytokine secretion profiles of DDS-and DDS-NO-specific TCC.
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B. DDS-NO-specific TCCs
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Figure 4.6: Cytokine secretion profiles of DDS-and DDS-NO-specific TCC generated from one and two 
hypersenstive patients respectively. ELISpot plates were pre-coated with human IFN-γ, IL-5, IL-13 and 
granzyme-B coating antibodies according to manufacturer’s instruction and incubated overnight at 4°C. TCC were 
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co-incubated with irradiated autologous EBV-transformed B-cells and DDS (0.125-0.5 mM) or DDS-NO (5-20 
µM) using culture medium as negative control.  The plates were incubated at 37°C, 5% CO2 for 48 h and plates 
developed for image visualisation and spot counts. A represent cytokine profile and images for DDS-specific TCC 
while B and C show cytokine profiles and images for DDS-NO-specific TCCs. 
4.3.6 Role of antigen presenting cells in the activation of TCC. 
Experiments were performed by incubating DDS-specific or DDS-NO-specific TCC with or 
without autologous APC to prove the role of HLA alleles in T-cell activation. Fast growing 
DDS-specific TCC generated from Patient 1 (P8) and DDS-NO-specific TCC from Patient 
P1&P8 were used for the APC assay. All DDS and DDS-NO-specific clones were stimulated 
to proliferate with drug in the presence but not in absence of APC (Figure 7). 
Antigen presenting cells are essential for the activation of DDS 
and DDS-NO-specific TCC. 
 
DDS- Specific TCC
DDS(mM)
P
ro
lif
er
at
io
n 
(c
pm
)
- A
PC
+ A
PC
0
5000
10000
15000
***
DDS-NO - Specific TCC ( Patient 1)
DDS-NO (M)
P
ro
lif
er
at
io
n 
(c
pm
)
- A
PC
+ A
PC
0
5000
10000
15000
20000
25000
*
DDS-NO - Specific TCC ( Patient 8)
DDS-NO (M)
P
ro
lif
er
at
io
n 
(c
pm
)
- A
PC
+ A
PC
0
10000
20000
30000
40000
***
A
B C
n=5
 
Chapter 4 
 
128 
 
 
Figure 4.7:  APC are important for the activation of A) DDS-specific TCCs and B, C) DDS-NO-specific TCC 
were co-cultured with or without irradiated autologous EBV-transformed B-cells and DDS and DDS-NO in a 96 
wells plate and incubated at 5% CO2 for 48 h. Proliferation was determined using radioactive thymidine 
incorporation during the final 16 hours of incubation and T-cell proliferation evaluated using scintillation 
counting.  
 
4.3.7 Cross reactivity of DDS-specific TCC with closely-related DDS analogues. 
Twelve clones generated from PBMC DDS-hypersensitive patients were tested for reactivity 
with closely related compounds. 2/12 TCC tested revealed a high proliferative responses with 
DDS and with 3DDS (Figure 4.8). Both DDS and 3DDS have aniline chemical groups at 
different positions on the aromatic rings. In contrast only one DDS-specific clone was 
activated with DDT at low concentrations. DDT contains the sulfone moiety seen in DDS. 
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DDS-specific TCC cross react with 3DDS and low concentration of 
DDT dapsone analogues. 
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Figure 4.8: A, B) Cross reactivity of DDS-specific TCCs with closely related analogues: DDS-specific TCC were 
co-incubated with irradiated autologous EBV-transformed B-cells in the presence of DDS and closely related 
analogues in a 96 well plate at 5% CO2 for 48 h. C) DDS analogues chemical structures.  
 
4.3.8 Cross reactivity of DDS-specific TCC with sulfonamide antimicrobials. 
12 clones generated from PBMC isolated from DDS-hypersensitive patients were used for the 
analysis. A high proliferative response was observed with DDS and sufadizine (SD) (Figure 4. 
9). All other compounds did not activate the clones. 
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DDS-specific TCC do not cross react with closely related 
sulphonamides except sulfadizine(SD).
 
Figure 4.9: A) Cross reactivity of DDS-specific TCCs with closely related sulfonamides: DDS-specific TCC 
were co-incubated with irradiated autologous EBV-transformed B-cells in the presence of DDS or different 
sulphonamides (SMX, SZ,SD, SN, SX,SCH- 0.5 mM) in  96 wells plate  at 5% CO2 for 48 h. (B)sulfonamide 
structures and abbreviated names . Cross reactivity was assessed using thymidine proliferation assay. 
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4.3.9 Cross reactivity of TCC with DDS metabolites. 
12 clones generated from PBMC isolated from DDS-hypersensitive patients were used for the 
analysis. A high proliferative response was observed with DDS hydroxylamine and DDS-NO 
for DDS-specific-TCCs as shown in (Figure 4.10A). The DDS-NO-specific TCC cross reacted 
with DDS hydroxylamine but not with parent drug (Figure 4.10). 
 
DDS-specific TCC cross react with dapsone hydroxylamine and 
nitroso-dapsone. 
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Figure 4.10: A) Cross reactivity of DDS-specific TCCs with closely related metabolites: DDS-specific TCC was 
co-incubated with irradiated autologous EBV-transformed B-cells in the presence of DDS or different metabolites 
(DDS-NO and DDS-NOH) 20 µM) in 96 wells plate at 5% CO2 for 48 h.B,C) Cross reactivity of DDS-NO-
specific TCCs with closely related metabolite and parent drug (DDS, DDS-NOH).  (D) Metabolites abbreviation 
and structure. Cross reactivity was then assessed using thymidine proliferation assay. 
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4.3.10 Glutathione inhibits activation of DDS-NO-specific, but not DDS-specific TCC. 
Glutathione acts as an antioxidant. It exists in high levels in most cells and tissues and plays a 
significant role in metabolism as well as for and removal of xenobiotic substances (Perricone 
et al. 2009). Our results shown glutathione reduces in the proliferative responses of DDS-NO-
specific TCC, but not the activation of DDS-specific TCC (Figure 4.11). 
Glutathione terminates the activation of DDS-NO-specific TCC. 
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Figure 4.11: Activation of TCC with DDS and DDS-NO in the presence and absence of glutathione A) DDS-
specific and B, C) DDS-NO TCCs were co-cultured with irradiated autologous EBV-transformed B-cells and 
DDS or DDS-NO in a 96 well plate at 5% CO2 for 48 h. Proliferation was determined using radioactive thymidine 
incorporation during the final 16 hours of incubation and T cell proliferation evaluated using scintillation counting.  
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4.3.11 Molecular mechanism for activation of DDS and DDS-NO-specific TCC. 
Anti-human MHC I and MHC II blocking antibodies were used to determine MHC-restricted 
T-lymphocyte activation in proliferation and ELISpot assays. Proliferation of both DDS and 
DDS-NO specific TCC was significantly decreased in the presence of an MHC II blocking 
antibody (Figure 4.12A, B&C). Furthermore,EBV-transformed B-cells pulsed with DDS (0.5 
mM) for 16 hours, failed to induce proliferation and interferon-gamma secretion from DDS-
specific TCC (Figure 4.12A). In contrast two DDS-NO-specific TCC were activated with APC 
pulsed with the nitroso metabolites (Figure 4.12B&C). Finally, APC fixed with glutaraldehyde 
before incubation with DDS (0.5 mM) induced the activation DDS-specific TCC proliferation 
and interferon-gamma secretion, whereas the response of two DDS-NO-specific reduced 
(Figure 4.12A, B&C). 
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Molecular mechanism of DDS and DDS-NO-specific TCC activation. 
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Figure 4.12: A) DDS-specific TCCs generated from one DHS patient. Proliferation was measured using [3H] 
thymidine. ELISpot plates were pre-coated with human IFN-γ coating antibodies according to manufacturer’s 
instruction and incubated overnight at 4°C to measure cytokines release from the TCC. TCCs were co-incubated 
with irradiated autologous EBV-transformed B-cells and DDS (0.125 -1 mM) using culture medium as negative 
controlin the presence either MHC I or MHC II blocking antibodies.  The plates were incubated at 37°C, 5% CO2 
for 48 h and plates developed for image visualisation and spot counts.B. EBV-transformed B-cells were pulsed 
with DDS for 24h and cells washed extensively to remove free drug. Drug-pulsed EBVs were then co-cultured 
with DDS-specific TCC, and proliferation and IFN-γ secretion determined as described above. C. EBVs were first 
treated with glutheraldehye to abolish antigen processing then co-cultured with DDS-specific TCC and DDS 
followed by assessment proliferation and IFN-γ ELISpot assay. B,C) DDS-NO-specific TCCs generated from two 
patients, MHC restriction, pulsing and Fixation assays were performed as describe above. 
4.3.12 T-cell Vβ receptor analysis. 
Examination of T-cell receptor expression on 11 DDS-specific TCC generated from patient 8   
revealed a distribution of TCR expression across five Vᵦ subclasses. TCCs expressed five different 
Vᵦ repertoires (Vᵦ2, Vᵦ3, Vᵦ4, Vᵦ8 and Vᵦ9; Figure 4.13A). The percentage of Vᵦ T-cell receptor 
usage observed Vᵦ2 (18%), Vᵦ3 (37%), Vᵦ4 (9%), Vᵦ8 (27%) and Vᵦ9 (9%) is shown in Figure 
4.13B. 
T cell Vβ receptor on DDS-specific TCC. 
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Figure 4.13- TCR Vβ analysis. T-cell suspensions (100 μL) were incubated with various TCR Vβ antibodies and 
TCR Vβ usage determined using flow cytometry and data analyzed.(A) Frequency graphical representation of 
TCR Vβ usage of DDS-specific TCC generated from 1 DDS-hypersensitive patient (P8). (B) Percentage TCR Vβ 
expression of 11 DDS-specific TCC. 
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4.3.13 Chemokines receptor analysis. 
Cell phenotyping was performed by flow cytometry on a BD FACSCanto II using CCR1, 
CCR2, CCR3, CCR4, CCR5, CCR8, CCR9, CCR10, CXCR3, CXCR6, and CLA antibodies 
(BD Biosciences). Ten DDS-specific clones with a strong growth pattern were selected to 
explore which clones expressed specific chemokines receptors and hence have the ability to 
migrate towards tissues. All clones expressed high level of CXCR3 and CCR4 (Figure 4.14A& 
B).Other receptors were expressed at lower level. Clones migrated in response to CCL17 but 
not CCL27 (Figure 4.14 C). 
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Figure 4.14 Chemokines receptor analysis. T-cell suspensions (100 μL) were incubated with various TCR Vβ 
antibodies and TCR Vβ usage determined using flow cytometry and data analyzed by cyflogic.(A) Frequency 
graphical representation of TCR Vβ usage of DDS-specific TCC generated from  DDS-hypersensitive patients . 
(B) Percentage TCR Vβ expression of 11 DDS-specific TCC. (C)TCC migration towards CCL17/or CCL27. 
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4.4 Discussion  
DDS has been used for the treatment of leprosy and other diseases for a number of years. The 
use of DDS may lead to a hypersensitivity reaction known as drug hypersensitivity syndrome. 
There are number of factors involved in DDS hypersensitivity syndrome and these factors are 
genetic and non-genetic.Several studies have concentrated on the role of the HLA allele in 
drug-induced hypersensitivity reactions (Chung et al. 2008; Mallal et al. 2008; Daly et al. 2009; 
Illing et al. 2012; Yun et al. 2012). The most important HLA gene involved in DDS 
hypersensetivity is HLA-B*13:01 (Zhang et al. 2013). Further risk factors that may relate to 
hypersensitivity include: the chemical structure of the drug (Guglielmi et al. 2006), viral 
infections such as HIV and herpes viruses (Coopman et al. 1993; Shiohara et al. 2006), gender 
(Schmid et al. 2006; Thong and Tan 2011), genetic predisposition other than HLA (Kim et al. 
2010) and T-cell receptor repertoire (Ko et al. 2011). 
To investigate the molecular mechanism of dapsone hypersensitivity, we synthesized DDS-NO 
by the chemical oxidation of DDS hydroxylamine as described in chapter 2.  6 DHS patients 
were recruited from China and several experiments such as LTT and T-cell cloning were 
performed to assess the nature of the drug that activates T-cell, cross reactivity, MHC 
restriction and mechanism of drug-specific T-cell activation.  
Lymphocyte from the hypersensitive patients were activated with both DDS and DDS-NO. 
This may be due to cross reactivity or the selective activation of individual clones by DDS and 
DDS-NO. To investigate this further, TCC were generated from dapsone hypersensitive 
patients. 
Using the serial dilution method to generate drug-specific TCC from DHS patients, we 
generated twelve DDS-specific clonesand one DDS-NO-specific TCC frompatient 8. One 
DDS-NO responsive clone was generated from patient 1, with SI ranging from 2 to 120 as 
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shown in Figure 4.3. 50% of the twelve DDS-specific clones tested showed cross-reactivity 
with DDS-NO (Figure 4.4) but not with nitroso sulfamethoxazole. In contrast, both DDS-NO-
specific clones showed no cross reactivity with parent drug or nitroso sulfamethoxazole. 
Furthermore, both DDS-specific clones and DDS-NO specific TCCs expressed the CD4+ cell 
surface protein (Figure 4.5). With respect to cytokine secretion profile, both DDS andDDS-
NO-specific TCC proliferated and secreted IFN-γ, IL-5, IL-13, and GB, IL-22 following drug 
stimulation (Figure 4.6). Somewhat surprisingly,  only few  DDS-NO-specific clones were 
generated. Furthermore, CD8+ clones activated with DDS or DDS-NO were not detected. In 
subsequent experiments since the completion of this thesis CD8+ T-cells have been separated 
prior to serial dilution after a 2 week culture period with DDS and DDS-NO. Researchers have 
successfully identified large number of CD8+ clones activated with both DDS and DDS-NO 
and are actively working to investigate whether the drug antigens bind selectively to HLA-B* 
13:01 to activate these T-cells. 
 In order to evaluate the role of APC in the stimulation of DDS and DDS-NO-specific TCC, 
we stimulated the TCC in presence or absence of irradiated autologous EBVs which act as 
APC. APC were required for the activation of DDS and DDS-NO-specific TCC (Figure 4.7). 
To determine, whether DDS-specific TCCs cross reacted with closely related sulfonamides, 
we evaluated the reactivity of DDS-specific clones with other sulfonamide compounds which 
included sulfamethoxazole, sulfamerazine, sulfadiazine, sulfanilamide, sulfadoxin  and 
sulfachloropyridazine. In a similar experiment, closely DDS analogues namely 4,4 
diaminodiphenyl sulfide (DDT) and 3,3 -diaminodiphenyl sulfone (3DDS) were also tested. All 
compounds were used at a optimised dose of 0.5mM. 3DDS which has structure similar to DDS 
was cross-reactive with DDS-specific TCC (Figure 4.8). In addition the DDS-specific TCC 
cross-reacted with both DDS metabolites namely DDS-NO and DDS hydroxylamine (Figure 
4.10). None of the TCC tested showed cross-reactivity with sulfonamides with exception of 
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the sulfadiazine (Figure 4.9). These data indicate that the sulfone group and at least one 
aromatic aniline moiety is needed to activate the TCC. Furthermore, the interaction is highly 
specific as subtle side chain modification beheads the T-cell response.  
 To characterise the HLA molecules involved in the presentation of drug antigen to DDS- and 
DDS-NO-specific TCC an MHC restriction assay was performed. This involves culturing 
antigen presenting cells, TCCs and drug in the presence of MHC class I and II blocking 
antibodies or isotype control and measuring the antigen-specific responses. The activation of 
DDS and DDS-NO-specific clones, whither were all CD4+, was MHC class II restricted 
(Figure 4.12). 
 To investigate further the mechanism of activation of DDS-specific TCC we performed an 
APC pulsing assay. Pulsed APC failed to stimulate DDS-specific TCC (Figure 4.12). In 
contrast, DDS-NO-specific pulsed APC succeeded to stimulate DDS-NO TTCs (Figure 4.12). 
These data suggested that DDS-NO binds covalently to APCs to activate T-cells, whereas the 
APC binding between DDS and MHC is labile and therefore reversible. 
Antigen presenting cell fixation abolishes the ability of APCs to take up and/or to process 
protein. In this study APC were fixed with glutaraldehyde and used to stimulate the DDS and 
DDS-NO-specific clones with addition of soluble DDS or DDS-NO. Fixation of APC did not 
abolish the activation of DDS-specific TCC but the response of DDS-NO TCC was inhibited 
(Figure 4.12). Thus activation of DDS-NO-specific clones is dependent on protein processing 
with APC.  TCRs are believed to play a significant role in the of T-cell reactivity to drug such 
as sulfamethoxazole and other structurally related compounds (Depta et al. 2004; Schmid et al. 
2006).Therefore, we explored the distribution of TCR repertoire on 11 DDS-responsive TCC 
generated from 1 patient. DDS-specific TCC expressed 5 different TCRVᵦ receptors (Vᵦ2, Vᵦ3, 
Vᵦ4, Vᵦ8 and Vᵦ9; Figure 4.13A).  The majority of clones analysed expressed Vᵦ3 (37%). The 
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Vᵦ2 has been associated in a number of immune-related diseases and cutaneous allergic 
reactions (Reantragoon et al. 2012; Watkins and Pichler 2013). According to silico docking 
studies the CDR2 and CDR3 regions of sulfamethoxazole-responsive clones needed to express 
TCRVᵦ2 for an interaction with sulfamethoxazole (Watkins and Pichler 2013). Chemokines  
play critical role in the regulation the steady-state and inflammatory migration of cutaneous 
dendritic cells (DCs). We analysed chemokine receptors which including; CDR1, CCR2, 
CCR3, CCR4, CCR5, CCR8, CCR9, CCR10, CXCR3, CXCR6, and CLA on 10 DDS-
responsive clones.Our data revealed most of clones expressed CCR4 (Figure 4.14), a skin 
homing receptor. Moreover, clones migrated toward the CCR4 ligand CCL17.  
In summary, data presented in this chapter shows that CD4+ T-cells isolated from DDS 
hypersensitive patients are activated with both DDS and the activate metabolites DDS-NO via 
different mechanisms. On-going experiments are attempting to investigate whether CD8+ 
clones are also activated by both forms of the drug antigen. 
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Chapter 5: Definition of the antigenicity and immunogenicity of dapsone, 
sulfamethaxzole of their metabolites in a mouse model. 
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5.1 Introduction  
The use of dapsone (DDS) is associated with many adverse effects such as anemia, hemolysis, 
methemoglobinemia, and DDS hypersensitivity syndrome (Cucinell et al., 1972, Coleman et 
al., 1996). The toxic effects of DDS is caused by its metabolites (Vyas et al., 2006). It has been 
proposed that the drug induced-hypersensitivity syndrome is an immune mediated response 
which involves activation of T-lymphocytes against a derivative of the drug (Ben M’Rad et al., 
2009). DDS hypersensitivity can cause irreversible organ damage and sometimes lead to death 
if not managed properly or recognized when it is too late (Singh et al.2016). DDS 
hypersensitivity reactions can develop in several weeks after the initiation of the treatment, 
with reported incidences ranging from 0.5% to 3% (Zhang et al., 2013). The cutaneous 
manifestations include: exfoliative dermatitis, erythroderma, popular erythematosus, erythema 
multi-formed, pustular eruptions, toxic epidermal necrosis, and Stevens-Johnson syndrome 
(Roujeau 2013). The liver is the major organ involved in DDS metabolism.DDS is oxidized to 
the reactive metabolite, DDS-NO via a hydroxylamine intermediate. (Uetrecht 1992; Reilly et 
al. 2000; Uetrecht 1992; Vyas et al., 2006, Roychowdhury et al., 2007, Sharma and Uetrecht, 
2014). 
The diagnosis of DDS hypersensitivity is dependent on the clinical presentation, along with the 
history of exposure to DDS. The pathogenesis of DDS hypersensitivity could be linked to 
formation of DDS-NO-protein adducts provoking a T-cell response. The bioactivation of many 
drugs to their respective reactive metabolites has been put forward as a critical factor in 
immunological reactions. For instance, lamotrigine, phenytoin and carbamezipine are all 
associated with a high incidence of immune reactions and have all been reported to generate 
highly reactive arene oxide metabolites that form protein adducts, resulting (Madden et al., 
1996; Maggs et al., 2000). In the previous chapters of this thesis DDS-NO was synthesized and 
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compared the immunogenicity of DDS and DDS-NO using PBMC from drug-naïve healthy 
donors and DDS hypersensitive patients. Both the parent drug and reactive nitroso metabolite 
activated T-cells in both experimental models. The current chapter focuses on the 
immunogenicity of DDS and DDS-NO in mice and compares the responses with those seen 
with nitroso sulfamethoxazole. The rodent system also allowed a comparison of the binding of 
DDS-NO and nitroso sulfamethoxazole to protein using mass spectrometry. 
5.1.1 Previous mouse immunogenicity studies. 
 The use of animal models to investigate drug hypersensitivity reactions is poorly 
developed and requires further research. In a study carried out by Farrell et al.(2003) to 
determine the immunogenicity of sulfamethoxazole (SMX) in animals such as male rats, mice 
and rabbits, animal were immunized with test drugs and drug-specific splenocyte proliferation 
was evaluated. The metabolism of SMX involves CYP450 and myeloperoxidase-catalyzed 
reactions, which leads to the formation of a hydroxylamine that is not protein reactive (Farrell 
et,.al 2003). SMX hydroxylamine in the peripheral circulation undergoes auto-oxidation in 
circumstances of oxidative stress to generate protein-reactive nitroso metabolites similar to 
DDS-NO. SMX-NO is highly unstable in solution, and degrades to produce nitro SMX, 
dimerization product (azo and azoxy adducts) and is reduced to SMX hydroxylamine and SMX 
as summarized in the schematic representation below (Figure 5.1). Splenocytes from mice 
immunized against SMX-NO, but not the parent drug, are stimulated to proliferate with the 
nitroso metabolite, which indicates that SMX-NO is highly immunogenic in these species.The 
lack of a response to the parent drug highlights a clear difference between human and rodent 
models. 
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Figure 5.1 Scheme describing the SMX- and SMX-oxidative metabolites in vivo adapted from (Farrell et, .al 
2003). 
 
According to Whritenour et al. (2014), animal models are useful tools for identifying drug 
candidates that activated immune cells (Whritenour et al. 2014).Other important animal models 
which have been developed to study hypersensitivity reactions are penicillamine-induced 
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autoimmunity in the Brown Norway Rat (Tournade et al, 1990), nevirapine-induced skin rash 
in the rat (Shenton et al., 2003), propylthiouracil-induced autoimmunity in the cat (Aucoin et 
al, 1985), sulfonamide-induced hypersensitivity in dogs (Trepanier,2004), amodiaquine-
induced agranulocytosis/hepatotoxicity in rats (Clarke et al, 1990), isoniazid-induced 
hepatotoxicity in the rabbit (Sarich et al, 1995) and lipopolysaccaride-potentiated 
hepatotoxicity in rats (Luyendyk et al, 2006).   
5.2 Aim of this study  
1- Explore the immunogencty/antigencity of DDS, SMX and their nitroso metabolites on 
using mouse model. 
2- Analysis of DDS-NO protein modification. 
5.3 Material and Methods 
5.3.1 Animals  
Female C57BL/6 wild type mice, (8-12 week old), weighing 25-30g were purchased from 
Charles River (Wilmington, MA, USA). All mice used in this study were kept in the animal 
housing unit of Liverpool University. All mice were given access to food and water after arrival 
to the facility.  All experiments were conducted under a project and personal license issued by 
the UK Home Office under the Animals (Scientific Procedures) Act 1986. Eight mice were 
divided into two groups with each group containing 4 mice. Every group was injected with the 
following: DDS-NO, or SMX-NO at (1mg/kg inj IP) once a day for four days in the first week. 
Dosing was repeated for second week. A week later mice were culled, spleen removed and 
splenocyte isolated for in-vitro experiments (Figure 5.2). 
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Schematic representation of dosing schedule and experiment design. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2:Schematic representation of the mouse experiments 
5.3.2 Drug administration  
All the drugs were dissolved in DMSO prior to intraperitoneal injection (1mg/kg) using a 27g 
needle. 
5.3.3 In vitro modification of His-GSTP with nitroso metabolites 
Expression and affinity purification of histidine-tagged human GSTP was carried out using 
protocols published previously (Jenkins et al.,2008). Briefly, the cDNA for histidine-tagged 
human GSTP (His-GSTP) was cloned into the vector pET-15b (Novagen) and expressed as 
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described previously. Transformed BL21 cells were grown on lysogeny broth (LB) medium 
containing ampicillin (50 µg/mL). A single colony was inoculated into 50 mL of LB medium 
and grown at 37oC until the absorbance at 600 nm reached approximately 0.5. An aliquot of 
this preculture was added to 1 L medium which was incubated on a shaker at room temperature. 
Protein expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside to a final 
concentration of 2 mM. After 18h, the cells were harvested by centrifugation at 4000 g for 5 
min, and the cell pellets were resuspended in 10 mL phosphate buffer and sonicated. The 
sonicated cells were centrifuged at 13,000 rpm for 10 min and the supernatant was collected 
and stored at -80oC.Purified His-GSTP captured on nickel beads was incubated with a range 
of molar ratios of nitroso metabolites to protein (1:1-10:1) in phosphate buffer, pH 7.4 for 16 
h. The beads were then washed with 5X100 µL phosphate buffer. The modified protein was 
subjected to on bead tryptic digestion followed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis. 
5.3.4 Ex Vivo Proliferation of Splenocytes to test Drugs. 
Red cell-depleted splenocytes isolated by density centrifugation using lymphoprep were 
incubated (1.5×105) with DDS (0.1-0.5 mM), sulfamethoxazole (0.1-0.5 mM), DDS-NO (5-20 
µM), SMX-NO (5-20 µM) and nitroso benzene (20 µM) at 37°C, 5% CO2. After 3 days, 
proliferation was measured by the addition of [3H] thymidine for the final 16 h of culture. 
5.3.5 Mass spectrometric analysis of DDS-NO and SMX-NO binding to mouse serum 
albumin. 
To investigate the covalent binding of DDS-NO and SMX-NO to mouse serum albumin (MSA) 
(Figure 5.8), DDS-NO freshly dissolved in DMSO was incubated with MSA (0.1 mM, 50 µL) 
in potassium phosphate buffer (10 mM, pH 7.4) at 37 oC for 16 h. The molar ratios of drug to 
protein were 0.1:1, 1:1, and 10:1. Protein was purified by ultrafiltration (3K cutoff) to remove 
the free drug, and then reduced with 10 mM dithiothreitol (15 min) and alkylated with 55 mM 
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iodoacetamide (15 min) at room temperature. The protein was reconstituted in 100 µL 50 mM 
ammonium hydrogencarbonate, and 165 µg (1.25 nmol) of protein was digested with 1.6 µg 
trypsin overnight at 37oC.The tryptic MSA peptides were analysed by a Q-TOF mass 
spectrometer as described previously (Jenkins et al. 2013).Briefly,  samples were delivered into 
a Triple TOF 5600 mass spectrometer (AB Sciex) by automated in-line reversed phase liquid 
chromatography, using an Eksigent NanoUltra cHiPLC System (AB Sciex) mounted with a 
microfluidic trap and analytical column (15 cm × 75 μm) packed with ChromXP C18−CL 3 
μm. A NanoSpray III source was fitted with a 10 μm inner diameter PicoTip emitter (New 
Objective). Samples were loaded in 0.1% formic acid onto the trap, which was then washed 
with 2% ACN/0.1% FA for 10 min at 2 μL/ min before switching in-line with the analytical 
column. A gradient of 2−50% (v/v) ACN/0.1% (v/v) FA over 90 min was applied to the column 
at a flow rate of 300 nL/min. Spectra were acquired automatically in positive ion mode using 
information-dependent acquisition, using mass ranges of 400−1600 amu in MS and 100−1400 
amu in MS/MS. Up to 25 MS/MS spectra were acquired per cycle (approximately 10 Hz) using 
a threshold of 100 counts per s, with dynamic exclusion for 12 s and rolling collision energy. 
Sequence coverage was determined using ProteinPilot software, v4.0 and the most recent 
version of the SwissProt database. Modified peptides were identified by filtering for specific 
fragment ions in PeakView 1.2.0.3 (AB Sciex) and manual inspection of the spectra. 
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5. 4 Results 
5.4.1 Splenocytes from immunized mice are activated with nitroso dapsone, but notthe 
parent drug.   
Previous studies have shown that splenocytes from mice immunized against SMX-NO are 
stimulated to proliferate in vitro in the presence of the nitroso metabolite. In contrast, 
splenocytes are not activated with the parent drug (Farrell et al., 2003). Herein, splenocytes 
from SMX-NO-sensitized mice were also shown to be activated with nitroso sulfamethoxaozle 
and no cross-reactivity was observed with either DDS-NO, nitroso benzene or SMX (Figure 
5.3B).  
Mice were also administered DDS and DDS-NO following the protocol established with SMX-
NO. Splenocytes from 2 DDS-NO immunized mice proliferated vigorously ex vivo in the 
presence of the nitroso metabolite (Figure 3A). Weaker DDS-NO-specific proliferative 
responses were detected with splenocytes from mice 3 and 4. Somewhat surprisingly, 
splenocytes from all 4 mice were also activated with SMX-NO. DDS and SMX did not activate 
the T-cells. Similarly splenocytes from mice immunized with DMSO alone were not activated 
with any of test the compounds.  
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Figure 5.3: Eight C57BL/6 mice were immunized with A) DDS-NO(1mg/kg)  or B) SMX-NO (1mg/kg) once a 
day intraperitoneally for 4 days for 2 weeks.  7 days later splenocytes were isolated counted and cultured in 96 U-
bottom well plates in the presence and absence of drugs. Cross reactivitywith (DDS,SMXand B-NO) were 
performed.Culture media was used as a negative control. The plate was incubated at 37°C for 48 hours. 
Proliferation was assessed by adding [3H]thymidine (0.5μCi) during the final 16 hours of incubation and T-
lymphocyte proliferation evaluated using scintillation counting. 
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5.4.2 SMX-NO and DDS-NO modification of cysteine in GSTP. 
To characterize the reactivity of nitroso metabolites with cysteine residues on proteins, human 
GSTP which contains several reactive cysteine residues was chosen as a model. His-GSTP 
captured on nickel beads was incubated with nitroso metabolites and the adducts were analyzed 
by LC-MS/MS. The modification of Cys47 by SMX-NO resulted in two types of adduct, 
corresponding to doubly charged ions at m/z 673.8 and 681.8, respectively. These adducts with 
a mass increase of 267 and 283 Da, were deduced to a sulfonamide and N-hydroxyl 
sulfonamide adducts, respectively (Figure 5.4A and 5.4B).  
Similar to the modification observed with SMX-NO, modification of GSTP by DDS-NO 
resulted in a sulfonamide and N-hydroxyl sulfonamide adduct with a mass addition of 278 and 
294, respectively (Figure 5 C-D). Interestingly, a third adduct with a mass addition of 262 was 
also detectable (Figure 5B). We deduced that this adduct could correspond to a sulfinamide, 
which is normally not stable and can be further oxidized to a sulfonamide. The modification of 
Cys47 by DDS-NO was confirmed by the MS/MS spectra in Figure 5 (B-D). In contrast to 
DDS-NO, no modification at Cys47 was observed when DDS was incubated with GSTP 
(Figure 5.5A). 
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Figure 5.4: MS/MS spectra showing adduction of reactive metabolite (SMX-NO) to GSTP . SMX-NO 
covalently bound to GSTP peptide ASCLYGQLPK at Cys47 and resulted in a sulfonamide (A) and N-hydroxyl 
sulfonamide (B) adduct with a mass addition of 267 Da and 283 Da, respectively. 
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Figure 5.5:LC-MS/MS analysis of DDS or DDS-NO modified GSTP peptides identified in vitro. MS/MS spectra 
showing no DDS adducts formed on peptide ASCLYGQLPK (A), and the formation of sulfinamide, sulfonamide, and 
N-hydroxyl sulfonamide adductswith Cys47 on GSTP with a mass addition of 262 Da (B), 278 Da (C), and 294 Da (D), 
respectively.  Peaks indicated correspond to m/z of y ions derived from peptides ASCLYGQLPK. 
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5.4.3 SMX-NO and DDS-NO modification cysteine residue in mouse serum albumin. 
SMX-NO has previously been shown to undergo multiple adduction reactions with cysteinyl 
residues of proteins such as human serum albumin and GSTp. GSTp was modified at Cys47 
forming sulfinamide, N-hydroxysulfinamide, and N-hydroxysulfonamide adducts. Human 
serum albumin was modified with nitroso sulfamethoxazole at Cys34 and in contrast to 
glutathione S-transferase pi, only the [2O] adduct was detected (Figure 5.6)  
Herein, DDS-NO and SMX-NO were incubated with mouse albumin for 16h and adduct 
formation was measured by mass spectrometry. Similar to the [2O] adduct observed with 
SMX-NO on MSA (Figure 5.6), stable DDS-NO cysteine adducts on MSA were detected 
(Figure 7). A representative MS/MS spectrum for a doubly charged ion at m/z 615.72 
corresponds to the tryptic peptide 34CSYDEHAK41 with an additional mass of 278amu, 
indicating that a [2O] adduct was formed. The peptide sequence was confirmed by the presence 
of a series of y and b ions. The modification site was confirmed by b2* (m/z 469.1), b3* (m/z 
632.2), and b6* (m/z 1013.3), and b7* (m/z 1084.3), all with adduction of 278 amu, giving 
evidence of modification at Cys34 (Figure 5.7). 
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Figure 5.6:Mass spectrometric detection of the SMX-NO adduct formed with MSA, Illustrative MS/MS spectra of 
peptide 34CSYDEHAK41 modified on cystine34. 
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Figure 5.7:Mass spectrometric detection of DDS-NO adduct formed with MSA, Illustrative MS/MS spectra of peptide 
34CSYDEHAK41 modified on cystine34. 
 
 
Figure 5.8: Amino acid sequence of mouse serum albumin. The red highlights show two free cysteine residues. 
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5.5 Discussion  
 DDS is used for the treatment of leprosy because of its antibiotic and anti-inflammatory 
properties (Uetrecht et al. 1988; Zhu & Stiller 2001). N-acetyltransferase enzymes catalyse the 
conversion of DDS to stable mono and diacetylated derivatives, while cytochrome P-450, 
flavin monooxygenase and peroxidase-mediated N-hydroxylation results in the formation DDS 
hydroxylamine (Zuidema et al. 1986; Roychowdhury et al. 2007; Piyush M. Vyas et al. 2006). 
DDS hydroxylamine is susceptible to auto-oxidation and the derived nitroso species has been 
shown to bind covalently to protein (Roychowdhury et al. 2007; Bhaiya et al. 2006; 
Roychowdhury et al. 2005). Despite this, the nature of the binding interaction has not been 
defined.In order to characterize the antigenic structure that stimulated immune cells, in-vitro 
incubations of DDS-NO with MSA were performed. DDS-NO was found to covalently modify 
cysteine residue in MSA. In contrast to DDS-NO glutathione adducts, only one type of cysteine 
adduct in MSA was detected, corresponding to either a N-hydroxysulfinamide or sulfonamide 
adduct (described in chapter 2). This is consistent with previous findings that SMX-NO formed 
only one stable Cys34 adduct with human serum albumin. Notably, when DDS-NO was 
incubated with GSTP, all three types of adducts were detectable, though the sulfinamide and 
N-hydroxysulfonamide adducts were present at very low levels. Docking of DDS-NO to the 
binding sites on proteins may allow us to explain the difference observed between MSA and 
GSTP. Nonetheless, it is worth noting that there are two reactive cysteine residues on MSA, 
Cys34 and Cys579, however, modification was only detected on Cys34. It is possible that DDS-
NO could modify both residues, however, the tryptic peptide containing modified Cys579 is 
too short to be detected by the current mass spectrometric method. 
In this thesis to date, the immunogenicity of DDS in human systems was investegated. Immune 
responses resulting from DDS, SMX and their reactivate nitroso metabolites were also 
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evaluated using a mouse model. Analysis of DDS-NO protein adducts formed were performed 
based on previous studies on SMX-NO. Briefly, mice were immunized over a 2 weeks, dosing 
protocol after which, splenocytes were isolated and dose-dependent in-vitro proliferative 
responses and cross-reactivity measured. DDS-NO and SMX-NO were found to activate naïve 
T-cells during the 2 weeks dosing protocol. When isolated and restimulated, proliferative 
response were detected with nitroso compounds, but there was no cross reactivity with the 
parent drugs. Moreover, the parent drugs did not prime naive T-cells. These data are in stark 
contrast to the previous findings with human T-cells where DDS and DDS-NO both stimulated 
T-cells proliferate and secreted cytokines via different mechanisms. Furthermore, the results 
indicate that rodent models are viable models to study immunogenicity of haptenic compounds, 
but they fail to reproduce to direct binding of drugs to human MHC molecules. 
Having successfully developed a model of DDS-NO in the mouse, the final section of the thesis 
focused on the assessment of DDS-NO modification of GSTpi and MSA using mass 
spectrometry.  
In summary, our data indicate that DDS-NO can activate mouse naïve T-cells via a hapten 
pathway. DDS-NO formed three types of adducts with GSTPi and only one type of adduct in 
MSA.There are two limitation to the use of mouse model to evaluate the immunogenicity 1) 
Absence of human MHC restriction in the mouse which is an important risk factor of drug 
hypersensitivity. 2) The mouse does not form enough of the human drug reactive metabolite. 
For instance, shortage of sulfotransferase in the animal skin leads to lower level of the  reactive 
sulfate metabolite of nevirapine (Sharma et al., 2013;Uetrecht & Naisbitt 2013).
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6. Final discussion 
 
 
Clinical symptoms of drug hypersensitivity can vary from insignificant reactions such as 
nausea and skin rashes to severe conditions such as anaphylaxis, toxic epidermal necrolysis 
and liver failure. Drug hypersensitivityreactions have a bearing on patients, medical 
practitioners, and drug manufacturers. They limit therapeutic alternatives to treat ailments and 
sometimes cause fatalities (Schulkes et al., 2015). In England, adverse drug reactions cost the 
NHS approximately £ 470 million annually. Furthermore, the development of a new drug takes 
about ten years with an average cost of about $ 6.3 billion per new drug. Consequently, the 
cost of removing a drug from the market is tremendous; hence,there is a needto predict and 
detect drug hypersensitivity at an early stage (Wu et al 2012). To do this requires an increased 
understanding of (1) patient susceptibility factors, (2) mechanisms of the drug-immune 
receptor interaction and (3) the nature of the immune cells responsible for initiating and 
propagating the reaction. In this thesis, we have focused on dapsone (DDS) hypersensitivity 
syndrome to explore each of these parameters.  
DDS is a diaminophenyl sulphone, which has been efficaciously utilized in the treatment of 
leprosy for many years. The drug also has anti-inflammatory and antibacterial activity, and it 
is used to treat a variety of inflammatory skin ailments such as dermatitis herpetiformis, chronic 
bullous dermatoses. Common side of the drug includes nausea, dizziness, hepatitis, insomnia, 
and fatigue (Reibel et al., 2015). The authors indicated that about 1-4% of the people treated 
with the DDS experience a drug hypersensitivity syndrome. These reactions are could be 
mediated by either the parent drug or a protein reactive metabolite. DDS is metabolized to a 
hydroxylamine metabolite that undergoes spontaneous oxidation to nitroso DDS (Uetrecht et 
al., 1988).Nitroso DDS may be detoxified through glutathione conjugation or bind to protein 
generating an adduct. It is hypothesized that formation of a DDS protein adduct is the molecular 
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initiating event in DDS hypersensitivity reactions. Thus, the primary objective of this research 
was to synthesize nitroso DDS as a reagent to compare its immunogenicity to the parent 
compound in human and murine systems. 
Nitroso DDS was synthesized through oxidation of DDS hydroxylamine using iron chloride. 
The nitroso compound is insoluble in the reaction mixtureand thus it was possible to separate 
it from the starting material in high purity through filtration. Similar to nitroso 
sulfamethoxazole, a highly immunogenic drug metabolite (Naisbitt et al., 1999; Farrell et al., 
2003; Castrejon et al., 2010), nitroso DDS bound covalently to cysteine moieties on glutathione 
and model proteins. Currently, there are two hypotheses that describe the activation of T-cells 
with drugs. First, the PI concept states that drugs interact with either HLA molecules or HLA 
binding peptides directly through readily reversible bonds. Second, the hapten concept states 
that drugs bind covalently to non-MHC associated protein and that peptides liberated through 
protein processing (which presumably contain the drug metabolite) interact with HLA 
molecules. Both hypotheses are similar in that T-cells seem to require signals from (1) an HLA 
molecule, (2) an HLA binding peptide and the drug, for activation. Our data shows that nitroso 
DDS binds covalently to protein under cell culture conditions provides evidence that we have 
a reliable system to explore the immunogenicity of the parent drug and metabolite.  
Our recently establishedin vitro priming assay can be used to explore the drug-specific 
stimulation of naïve T-cells from healthy donors (Faulkner et al. 2012). In this study, naïve T 
cells were primed in the presence of both DDS and nitroso DDS.  The assay involved an initial 
co-culture period of naïve T-cells and dendritic cells with the drug or metabolite for two weeks. 
The primed T-cells were subsequently restimulated with a second batch of dendritic cells and 
both drugs to explore cross priming.Our study revealed that naïve T cells from HLA-B*13:01 
negative donors were sensitized to DDS andnitroso DDS in a dose-dependent manner. Thus, 
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we next cloned individual T-cells from the priming assays to explore cellular phenotype and 
function.  
Cytokines play a significant role in the immune reaction. They are soluble proteins that are 
secreted by cells of the immune system. The primary function of these cytokines is to alter the 
behaviour and properties of different cell types within and outside the immune system.  
Cytokine profiling is a fundamental parameter in understanding antigen-specific immune 
responses as it helps to define the behaviour of the various cells involved (O’Garra & Murphy 
1994). There are many cytokine bioassays and these include; enzyme-linked immunosorbent 
assays (ELISAs), radioactive immunosorbent assays, microarrays and multiplex assays for 
detection of cytokines at the protein or mRNA level (Halmine et al., 1999). In regards to this 
study, we focused on an ELIspot method to profile the secretion of cytokines from drug-treated 
dendritic cells and T-cell clones. DDS and nitroso DDS-responsive clones isolated from the 
priming assay secreted IFN- and IL-13, but not IL-5 or the cytolytic molecule granzyme B. 
Results from these studies prompted us to investigate the cytokines secreted by cloned T-cells 
from patients with DDS hypersensitivity syndrome (see below).   
To evaluate the role of APC in the stimulation of DDS-specific T-cell clones, cloneswere 
stimulated with DDS or nitroso DDS in presence or absence of irradiated autologous EBV 
transformed B-cells, which act as antigen presenting cells in the assay. Antigen presenting cells 
werefound to be required for the activation of DDS-specific clones.To investigate further the 
mechanism of activation of DDS-specific clones, antigen presenting cell pulsing assays were 
performed. Pulsed APC failed to stimulate DDS-specific clones, which suggests that the drug 
is binding to HLA molecules in a labile manner. Furthermore, fixation of antigen presenting 
cells with glutaraldehyde, which blocks antigen processing, did not abolish activation of the 
DDS-specific T-cell clones. Thus, it is highly likely that clones were activated via a 
pharmacological interaction of the drug with immune receptors as originally proposed by 
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Pichler (2003). HLA molecules play a significant role in the T-cell response by providing an 
environment on the cell surface where peptides can be displayed to neighbouring cells (Pavlos 
et al., 2014). The DDS-specific clones all expressed the CD4+ cells surface protein and as 
expected the drug-specific response was restricted to MHC class II.  
A limited number of nitroso DDS-responsive clones were generated from the healthy donor 
PBMC. Of these, only one CD8+ clones could be expanded in sufficient numbers for detailed 
analysis. In contrast to the DDS-responsive clones, the nitroso DDS responsive clone was 
activated via a hapten mechanism. Antigen presenting cells pulsed with nitroso DDS activated 
the clone, while fixation of antigen presenting cells significantly reduced the intensity of the 
response.   
To investigate how these findings with PBMC and cloned T-cells compares to the response 
observed in hypersensitive patients, a new collaboration was initiated with clinical researchers 
in China. Six patients with DDS hypersensitivity syndrome were recruited. Patients presented 
with a range of symptoms including fever, skin rash and abnormal liver function tests. 
Importantly, all expressed the HLA risk allele HLA-B*13:01, which is strongly associated with 
the development of DDS hypersensitivity in the Chinese (Zhang et al., 2013). The lymphocyte 
transformation test, a diagnostic assay based on a comparison of levels of proliferation in drug- 
and medium-treated PBMC (Nyfeler and Pichler, 1997), and IFN-γ ELIspot were used to detect 
DDS and nitroso DDS-specific T-cell response in the patients. Patient PBMC were found to 
proliferate and secrete IFN-γ with both the parent drug and metabolite. Serial dilution was then 
used to isolate drug-responsive clones from the patients PBMC. DDS-specific and nitroso 
DDS-specific CD4+ cloneswith a stimulation index ranging from 2 to 120 were identified. Six 
of the DDS-specific clones showed a degree of cross-reactivity with nitroso DDS and/or the 
hydroxylamine metabolite. In contrast, clones were not activated with nitroso 
sulfamethoxazole. To determine whether DDS-specific clones cross reacted with closely 
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related sulphonamides and DDS analogues, we evaluated the reactivity of four DDS-specific 
clones to sulfamethoxazole, sulfamerazine, sulfadiazine, sulfanilamide, sulfadoxin, 
sulfachloropyridazine, 4, 4 diaminodiphenyl sulfide (DDT) and 3,3 -diaminodiphenyl sulfone 
(3DDS). 3DDS, which has high structural similarity to DDS,was found to activate clones; 
however, the other compounds yielded largely negative results.The nitroso DDS-specific 
clones showed no cross reactivity with DDS or nitroso sulfamethoxazole. Collectively, these 
data highlight the fine specificity of T-cells towards the structures of DDS and nitroso DDS. 
The pathways of activation of clones with DDS and nitroso DDS were the same as that 
observed with healthy volunteers. Namely, DDS-responsive clones were activated via a pi 
mechanism, whereas, nitroso DDS-responsive clones were activated via a hapten mechanism. 
With respect to cytokine secretion profiles, both DDS and DDS-NO specific secreted IFN-ϒ, 
IL-5, IL-13, and GB, IL-22 after drug treatment. The detection of granzyme B from the drug 
stimulated patient clones, but not with clones from healthy donors, indicates that the patient 
clones have a greater capacity to cause tissue injury.  
Somewhat disappointedly, DDS- and nitroso DDS-responsive CD8+ clones were not detected 
in the cloning experiments with patient PBMC. These would have been interesting to study as 
the availability of antigen presenting cells from our frozen HLA-typed biobank containing 
PBMC from 1200 donors (Alfirevic et al., 2012) would have allowed us to explore whether 
DDS and/or nitroso DDS bind selectively to HLA-B*13:01 to activate T-cells. Importantly, in 
experiments conducted by other researchers in the Naisbitt research group since completion of 
my thesis, large numbers of CD8+ clones responsive towards both DDS and nitroso DDS have 
been generated through firstly purifying CD8+ T-cells prior to serial dilution. Initial studies 
suggest that both the parent drug and DDS-modified peptides selectively bind to HLA-B*13:01 
to activate some of the CD8+ clones.   
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 This study concluded by conducting a series of experiments using mice to explore the in vivo 
immunogenicity of DDS and nitroso DDS. Splenocytes were isolated from mice sensitized 
with DDS-NO and DDS, andin vitroproliferation assays were conducted to explore the extent 
of sensitization. Splenocytes from DDS-NO but not DDS sensitized mice were stimulated to 
proliferate in vitro, but only in the presence of the nitroso metabolite. These data add to the 
growing evidence that murine models can be used to explore the immunogenicity of drug 
haptens; however, they do not reproduce the T-cell responses to parent drugs that are seen in 
humans.   
The detection of nitroso DDS-modified cysteine in mouse serum albumin by mass 
spectrometry revealed that a stable 2[O] adduct was formed. The cysteine adduct might be 
formed by two pathways: firstly, nucleophilic addition of cysteine thiolate to the aryl nitroso 
could result in a semimercaptal adduct, which can be further oxidized to a stable N-hydroxy 
sulfinamide; alternatively, cysteine could be oxidized to a cysteine sulfenic acid, followed by 
the nucleophilic addition to nitroso compound. The detection of the semimercaptal Cys47 
adduct on GSTP suggests that the first pathway is highly possible. However, the general 
occurrence of protein sulphenic acids is also documented (Paulsen and Carroll, 2013). 
Sulphinic acids are well known to be soft nucleophiles due to their low pKa and can attack the 
nitrogen of the nitroso compounds to form an N-hydroxy sulphonamide.  
In summary, our data indicates that nitroso DDS-NO can activate human and mouse naïve T-
cells via a hapten pathway. In contrast, the parent drug only needs to bind reversibly to HLA 
molecules expressed on the surface of human antigen presenting cells to activate T-cells. It is 
important to emphasize that our healthy donors did not express the HLA risk allele HLA-
B*13:01. Thus, both pathways of T-cell activation are feasible in donors expressing different 
HLA alleles. In on-going studies the Naisbitt group is exploring the nature of the drug-specific 
T-cell response and whether DDS and/or DDS-NO bind preferentially to HLA-B*13:01 to 
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selectively activate CD8+ T-cells.The data presented herein provides an initial understanding 
of the mechanisms of DDS hypersensitivity. A universal approach encompassing all the 
different aspects of drug hypersensitivity research will in the near future provide a complete 
and clear molecular pattern for understanding the pathogenesis of the reaction. We hope that 
sustained research will allow basic mechanistic observations to be translated into (1) the clinic 
to assistthe development of tests that aid patient diagnosis and (2) Pharmaceutical industry 
through better drug design and synthesis. 
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